Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
a6e974449e1e18e950fba948935454a249bf1389bdf30a8ace63d7373f6a7fac.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="2">Odds ratio (95% CI), <i>P </i>Value</td></tr><tr><td>Before accounting for confounding by indication<sup>a</sup></td><td>After accounting for confounding by indication</td></tr><tr><td>Methicillin-sensitive <i>S. aureus</i> carrier</td><td>0.5 (0.3, 1.0), 0.03</td><td>0.4 (0.2, 0.8), 0.01</td></tr><tr><td>Intubation</td><td>4.7 (1.8, 12.3), 0.002</td><td>5.3 (2.0, 14.4), 0.001</td></tr><tr><td>Fluoroquinolone</td><td>1.9 (1.2, 3.0), 0.01</td><td>-</td></tr><tr><td>Aminoglycoside</td><td>-</td><td>0.3 (0.1, 0.7), 0.003</td></tr><tr><td>Days from ICU admission to negative swab</td><td>&lt; .0001</td><td>&lt; .0001</td></tr><tr><td>1</td><td>1.0, reference</td><td>1.0, reference</td></tr><tr><td>2</td><td>2.0 (1.2, 3.3)</td><td>2.2 (1.3, 3.7)</td></tr><tr><td>&#8805; 3</td><td>15.6 (8.4, 29.0)</td><td>19.6 (10.4, 37.1)</td></tr><tr><td>Chronic liver disease</td><td>-</td><td>4.1 (1.2, 13.6), 0.02</td></tr></table>
cae44f224f9ff5ab1cfe1e626a1476c2505a64dad4c8a2c6244f67a8c88884b0.png
complex
<table><tr><td> </td><td>Everolimus 1.5 mg (<i>n </i>= 61)</td><td>MMF 2 g (<i>n </i>= 61)</td></tr><tr><td colspan="3">Recipient characteristics</td></tr><tr><td>Age (years)</td><td> </td><td> </td></tr><tr><td> Mean &#177; standard deviation</td><td>42.5 &#177; 14.13</td><td>38.6 &#177; 11.36</td></tr><tr><td> Median (range)</td><td>42.0 (18 to 65)</td><td>36.0 (20 to 64)</td></tr><tr><td>Gender, <i>n</i> (%)</td><td> </td><td> </td></tr><tr><td> Male</td><td>46 (75.4)</td><td>37 (60.7)</td></tr><tr><td> Female</td><td>15 (24.6)</td><td>24 (39.3)</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td> </td><td> </td></tr><tr><td> Mean &#177; standard deviation</td><td>22.46 &#177; 4.03</td><td>21.79 &#177; 2.78</td></tr><tr><td> Median (range)</td><td>21.97 (15.5 to 37.5)</td><td>21.09 (16.0 to 27.6)</td></tr><tr><td>Primary disease leading to transplantation, <i>n</i> (%)</td><td> </td><td> </td></tr><tr><td> Glomerulonephritis/glomerular disease</td><td>16 (26.2)</td><td>9 (14.8)</td></tr><tr><td> Polycystic disease</td><td>3 (4.9)</td><td>3 (4.9)</td></tr><tr><td> Hypertension/nephrosclerosis</td><td>5 (8.2)</td><td>2 (3.3)</td></tr><tr><td> Diabetes mellitus</td><td>3 (4.9)</td><td>5 (8.2)</td></tr><tr><td> Interstitial nephritis</td><td>2 (3.3)</td><td>0 (0.0)</td></tr><tr><td> Obstructive disorder/reflux</td><td>6 (9.8)</td><td>3 (4.9)</td></tr><tr><td> IgA nephropathy</td><td>11 (18.0)</td><td>16 (26.2)</td></tr><tr><td> Unknown</td><td>8 (13.1)</td><td>16 (26.2)</td></tr><tr><td> Other</td><td>7 (11.5)</td><td>7 (11.5)</td></tr><tr><td>Current dialysis</td><td> </td><td> </td></tr><tr><td> None</td><td>12 (19.7)</td><td>8 (13.1)</td></tr><tr><td> Hemodialysis</td><td>42 (68.9)</td><td>48 (78.7)</td></tr><tr><td> Peritoneal dialysis</td><td>7 (11.5)</td><td>5 (8.2)</td></tr><tr><td>HLA mismatches</td><td> </td><td> </td></tr><tr><td> 1</td><td>7 (11.5)</td><td>2 (3.3)</td></tr><tr><td> 2</td><td>9 (14.8)</td><td>16 (26.2)</td></tr><tr><td> 3</td><td>25 (41.0)</td><td>24 (39.3)</td></tr><tr><td> &lt;3</td><td>16 (26.2)</td><td>18 (29.5)</td></tr><tr><td> &#8805;3</td><td>45 (73.8)</td><td>43 (70.5)</td></tr><tr><td colspan="3">Donor characteristics</td></tr><tr><td>Mean &#177; standard deviation age (years)</td><td>52.3 &#177; 8.99</td><td>55.2 &#177; 8.23</td></tr><tr><td>Deceased heart beating, <i>n</i> (%)</td><td>1 (1.6)</td><td>0 (0.0)</td></tr><tr><td>Deceased nonheart beating, <i>n</i> (%)</td><td>0 (0.0)</td><td>1 (1.6)</td></tr><tr><td>Living related, <i>n</i> (%)</td><td>36 (59.0)</td><td>43 (70.5)</td></tr><tr><td>Living unrelated, <i>n</i> (%)</td><td>24 (39.3)</td><td>17 (27.9)</td></tr></table>
90dc2be5ee263fc9bafb3fecebe7deb068ea7567db03d9c2512bf2c0a191f0de.png
simple
<table><tr><td>Shape</td><td>S-12</td><td>S-11</td><td>S-10</td><td>S-9</td><td>S-8</td><td>S-7</td><td>S-6</td><td>S-5</td><td>S-4</td><td>S-3</td><td>S-2</td><td>S-1</td><td>S-0</td></tr><tr><td>Asymmetry_NEF Value</td><td>0.002</td><td>0.304</td><td>1.544</td><td>2.900</td><td>3.328</td><td>3.545</td><td>5.149</td><td>3.830</td><td>4.944</td><td>5.665</td><td>2.469</td><td>0.615</td><td>0.0002</td></tr></table>
77d2d93119c615b2c7195c3aea2ab4f6500efea4f4d4be88113732d1f5ceecbb.png
simple
<table><tr><td>Core/HP</td><td>Sample Depth</td><td>PCR-Product cp77444</td><td>PCR-Product cp103595</td><td>Cloning Success cp77444</td><td>Cloning Success cp103595</td><td>No. of Retrieved Sequences cp77444</td><td>Detected Variants cp77444</td><td>No. of Retrieved Sequences cp103595</td><td>Detected Variants cp103595</td></tr><tr><td>L14-02</td><td>7.53 m</td><td>+</td><td>+</td><td>+</td><td>-</td><td>0</td><td>-</td><td>-</td><td>-</td></tr><tr><td>-</td><td>EN2</td><td>-</td><td>-</td><td>n. c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>L14-03</td><td>6.72 m</td><td>+</td><td>+</td><td>+</td><td>+</td><td>0</td><td>-</td><td>13</td><td>T</td></tr><tr><td>-</td><td>EN3</td><td>-</td><td>-</td><td>n.c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>L14-03</td><td>7.59 m</td><td>+</td><td>-</td><td>+</td><td>n.c.</td><td>11</td><td>A</td><td>-</td><td>-</td></tr><tr><td>L14-03</td><td>8.56 m</td><td>+</td><td>+</td><td>+</td><td>+</td><td>8</td><td>A</td><td>7</td><td>3&#215; C, 4&#215; T</td></tr><tr><td>L14-03</td><td>9.61 m</td><td>-</td><td>-</td><td>n.c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>L14-03</td><td>10.11 m</td><td>-</td><td>-</td><td>n.c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>L14-03</td><td>11.77 m</td><td>+</td><td>+</td><td>+</td><td>+</td><td>9</td><td>A</td><td>3</td><td>T</td></tr><tr><td>-</td><td>EN5</td><td>-</td><td>-</td><td>n.c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>L14-05</td><td>3.3 m</td><td>-</td><td>+</td><td>+</td><td>+</td><td>1</td><td>A</td><td>1</td><td>T</td></tr><tr><td>L14-05</td><td>3.7 m</td><td>-</td><td>-</td><td>n.c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>-</td><td>EN6</td><td>-</td><td>-</td><td>n.c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>L14-04</td><td>6.15 m</td><td>-</td><td>+</td><td>n.c.</td><td>+</td><td>-</td><td>-</td><td>2</td><td>C</td></tr><tr><td>L14-04</td><td>7.27 m</td><td>+</td><td>+</td><td>+</td><td>+</td><td>7</td><td>A</td><td>13</td><td>T</td></tr><tr><td>-</td><td>EN7</td><td>-</td><td>-</td><td>n.c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>L14-04</td><td>8.03 m</td><td>+</td><td>+</td><td>+</td><td>+</td><td>7</td><td>3&#215; C, 4&#215; A</td><td>7</td><td>1&#215; C, 6&#215; T</td></tr><tr><td>L14-04C</td><td>2.05 m</td><td>+</td><td>+</td><td>+</td><td>+</td><td>9</td><td>A</td><td>11</td><td>C</td></tr><tr><td>L14-04C</td><td>3.15 m</td><td>+</td><td>+</td><td>+</td><td>+</td><td>10</td><td>A</td><td>15</td><td>8&#215; C, 7&#215; T</td></tr><tr><td>L14-04C</td><td>3.55 m</td><td>+</td><td>+</td><td>+</td><td>+</td><td>6</td><td>A</td><td>13</td><td>2&#215; C, 11&#215; T</td></tr><tr><td>-</td><td>EN8</td><td>-</td><td>-</td><td>n.c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>-</td><td>NTCs</td><td>-</td><td>-</td><td>n.c.</td><td>n.c.</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table>
beb10114c0b279917f56518e1a7eea5ec07b8ab674d4da5e83ddb3917ca765f5.png
complex
<table><tr><td>Metabolite</td><td>Number of neighbors</td><td><i>P </i>value</td></tr><tr><td colspan="3">Reporter metabolites (up)</td></tr><tr><td>Glutathione [c]</td><td>10</td><td>6.0E-05</td></tr><tr><td>UDP-glucose [c]</td><td>11</td><td>3.1E-04</td></tr><tr><td>D-galactose [e]</td><td>6</td><td>2.5E-03</td></tr><tr><td>Alpha,alpha-trehalose 6-phosphate [c]</td><td>4</td><td>3.7E-03</td></tr><tr><td>Alpha,alpha-trehalose [c]</td><td>4</td><td>6.0E-03</td></tr><tr><td>Alpha-D-glucose 6-phosphate [c]</td><td>8</td><td>8.2E-03</td></tr><tr><td>Oxidized glutathione [c]</td><td>4</td><td>6.6E-03</td></tr><tr><td>CDP-diacylglycerol [m]</td><td>4</td><td>8.6E-03</td></tr><tr><td>Alpha-D-glucose [c]</td><td>23</td><td>2.2E-02</td></tr><tr><td>D-glucose 1-phosphate [c]</td><td>6</td><td>1.2E-02</td></tr><tr><td colspan="3">Reporter metabolites (down)</td></tr><tr><td>AMP [c]</td><td>42</td><td>5.4E-09</td></tr><tr><td>ATP [c]</td><td>83</td><td>1.1E-08</td></tr><tr><td>5-phospho-alpha-D-ribose 1-diphosphate [c]</td><td>15</td><td>2.5E-06</td></tr><tr><td>L-glutamine [c]</td><td>17</td><td>6.6E-06</td></tr><tr><td>L-histidine [c]</td><td>7</td><td>8.2E-05</td></tr><tr><td>L-aspartate [c]</td><td>12</td><td>8.7E-05</td></tr><tr><td>CO<sub>2 </sub>[m]</td><td>10</td><td>1.3E-04</td></tr><tr><td>Isocitrate[m]</td><td>5</td><td>2.5E-04</td></tr><tr><td>Phosphate [c]</td><td>49</td><td>8.5E-05</td></tr><tr><td>Glycine [m]</td><td>4</td><td>9.6E-04</td></tr></table>
a513ac4b559a50c0ea038804e7acc9f76584edb5687c684c0d8d4e36109c05f9.png
complex
<table><tr><td></td><td>No nGER (<i>n</i> = 42)</td><td>nGER (<i>n</i> = 48)</td><td><i>p</i>-value</td></tr><tr><td colspan="4">Exhaled air:</td></tr><tr><td> FeNO (ppb)</td><td>15 (13&#8211;20)</td><td>17 (11&#8211;25)</td><td>0.48</td></tr><tr><td colspan="4">EBC:</td></tr><tr><td> Substance P (pg/ml)</td><td>623 (562&#8211;676)</td><td>741 (626&#8211;821)</td><td>&lt;0.001</td></tr><tr><td> Neurokinin A (% detected)</td><td>17 %</td><td>30 %</td><td>0.13</td></tr><tr><td> Pepsin (ng/ml)</td><td>0.8 (0.8&#8211;3.6)</td><td>2.5 (0.8&#8211;5.8)</td><td>0.03</td></tr><tr><td> IL-8 EBC (% detected)</td><td>12 %</td><td>19 %</td><td>0.37</td></tr><tr><td> 8-isoprostane (pg/ml)</td><td>2.6 (2.2&#8211;2.9)</td><td>3.0 (2.7&#8211;3.9)</td><td>0.002</td></tr><tr><td colspan="4">PEx:</td></tr><tr><td> Albumin (mg/g<sup>a</sup>)</td><td>73 (57&#8211;91)</td><td>48 (31&#8211;69)</td><td>&lt;0.001</td></tr><tr><td> SP-A (mg/g<sup>a</sup>)</td><td>38 (31&#8211;43)</td><td>25 (20&#8211;35)</td><td>&lt;0.001</td></tr><tr><td> Albumin/SP-A (ratio)</td><td>1.92 (1.50&#8211;2.64)</td><td>1.74 (1.26&#8211;2.95)</td><td>0.79</td></tr><tr><td colspan="4">Plasma:</td></tr><tr><td> hs-CRP (mg/l)</td><td>1.05 (0.68&#8211;2.26)</td><td>1.08 (0.62&#8211;1.94)</td><td>0.96</td></tr><tr><td> IL-8 plasma (% detected)</td><td>57 %</td><td>52 %</td><td>0.63</td></tr><tr><td> SP-A (ng/ml)</td><td>34.7 (29.8&#8211;48.6)</td><td>35.6 (27.6&#8211;47.0)</td><td>0.81</td></tr></table>
973f7b1df2a47077d9ef12603a6e08728ba7bc3310d9fe024b71b5fb14927e88.png
complex
<table><tr><td>Treatment</td><td>Belief</td><td><i>N</i></td><td>Recommendations</td><td><i>N</i></td><td>Adherence</td><td><i>N</i></td><td>Challenges to Adherence</td></tr><tr><td rowspan="3">Blood pressure</td><td rowspan="3">Believes blood pressure affects PKD</td><td rowspan="3">16</td><td rowspan="3">Prescribed blood pressure medication</td><td rowspan="3">16</td><td>Number of days per week when remember to take medication:</td><td></td><td rowspan="3">&#8226; Believes diet and exercise are better than drugs&#8226; Forgets when feeling well&#8226; Forgets when rushed, busy, or tired</td></tr><tr><td>&lt;7 days/week</td><td>4</td></tr><tr><td>7 days/week</td><td>12</td></tr><tr><td>Exercise</td><td>Believes exercise or physical activity affects PKD</td><td>14</td><td>Told to avoid certain types of exercise or physical activity</td><td>11</td><td>Does not adhere to recommendations to avoid certain exercises of physical activity</td><td>2</td><td>&#8226; Activity helps mentally&#8226; Disagrees with recommendations (that exercise is harmful)</td></tr><tr><td rowspan="4">Diet</td><td rowspan="4">Believes diet affects PKD</td><td rowspan="4">16</td><td>Told to follow certain diets</td><td>15</td><td>Adherence to low-salt diet:</td><td></td><td rowspan="4">&#8226; Absence of or conflicting recommendations&#8226; Affects social aspects of eating&#8226; Difficult to measure</td></tr><tr><td rowspan="3"> &#8226; By non-physician sources</td><td rowspan="3">10</td><td>Does not add salt to food</td><td>12</td></tr><tr><td>Avoids salty food</td><td>4</td></tr><tr><td>Does not eat out/Cooks own meals</td><td>4</td></tr><tr><td rowspan="3">Water Intake</td><td rowspan="2">Believes drinking a lot of water affects PKD</td><td rowspan="2">10</td><td>Told to drink &#8220;a lot of water&#8221;</td><td>12</td><td>Adheres to recommendations</td><td>10</td><td rowspan="3">&#8226; Frequent urination&#8226; Experiences symptoms&#8226; Difficult to develop habit</td></tr><tr><td rowspan="2"> &#8226; By non-physician sources</td><td rowspan="2">3</td><td>Does not adhere to recommendations</td><td>1</td></tr><tr><td>Uncertain</td><td>5</td><td>Uncertain but tries to adhere to recommendations</td><td>5</td></tr></table>
1bc760c1be03314ffaa98d4d97a48bb740e6ec186b20a4e1c2deeb2c11465679.png
complex
<table><tr><td rowspan="3"></td><td colspan="4">Maternal age (years)</td></tr><tr><td colspan="2">&#8804;15</td><td colspan="2">16&#8211;19</td></tr><tr><td>Adjusted OR (95% CI)</td><td>p-value</td><td>Adjusted OR (95% CI)</td><td>p-value</td></tr><tr><td>Antenatal medical issue<sup>a</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Previous cesarean history</td><td>0.09 (0.04&#8211;0.20)</td><td>&lt;0.001</td><td>0.43 (0.41&#8211;0.46)</td><td>&lt;0.001</td></tr><tr><td>Prolonged pregnancy</td><td>0.54 (0.39&#8211;0.77)</td><td>&lt;0.001</td><td>0.84 (0.79&#8211;0.90)</td><td>&lt;0.001</td></tr><tr><td>Preeclampsia</td><td>0.69 (0.47&#8211;1.02)</td><td>0.063</td><td>0.98 (0.91&#8211;1.05)</td><td>0.501</td></tr><tr><td>PIH</td><td>0.52 (0.31&#8211;0.88)</td><td>0.014</td><td>0.93 (0.86&#8211;1.02)</td><td>0.11</td></tr><tr><td>Anemia</td><td>1.00 (0.73&#8211;1.38)</td><td>0.991</td><td>1.32 (1.24&#8211;1.40)</td><td>&lt;0.001</td></tr><tr><td>IUGR</td><td>1.37 (1.00&#8211;1.89)</td><td>0.042</td><td>1.30 (1.21&#8211;1.40)</td><td>&lt;0.001</td></tr><tr><td>Oligohydramnios</td><td>0.82 (0.54&#8211;1.25)</td><td>0.349</td><td>1.21 (1.12&#8211;1.32)</td><td>&lt;0.001</td></tr><tr><td>Antepartum hemorrhage, abruptio/previa placenta</td><td>0.77 (0.53&#8211;1.12)</td><td>0.175</td><td>0.76 (0.70&#8211;0.82)</td><td>&lt;0.001</td></tr><tr><td>Perinatal medical issue<sup>b</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Premature ROM</td><td>0.80 (0.60&#8211;1.07)</td><td>0.131</td><td>0.97 (0.92&#8211;1.03)</td><td>0.294</td></tr><tr><td>Failed labor induction</td><td>1.33 (0.97&#8211;1.83)</td><td>0.075</td><td>1.33 (1.24&#8211;1.43)</td><td>&lt;0.001</td></tr><tr><td>Dystocia</td><td>0.82 (0.67&#8211;1.01)</td><td>0.066</td><td>0.86 (0.83&#8211;0.90)</td><td>&lt;0.001</td></tr><tr><td>Malpresentation</td><td>0.94 (0.75&#8211;1.17)</td><td>0.57</td><td>0.92 (0.88&#8211;0.97)</td><td>&lt;0.001</td></tr><tr><td>Fetal distress</td><td>0.78 (0.58&#8211;1.05)</td><td>0.102</td><td>1.20 (1.14&#8211;1.26)</td><td>&lt;0.001</td></tr><tr><td>Preterm delivery</td><td>2.98 (2.48&#8211;3.58)</td><td>&lt;0.001</td><td>1.58 (1.51&#8211;1.66)</td><td>&lt;0.001</td></tr><tr><td>Postpartum hemorrhage</td><td>1.03 (0.74&#8211;1.43)</td><td>0.856</td><td>1.00 (0.94&#8211;1.08)</td><td>0.917</td></tr></table>
00c9e071776fc00e8560fe7939fd2a7aac66723923ce98d06a20a654b4766367.png
simple
<table><tr><td>Metric</td><td>Questions</td><td>Average</td><td>Standard</td></tr><tr><td></td><td></td><td>response</td><td>deviation</td></tr><tr><td>Overall usability</td><td>1&#8211;19</td><td>6.02</td><td>1.04</td></tr><tr><td>System usefulness</td><td>1&#8211;8</td><td>6.13</td><td>0.93</td></tr><tr><td>Information quality</td><td>9&#8211;15</td><td>5.66</td><td>1.20</td></tr><tr><td>Interface quality</td><td>16&#8211;18</td><td>6.24</td><td>0.99</td></tr></table>
490e3f2c4a0d07f280758d0de6603fdbc65657ddbdc9aab4aeeae6faf311af35.png
simple
<table><tr><td>Functional traits</td><td>Interpretation</td></tr><tr><td>Calvin&#8211;Benson cycle</td><td>CO<sub>2</sub> fixation</td></tr><tr><td>Utilization of various carbon sources</td><td>Adaptation to the diverse organic matter in sponge mesohyl</td></tr><tr><td>Anaerobic respiration</td><td>Energy supply in anoxic environment</td></tr><tr><td>Denitrification</td><td>Energy supply in anoxic environment</td></tr><tr><td>Sulfate reduction</td><td>Energy supply in anoxic environment</td></tr><tr><td>Peptidase</td><td>Compensation for the reduced amino acid synthesis capacity</td></tr><tr><td>Endospore formation</td><td>Resistance to environmental threats; widespread distribution</td></tr><tr><td>Metal resistance</td><td>Resistance to environmental threats</td></tr><tr><td>Antibiotic resistance</td><td>Competition in symbiotic communities; resistance to environmental threats</td></tr><tr><td>Eukaryotic-like proteins</td><td>Host&#8211;microbe recognition</td></tr><tr><td>Type II secretion system</td><td>Interaction with host environment</td></tr><tr><td>Widespread Colonization Island</td><td>Tight adhesion</td></tr><tr><td>Type VI secretion system</td><td>Host&#8211;microbe interaction, microbe&#8211;microbe competition</td></tr></table>
6f24685b70e1c8f1c1b57c0b4da3ad1b89399e6fcc587a166ae00d8e37dd0fca.png
simple
<table><tr><td></td><td>Controls</td><td>COPD</td><td>P value</td></tr><tr><td>Gender M:F</td><td>2:6</td><td>9:7</td><td></td></tr><tr><td>Age - median (range)</td><td>63.5 (56-78)</td><td>65.5 (49-78)</td><td>0.779</td></tr><tr><td>Smoking history (pack years)</td><td></td><td></td><td></td></tr><tr><td>Median (range)</td><td>50.0 (2-110)</td><td>51.5 (5-180)</td><td>0.625</td></tr><tr><td>FEV1 (% predicted)</td><td></td><td></td><td></td></tr><tr><td>Median (range)</td><td>88.0 (78-107)</td><td>43.5 (27-75)</td><td>&lt;0.001</td></tr><tr><td>FEV1/FVC - Median</td><td>101.5</td><td>59.7</td><td>&lt;0.001</td></tr><tr><td>DLCO (% predicted)</td><td></td><td></td><td></td></tr><tr><td>Median (range)</td><td>62.0 (34-122)</td><td>54.0 (27-99)</td><td>0.416</td></tr></table>
ad29e3a10e5d16aaf3f1cb3068bf932c29aa399d07764b98b1a8ef1ec0a07dd1.png
complex
<table><tr><td>Procedures</td><td>References</td><td>Detergents</td><td>Detergent concentrations (C)</td><td>Ultrasound treatment (S)<sup>1)</sup></td><td>Homogenization (H)<sup>2)</sup></td><td>Filtration (F)</td></tr><tr><td rowspan="2">1</td><td>S.B. Singh-Verma (1968), LR. Bakken (1985)</td><td>Sodium hexametaphosphate</td><td>C1) 0,2% (w/v)</td><td>S1) 40 W, 60 sec, 5 impulses/sec (different repetitions)</td><td>H1) none</td><td>F1 none</td></tr><tr><td> </td><td> </td><td>C2) 0,5% (w/v)</td><td>S2) 65 W, 60 sec, 5 impulses/sec (different repetitions)</td><td>H2) 60 sec, speed 5 (different repetitions)</td><td>F2) 12&#8211;15 &#956;m filter</td></tr><tr><td rowspan="2">2</td><td>S.B. Singh-Verma (1968), LR. Bakken (1985)</td><td>Bromhexine hydrochloride</td><td>C1) 0,2% (w/v)</td><td>S1) 40 W, 60 sec + 65 W, 60 sec, 5 impulses/sec</td><td>H1) none</td><td>n.a.</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>H2) 2&#215; 60 sec, speed 5</td><td> </td></tr><tr><td rowspan="3">3</td><td>W.B. Yoon and R.A. Rosson (1990)</td><td>Tween</td><td>C1) 5 &#956;g/ml</td><td>S1) 15 W, 30 sec, 5 impulses/sec</td><td>H1) none</td><td>n.a.</td></tr><tr><td> </td><td> </td><td>C2) 10 &#956;g/ml</td><td>S2) 35 W, 30 sec, 5 impulses/sec</td><td>H2) 5 min, speed 5</td><td> </td></tr><tr><td> </td><td> </td><td>C3) 25 &#956;g/ml</td><td> </td><td> </td><td> </td></tr><tr><td>4</td><td>E.L Schmidt (1974)</td><td>Tween 80 + 0.007 g ml<sup>-1</sup> flocculation reagent (Ca (OH)<sub>2</sub>: MgCO<sub>3</sub> (2:5))</td><td>C1) 25 &#956;l/ml</td><td>n.a.</td><td>n.a.</td><td>n.a.</td></tr><tr><td rowspan="2">5</td><td>O. Resina-Pelfort et al. (2003)</td><td>Triton X-100</td><td>C1) 10 &#956;g/ml</td><td>S1) 35 W, 30 sec, 5 impulses/sec</td><td>H1) none</td><td>n.a.</td></tr><tr><td> </td><td> </td><td>C2) 20 &#956;g/ml</td><td>S2) 45 W, 30 sec, 5 impulses/sec</td><td>H2) 5 min, speed 5</td><td> </td></tr><tr><td>6</td><td>L R. Bakken (1985)</td><td>Sodium pyrophosphate</td><td>C1) 0,2% (w/v)</td><td>S1 3&#215; 40 W, 60 sec, 5 impulses/sec</td><td>H1) 3&#215; 60 sec, speed 5</td><td>n.a.</td></tr></table>
f1d5459eb6d1993d4c5a6632087d47fd067feb6b6bae975b128780aa6ff8e251.png
simple
<table><tr><td>Programme, <i>Country</i></td><td>Water Frequency <sup>1</sup></td><td>Fruit Juices Frequency <sup>2</sup></td><td>Soft Drinks Frequency <sup>2</sup></td></tr><tr><td>VIASANO, <i>Belgium</i></td><td>4 (4&#8211;5)</td><td>6 (4&#8211;6)</td><td>4 (2&#8211;5)</td></tr><tr><td>Healthy kids in Bulgaria, <i>Bulgaria</i></td><td>6 (5&#8211;6)</td><td>4 (3&#8211;5)</td><td>2 (1&#8211;4)</td></tr><tr><td>EPODE Flandre Lys, <i>France</i></td><td>4 (4&#8211;5)</td><td>6 (4&#8211;6)</td><td>3 (2&#8211;5)</td></tr><tr><td>Paideiatrofi, <i>Greece</i></td><td>5 (5&#8211;6)</td><td>4 (4&#8211;5)</td><td>1 (1&#8211;2)</td></tr><tr><td>MAIA, <i>Portugal</i></td><td>5 (4&#8211;6)</td><td>4 (2&#8211;4)</td><td>2 (1&#8211;3)</td></tr><tr><td>SETS, <i>Romania</i></td><td>5 (5&#8211;6)</td><td>4 (3&#8211;5)</td><td>2 (2&#8211;4)</td></tr><tr><td>JOGG Zwolle, <i>The Netherlands</i></td><td>4 (3&#8211;4)</td><td>3 (2&#8211;5)</td><td>3 (2&#8211;6)</td></tr><tr><td>Total</td><td>5 (4&#8211;6)</td><td>4 (3&#8211;6)</td><td>2 (1&#8211;4)</td></tr></table>
65d85800cc76c27a83351796435840266390d80d36d197f1afeb00b6d7529aa4.png
simple
<table><tr><td>Authors </td><td>Results </td></tr><tr><td>Gavini <i>et al.</i> [25]</td><td>Ion-implanted instruments reached significantly higher cycle numbers before fracture compared to annealed and non-implanted files.</td></tr><tr><td>Wolle<i> et al. </i>[26]</td><td>Argon II improved the performance of S1 files moderately, whereas nitrogen ion-implanted files performed worse in the fatigue test.</td></tr></table>
d949b39e331a4b588e4710372e08a0218c128f2d906a2c6b4ca3d2fd71428a59.png
simple
<table><tr><td>Cause of corneal opacification</td><td>Eyes</td></tr><tr><td>Posttrauma</td><td>25</td></tr><tr><td>Postcorneal ulcer</td><td>20</td></tr><tr><td>Glaucoma</td><td>4</td></tr><tr><td>Unknown</td><td>4</td></tr></table>
581bdadd47c441eff0c729e501435122e222f359774d87f3df552e6b900d50c2.png
simple
<table><tr><td>Age group (years)</td><td>Total</td><td>RVID (cm)</td><td>PADP (mm Hg)</td><td>TRVel (m/s)</td><td>PASP (mm Hg)</td><td>TVI<sub>RVOT</sub> (cm)</td><td>PVCSA (cm<sup>2</sup>)</td><td>PBF (L/min)</td><td>PVR<sub>ECHO</sub> (Woods Unit)</td></tr><tr><td>Study group</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>A (18 - 25)</td><td>30</td><td>2.93</td><td>10.4</td><td>2.23</td><td>19.3</td><td>25.7</td><td>3.48</td><td>7.54</td><td>1.103</td></tr><tr><td>B (26 - 32)</td><td>15</td><td>2.92</td><td>10.4</td><td>2.26</td><td>20.2</td><td>25.4</td><td>3.57</td><td>7.58</td><td>1.04</td></tr><tr><td>C (33 - 40)</td><td>11</td><td>3.13</td><td>10.9</td><td>2.27</td><td>20.1</td><td>25.36</td><td>3.52</td><td>7.53</td><td>1.07</td></tr><tr><td>Total</td><td>56</td><td>2.94</td><td>10.5</td><td>2.24</td><td>19.8</td><td>25.45</td><td>3.52</td><td>7.5</td><td>1.04</td></tr><tr><td>Control group</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>A (18 - 25)</td><td>8</td><td>2.59</td><td>10</td><td>2.30</td><td>20.5</td><td>20.5</td><td>3.5</td><td>5.3</td><td>1.27</td></tr><tr><td>B (26 - 32)</td><td>4</td><td>2.71</td><td>10.2</td><td>2.33</td><td>22.4</td><td>20.7</td><td>3.51</td><td>5.1</td><td>1.28</td></tr><tr><td>C (33 - 40)</td><td>3</td><td>2.78</td><td>9.8</td><td>2.32</td><td>22</td><td>20.6</td><td>3.5</td><td>5.4</td><td>1.32</td></tr><tr><td>Total</td><td>15</td><td>2.67</td><td>10.1</td><td>2.3</td><td>21.2</td><td>20.5</td><td>3.5</td><td>5.3</td><td>1.28</td></tr></table>
94a3df4e7d6975c681b5803ad857439c4b580ba4a5645d2b8dd45bae5b5b1f49.png
complex
<table><tr><td colspan="3">Domains</td><td>mean (SD)</td><td>Difference</td><td><i>P</i></td></tr><tr><td rowspan="2">1.</td><td rowspan="2">Activities</td><td>before</td><td>3.52 (1.41)</td><td rowspan="2">2.84</td><td rowspan="2">&lt; 0,001</td></tr><tr><td>after</td><td>0.68 (0.93)</td></tr><tr><td rowspan="2">2.</td><td rowspan="2">Sleep</td><td>before</td><td>2.48 (1.8)</td><td rowspan="2">2.17</td><td rowspan="2">&lt; 0,001</td></tr><tr><td>after</td><td>0.31 (0.58)</td></tr><tr><td rowspan="2">3.</td><td rowspan="2">General problems</td><td>before</td><td>1.79 (1.55)</td><td rowspan="2">1.3</td><td rowspan="2">&lt; 0.001</td></tr><tr><td>after</td><td>0.49 (0.77)</td></tr><tr><td rowspan="2">4.</td><td rowspan="2">Practical problems</td><td>before</td><td>3.57 (1.68)</td><td rowspan="2">2.89</td><td rowspan="2">&lt; 0.001</td></tr><tr><td>after</td><td>0.68 (1.01)</td></tr><tr><td rowspan="2">5.</td><td rowspan="2">Nasal symptoms</td><td>before</td><td>3.91 (1.66)</td><td rowspan="2">3.17</td><td rowspan="2">&lt; 0.001</td></tr><tr><td>after</td><td>0.74 (0.99)</td></tr><tr><td rowspan="2">6.</td><td rowspan="2">Eye symptoms</td><td>before</td><td>2.92 (2.01)</td><td rowspan="2">2.53</td><td rowspan="2">&lt; 0.001</td></tr><tr><td>after</td><td>0.39 (0.74)</td></tr><tr><td rowspan="2">7.</td><td rowspan="2">Emotions</td><td>before</td><td>3.03 (1.43)</td><td rowspan="2">2.65</td><td rowspan="2">&lt; 0.001</td></tr><tr><td>after</td><td>0.38 (0.69)</td></tr><tr><td rowspan="2" colspan="2">Overall QoL</td><td>before</td><td>2.95 (1.32)</td><td rowspan="2">2.19</td><td rowspan="2">&lt;0.001</td></tr><tr><td>after</td><td>0.76 (0.55)</td></tr></table>
d7ff08570b0b7f5e4c7ecbe5e09035fc53aa5abaa5026101ce4b5db730be83d2.png
simple
<table><tr><td>GenBank accession no.</td><td>Original name</td><td>Country</td></tr><tr><td>HQ591366</td><td>PCV2 , isolate 90-08-21</td><td>Croatia, 2008</td></tr><tr><td>HQ591367</td><td>PCV2, isolate 110-08-2</td><td>Croatia, 2008</td></tr><tr><td>AY256460</td><td>PCV2, strain 375</td><td>Hungary, 2003</td></tr><tr><td>AY424405</td><td>PCV2, isolate AUT5</td><td>Austria, 2003</td></tr><tr><td>HQ591368</td><td>PCV2, isolate 126-07-5</td><td>Croatia, 2007</td></tr><tr><td>HQ591369</td><td>PCV2, isolate 147-07-7</td><td>Croatia, 2007</td></tr><tr><td>HQ591370</td><td>PCV2, isolate 161-08-2</td><td>Croatia, 2008</td></tr><tr><td>HQ591365</td><td>PCV2, isolate 70-08-2</td><td>Croatia, 2008</td></tr><tr><td>AY180397</td><td>PCV2, strain Pingtung-5</td><td>Taiwan, 2002</td></tr><tr><td>AY484410</td><td>PCV2, isolate NL-control-4</td><td>Netherlands, 2003</td></tr><tr><td>AF311296</td><td>BFDV</td><td>Australia, 2000</td></tr><tr><td>AF071879</td><td>PCV1</td><td>SAD, 1998</td></tr><tr><td>GU930366</td><td>PRRSV, isolate Hun06</td><td>Hungary, 2009</td></tr><tr><td>AY035960</td><td>PRRSV, isolate 361-4</td><td>Denmark, 1994</td></tr><tr><td>JQ043210</td><td>PRRSV, 174-07-1</td><td>Croatia, 2007</td></tr><tr><td>DQ324711</td><td>PRRSV, isolate Prz-87</td><td>Poland, 2005</td></tr><tr><td>JQ043212</td><td>PRRSV, isolate 660-07-2</td><td>Croatia, 2007</td></tr><tr><td>JQ043213</td><td>PRRSV, isolate 1152-08-10</td><td>Croatia, 2008</td></tr><tr><td>AY035976</td><td>PRRSV, strain 2567/96</td><td>Italy, 1996</td></tr><tr><td>AY035961</td><td>PRRSV, isolate 48/92-1</td><td>Denmark, 2001</td></tr><tr><td>AY035975</td><td>PRRSV, isolate 2481/97</td><td>Denmark, 2001</td></tr><tr><td>M96262</td><td>Lelystad virus</td><td>Netherlands, 1991</td></tr><tr><td>JQ043211</td><td>PRRSV, 177-07-2-1</td><td>Croatia, 2007</td></tr><tr><td>GU930368</td><td>PRRSV, isolate Hun08</td><td>Hungary, 2009</td></tr><tr><td>DQ324708</td><td>PRRSV, strain Okt-46</td><td>Belarus, 2004</td></tr><tr><td>DQ324719</td><td>PRRSV, strain Soz-6</td><td>Belarus, 2004</td></tr><tr><td>DQ324727</td><td>PRRSV, strain Yuz-34</td><td>Belarus, 2004</td></tr><tr><td>EU071271</td><td>PRRSV, strain KR</td><td>Russia, 2007</td></tr><tr><td>AF438362</td><td>PRRSV, strain Aus</td><td>Lithuania, 2000</td></tr><tr><td>DQ324701</td><td>PRRSV, strain Bor-41</td><td>Belarus, 2004</td></tr><tr><td>DQ324702</td><td>PRRSV, strain Bor-54</td><td>Belarus, 2004</td></tr><tr><td>L39363</td><td>PRRSV, isolate IL1</td><td>United States, 1996</td></tr><tr><td>L39362</td><td>PRRSV, isolate IA6</td><td>United States, 1996</td></tr><tr><td>U18750</td><td>PRRSV, isolate ISU-3927</td><td>United States, 1996</td></tr></table>
983e0c1b99412b3bc6398a8b33e6129eb21ab4d5e22b8fdf921d962bda4e32d8.png
complex
<table><tr><td></td><td colspan="2">Total</td><td colspan="2">Men</td><td colspan="2">Women</td></tr><tr><td>Descriptor</td><td>Cases/total study group, n</td><td>ID (95% CI)<sup>c</sup></td><td>Cases/total study group, n</td><td>ID (95% CI)<sup>c</sup></td><td>Cases/total study group, n</td><td>ID (95% CI)<sup>c</sup></td></tr><tr><td>DM without OAAs</td><td>42/5619</td><td>74.7 (52.2 to 97.3)</td><td>11/2599</td><td>42.3 (17.4 to 67.3)</td><td>31/3019</td><td>102 (66.7 to 138)</td></tr><tr><td>Met only</td><td>43/5627</td><td>76.4 (53.7 to 99.2)</td><td>18/2637</td><td>68.2 (36.8 to 99.7)</td><td>25/2989</td><td>83.6 (51.0 to 116)</td></tr><tr><td>DM without OAAs</td><td>140/14503</td><td>96.5 (80.6 to 112)</td><td>52/7101</td><td>73.2 (53.4 to 93.1)</td><td>88/7402</td><td>118 (94.2 to 143)</td></tr><tr><td>SUs only</td><td>145/13370</td><td>108 (90.9 to 126)</td><td>59/6581</td><td>89.6 (66.9 to 112)</td><td>86/6788</td><td>126 (100 to 153)</td></tr><tr><td>DM without OAAs</td><td>282/30957</td><td>91.1 (80.5 to 101)<sup>d</sup></td><td>100/14064</td><td>71.1 (57.2 to 85.0)<sup>e</sup></td><td>182/16893</td><td>107 (92.2 to 123)<sup>f</sup></td></tr><tr><td>SUs + Met</td><td>127/32236</td><td>39.4 (32.6 to 46.2)<sup>d</sup></td><td>45/14791</td><td>30.4 (21.5 to 39.3)<sup>e</sup></td><td>82/17444</td><td>47.0 (36.9 to 57.2)<sup>f</sup></td></tr></table>
083d380d19c7bfe563a76565a839e85de3c87cb02a2b8e0793427752396b2b60.png
simple
<table><tr><td>Variable</td><td>No. patients (n = 41)*</td><td>Median expression Survivin DeltaEx3</td><td><i>AD</i></td><td><i>p</i></td></tr><tr><td>FIGO stage</td><td></td><td></td><td></td><td></td></tr><tr><td>IB</td><td>0 (8)</td><td>0</td><td>0</td><td>0.59</td></tr><tr><td>IIB</td><td>2 (16)</td><td>0.09</td><td>24.51</td><td></td></tr><tr><td>IIIB</td><td>2 (17)</td><td>0.11</td><td>35.68</td><td></td></tr><tr><td>Histology of tumors</td><td></td><td></td><td></td><td></td></tr><tr><td>Squamous cell</td><td>2 (34)</td><td>0.01</td><td>16.99</td><td>0.04</td></tr><tr><td>Adenocarcinoma</td><td>2 (5)</td><td>0.22</td><td>60.12</td><td></td></tr><tr><td>Adenosquamous</td><td>0 (2)</td><td>0</td><td>0</td><td></td></tr><tr><td>Menopause</td><td></td><td></td><td></td><td></td></tr><tr><td>Pre-Menopause</td><td>2 (10)</td><td>0.14</td><td>48.94</td><td>0.33</td></tr><tr><td>Menopause</td><td>1 (8)</td><td>0.02</td><td>10.65</td><td></td></tr><tr><td>Post-Menopause</td><td>1 (23)</td><td>0.01</td><td>14.99</td><td></td></tr></table>
ea147ad4858550794d934d4c132516dba8ad78822faa59752cf85f542fef5b1f.png
simple
<table><tr><td></td><td>Independent association with increasing RANKL expression (<i>P</i>value)</td><td>Independent association with increasing RANK expression (<i>P</i>value)</td></tr><tr><td>Diagnosis during pregnancy (yes vs. no)</td><td>&lt;0.001</td><td>0.67</td></tr><tr><td>Tumor size (&#8804;2 cm vs. &gt;2 cm)</td><td>0.23</td><td>0.87</td></tr><tr><td>Nodal involvement (negative vs. positive)</td><td>0.15</td><td>0.19</td></tr><tr><td>Histological grade (I vs. II vs. III)</td><td>0.09</td><td>0.7</td></tr><tr><td>Breast cancer subtypes (luminal A vs. luminal B vs. HER2 vs. triple negative)</td><td>0.75</td><td>&lt;0.001</td></tr><tr><td>Increasing progesterone receptor expression by IHC (continuous variable)</td><td>&lt;0.001</td><td>0.17</td></tr><tr><td>Neoadjuvant chemotherapy (yes vs. no)</td><td>0.69</td><td>&lt;0.001</td></tr></table>
9af405af9bd6ef5cc630b8a896ecc0ce792ba1d85c482d3526a66ac5496fe690.png
simple
<table><tr><td>Variable</td><td>PHDs cohort<i>N</i> = 1,346 (%)</td><td>Comparison cohort<i>N</i> = 5,384 (%)</td><td><i>p</i>-value</td></tr><tr><td>Age, years (SD)<sup>a</sup></td><td>47.38 (14.56)</td><td>46.74 (15.77)</td><td>0.183</td></tr><tr><td> &lt;45</td><td>820 (60.92)</td><td>3,280 (60.92)</td><td></td></tr><tr><td> 45&#8211;64</td><td>404 (30.01)</td><td>1,616 (30.01)</td><td></td></tr><tr><td> &#8805;65</td><td>122 (9.07)</td><td>488 (9.07)</td><td></td></tr><tr><td>Sex</td><td></td><td></td><td>0.999</td></tr><tr><td> Female</td><td>959 (71.25)</td><td>3,836 (71.25)</td><td></td></tr><tr><td> Male</td><td>387 (28.75)</td><td>1,548 (28.75)</td><td></td></tr><tr><td>Co-morbidities</td><td></td><td></td><td></td></tr><tr><td> Hypertension</td><td>72 (5.35)</td><td>305 (5.66)</td><td>0.342</td></tr><tr><td> DM</td><td>25 (1.86)</td><td>101 (1.88)</td><td>0.732</td></tr><tr><td> IHD</td><td>14 (1.04)</td><td>53 (0.98)</td><td>0.476</td></tr><tr><td>Hyperlipidaemia</td><td>22 (1.63)</td><td>99 (1.84)</td><td>0.142</td></tr><tr><td> AF</td><td>1 (0.07)</td><td>7 (0.13)</td><td>0.503</td></tr><tr><td>Event (strokes) in the endpoint</td><td>100 (7.43)</td><td>287 (5.33)</td><td>0.002</td></tr><tr><td> Years of follow-up (SD)<sup>a</sup></td><td>4.57 (1.22)</td><td>4.60 (1.20)</td><td>0.465</td></tr></table>
0c8be69c011b255a281806d5232d90ab2e0b874555424d12491d9a7d0621e42f.png
complex
<table><tr><td>Variable</td><td>Admission Serum Chloride (Cl<sub>0</sub>)&#8805;110 mEq/L(<i>n</i> = 303)</td><td>Admission Serum Chloride (Cl<sub>0</sub>)101&#8211;109 mEq/L(<i>n</i> = 561)</td><td>Admission Serum Chloride (Cl<sub>0</sub>)&#8804;100 mEq/L(<i>n</i> = 181)</td><td><i>P</i>-value</td></tr><tr><td colspan="5"><i>Demographics</i></td></tr><tr><td> Age, years, mean &#177; SD</td><td>67.9 &#177; 15.6</td><td>64.8 &#177; 16.7</td><td>67.0 &#177; 14.6</td><td>0.0146*</td></tr><tr><td> Male, %</td><td>44.9%</td><td>53.7%</td><td>55.8%</td><td>0.0214*</td></tr><tr><td> African-American, %</td><td>42.6%</td><td>33.2%</td><td>24.9%</td><td>0.0002*</td></tr><tr><td colspan="5"><i>Chronic conditions</i></td></tr><tr><td> Baseline SCr, mg/dl, median (IQR)</td><td>1.2 (0.9&#8211;1.7)</td><td>1.2 (0.9&#8211;1.6)</td><td>1.2 (0.9&#8211;1.6)</td><td>0.0794</td></tr><tr><td> Baseline eGFR, mL/min/1.73m<sup>2</sup>, median (IQR)</td><td>57.0 (40.4&#8211;76.8)</td><td>63.1 (44.2&#8211;87.9)</td><td>61.2 (42.1&#8211;88.0)</td><td>0.1032</td></tr><tr><td> Diabetes, %</td><td>23.8%</td><td>20.1%</td><td>21.6%</td><td>0.4648</td></tr><tr><td> Hypertension, %</td><td>46.5%</td><td>46.5%</td><td>43.7%</td><td>0.8050</td></tr><tr><td> Heart failure, %</td><td>3.3%</td><td>2.1%</td><td>4.4%</td><td>0.2423</td></tr><tr><td> Anemia, %</td><td>88.6%</td><td>85.1%</td><td>74.4%</td><td>0.0001*</td></tr><tr><td colspan="5"><i>Drug Exposure</i></td></tr><tr><td> Diuretic, %</td><td>44.2%</td><td>44.0%</td><td>55.8%</td><td>0.0161*</td></tr><tr><td> Statin, %</td><td>28.7%</td><td>30.8%</td><td>30.4%</td><td>0.8073</td></tr><tr><td> Iodine contrast, %</td><td>27.7%</td><td>33.9%</td><td>29.3%</td><td>0.1446</td></tr><tr><td> Aminoglycoside, %</td><td>8.3%</td><td>6.1%</td><td>1.7%</td><td>0.0119*</td></tr><tr><td colspan="5"><i>Critical indicators</i></td></tr><tr><td> Oliguria, %</td><td>9.0%</td><td>6.2%</td><td>5.3%</td><td>0.2467</td></tr><tr><td> CFB 72 h, liters, median (IQR)</td><td>3.1 (&#8722;0.1&#8211;8.0)</td><td>2.0 (&#8722;0.5&#8211;5.4)</td><td>0.75 (&#8722;2.1&#8211;3.8)</td><td>0.0005*</td></tr><tr><td> Pressor or inotrope, %</td><td>37.3%</td><td>30.1%</td><td>27.6%</td><td>0.0408*</td></tr><tr><td> Mechanical ventilation, %</td><td>51.2%</td><td>39.4%</td><td>33.2%</td><td>&lt;0.0001*</td></tr><tr><td> Red blood cell transfusion, %</td><td>6.6%</td><td>2.0%</td><td>0.6%</td><td>&lt;0.0001*</td></tr><tr><td> Base Deficit, mmol/L Median (IQR)</td><td>3.6 (1.7&#8211;6.4)</td><td>1.1 (&#8722;1.7&#8211;4.0)</td><td>&#8722;2.6 (&#8722;7.4&#8211;2.4)</td><td>&lt;0.0001</td></tr><tr><td> APACHE II score, mean &#177; SD</td><td>14.9 &#177; 7.0</td><td>12.1 &#177; 5.9</td><td>11.80 &#177; 5.06*</td><td>&lt;0.0001</td></tr><tr><td> SOFA score, mean &#177; SD</td><td>5.8 &#177; 3.8</td><td>4.5 &#177; 3.4</td><td>4.4 &#177; 3.4*</td><td>&lt;0.0001</td></tr></table>
881ea85790481093149031398a67d343213511701caecd6265dfcb2398709bde.png
complex
<table><tr><td colspan="2">Overall ranking scale (on a scale from 1&#8211;10)</td></tr><tr><td>Question: In the last two days of care, how well did the doctors, nurses and other professional staff...</td><td>Average</td></tr><tr><td>Provide medical care that respected his/her wishes?</td><td>8.2</td></tr><tr><td>Make sure that [patient] died with dignity &#8211; that is died on her/his own terms?</td><td>8.2</td></tr><tr><td>Make sure [patient&#8217;s] symptoms were controlled to a degree acceptable to her/him?</td><td>8</td></tr><tr><td>Communicate with patient and family about the illness and likely outcomes of care?</td><td>7.3</td></tr><tr><td>Provide emotional support for you and [patient&#8217;s] family and friends?</td><td>6.8</td></tr><tr><td>What number would you give the overall care that [patient] received in the last two days of life?</td><td>7.7</td></tr><tr><td>Scale score</td><td>7.7</td></tr><tr><td colspan="2">Comparison of Domain Scores (range: 0 to 1)</td></tr><tr><td>Advance care planning</td><td>0.10</td></tr><tr><td>Coordination</td><td>0.16</td></tr><tr><td>Focus on individual</td><td>0.27<sup>1</sup></td></tr><tr><td>Informing &amp; decision making</td><td>0.30<sup>1</sup></td></tr><tr><td>Attend to family</td><td>0.51<sup>1</sup></td></tr></table>
6d2b4d26985de3871b8748c857572ab0247234127aac9d6d050269bc133bf460.png
complex
<table><tr><td rowspan="2"></td><td colspan="4">General CVRM networks</td><td colspan="4">Specific CVRM networks</td></tr><tr><td>Mean</td><td>SD</td><td>Min</td><td>Max</td><td>Mean</td><td>SD</td><td>Min</td><td>Max</td></tr><tr><td>Density</td><td>0.38</td><td>0.17</td><td>0.08</td><td>0.83</td><td>0.37</td><td>0.22</td><td>0</td><td>0.83</td></tr><tr><td>Number of high frequency contacts</td><td>8.87</td><td>5.64</td><td>0</td><td>20</td><td>10.65</td><td>8.24</td><td>0</td><td>33</td></tr><tr><td>Centrality of CVRM coordinator</td><td>6.61</td><td>3.38</td><td>2.00</td><td>16</td><td>7.07</td><td>4.97</td><td>0</td><td>24</td></tr><tr><td>Homophily on SBP targets</td><td>0.60</td><td>0.43</td><td>&#8722;0.42</td><td>1.00</td><td>0.55</td><td>0.46</td><td>&#8722;0.46</td><td>1.00</td></tr><tr><td>Homophily on LDL targets</td><td>0.53</td><td>0.49</td><td>&#8722;0.87</td><td>1.00</td><td>0.52</td><td>0.52</td><td>&#8722;0.87</td><td>1.00</td></tr></table>
2bb1bba18fdd87f06a2e632bf9779e8f8e847750002cdd0cbe509fcc96a4eeaa.png
complex
<table><tr><td> </td><td>Healthy population</td><td colspan="2">Clinic population<sup>a</sup></td><td colspan="3">Pairwise comparisons</td></tr><tr><td> </td><td>BV = 0</td><td>BV = 0</td><td>BV = 1</td><td rowspan="2">HP vs. CPBVneg</td><td rowspan="2">HP vs. CPBVpos</td><td rowspan="2">CPBVneg vs. CPBVpos</td></tr><tr><td> </td><td>N = 30</td><td>N = 29</td><td>N = 12</td></tr><tr><td> </td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>p-value</td><td>p-value</td><td>p-value</td></tr><tr><td><i>L. crispatus</i></td><td>23 (77)</td><td>23 (79)</td><td>5 (42)</td><td>1.000</td><td>0.067</td><td>0.029</td></tr><tr><td><i>L. iners</i></td><td>20 (67)</td><td>25 (86)</td><td>10 (83)</td><td>0.125</td><td>0.453</td><td>1.000</td></tr><tr><td><i>L. jensenii</i></td><td>17 (57)</td><td>15 (52)</td><td>3 (25)</td><td>0.796</td><td>0.091</td><td>0.171</td></tr><tr><td><i>L. gasseri</i></td><td>19 (63)</td><td>7 (24)</td><td>1 (8)</td><td>0.004</td><td>0.002</td><td>0.214</td></tr><tr><td><i>L. vaginalis</i></td><td>22 (73)</td><td>18 (62)</td><td>1 (8)</td><td>0.421</td><td>&lt;0.001</td><td>0.002</td></tr><tr><td><i>G. vaginalis</i></td><td>10 (33)</td><td>20 (69)</td><td>12 (100)</td><td>0.009</td><td>&lt;0.001</td><td>0.039</td></tr><tr><td><i>A. vaginae</i></td><td>4 (13)</td><td>8 (28)</td><td>11 (92)</td><td>0.209</td><td>&lt;0.001</td><td>&lt;0.001</td></tr></table>
e753d735860ea274a057805af2fe8ba4eea16d5b5b4f4dae0c2ad114b3cef630.png
complex
<table><tr><td></td><td>P-3075</td><td>Placebo</td></tr><tr><td colspan="3">Gender, N (%)</td></tr><tr><td> Males</td><td>8 (28.6)</td><td>3 (21.4)</td></tr><tr><td> Females</td><td>20 (71.4)</td><td>11 (78.6)</td></tr><tr><td colspan="3">Age, years</td></tr><tr><td> Mean &#177; SD</td><td>40.3 &#177; 11.3</td><td>39.3 &#177; 11.3</td></tr><tr><td> Median</td><td>40</td><td>34</td></tr><tr><td> Range</td><td>20&#8211;60</td><td>26&#8211;60</td></tr></table>
46875d1765592cff7d684b1b7916ea9f805e231eca3ecb869b7da67f6a3a59f3.png
simple
<table><tr><td>Partner Medicines</td><td>Below 85 %</td><td>Within 85&#8211;115 %</td><td>Above 115 %</td><td>Total <i>N</i> = 254</td></tr><tr><td>Amodiaquine<sup>a</sup>n (%)</td><td>28 (25.2)</td><td>64 (57.7)</td><td>19 (17.1)</td><td>111 (100.0)</td></tr><tr><td>Median (IQR)</td><td>80.6 (72.6&#8211;82.9)</td><td>92.7 (88.3&#8211;97.2)</td><td>118.8 (117.2&#8211;121.4)</td><td>92.0 (84.9&#8211;101.7)</td></tr><tr><td>Lumefantrine<sup>b</sup>n (%)</td><td>4 (3.0)</td><td>120 (89.6)</td><td>10 (7.5)</td><td>134 (100.0)</td></tr><tr><td>Median (IQR)</td><td>83.3 (77.4&#8211;84.4)</td><td>99.4 (93.2&#8211;105.0)</td><td>117.6 (116.2&#8211;118.5)</td><td>100.3 (93.1&#8211;107.1)</td></tr><tr><td>Piperaquine<sup>c</sup>n (%)</td><td>0 (0.0)</td><td>3 (33.3)</td><td>6 (66.7)</td><td>9 (100.0)</td></tr><tr><td>Median (IQR)</td><td>0</td><td>112.1 (111.5&#8211;114.7)</td><td>121.1 (117.5&#8211;123.8)</td><td>117.5 (114.7&#8211;121.7)</td></tr><tr><td>Combinedn (%)</td><td>32 (12.6)</td><td>187 (73.6)</td><td>35 (13.8)</td><td>254 (100.0)</td></tr><tr><td>Median (IQR)</td><td>81.4 (72.8&#8211;83.0)</td><td>96.6 (91.6&#8211;103.4)</td><td>118.7 (117.2&#8211;120.7)</td><td>96.8 (88.9&#8211;108.4)</td></tr></table>
497646d9f3735a40de11732afe5b29e4d243af4dabd674860564f224e7566296.png
simple
<table><tr><td>Code</td><td>Alkali Treatment</td><td>Silane Coupling Agent</td><td>Volume Fraction of Fiber <i>V<sub>f</sub></i> (vol %)</td></tr><tr><td>PA1010</td><td>-</td><td>-</td><td>-</td></tr><tr><td>HF</td><td>-</td><td>-</td><td>20</td></tr><tr><td>HF-S1</td><td>NaOH</td><td>S1 (Aminosilane)</td><td>20</td></tr><tr><td>HF-S2</td><td>NaOH</td><td>S2 (Epoxysilane)</td><td>20</td></tr><tr><td>HF-S3</td><td>NaOH</td><td>S3 (Ureidosilane)</td><td>10, 20, 30</td></tr></table>
94080a8bd73a6e8532d5158df07a04c40694b4f9663994c72e5ea54917858845.png
simple
<table><tr><td>Purification step</td><td>Total fused peptide (mg)</td><td>Total p53pAnt (mg)</td><td>Purity (%)</td><td>Yield (%)</td></tr><tr><td>Total protein extract</td><td>n.d</td><td>n.d</td><td>43*</td><td>100</td></tr><tr><td>Inclusion bodies</td><td>n.d</td><td>n.d</td><td>79*</td><td>-</td></tr><tr><td>First affinity chromatography</td><td>184**</td><td>43</td><td>90*</td><td>-</td></tr><tr><td>Precipitation recovery</td><td>184</td><td>43</td><td>-</td><td>100*</td></tr><tr><td>Thrombin cleavage</td><td>-</td><td>-</td><td>-</td><td>95*</td></tr><tr><td>Second affinity chromatography</td><td>-</td><td>34**</td><td>95</td><td>85*</td></tr></table>
08f4647dc26ab4b2221745fdf58dd6d7a56102d91ae6417cd7250d175002a014.png
simple
<table><tr><td>Variables</td><td>Chlorhexidine</td><td>Placebo</td><td>Dry cord</td></tr><tr><td>Hospital data</td><td>(<i>n</i> = 86)</td><td>(<i>n</i> = 86)</td><td>(<i>n</i> = 75)</td></tr><tr><td> Age of mother (years, mean &#177; SD)</td><td>23.87 &#177; 2.54</td><td>23.77 &#177; 2.86</td><td>25.12 &#177; 3.24</td></tr><tr><td> Vaginal delivery</td><td>100.0</td><td>100.0</td><td>100.0</td></tr><tr><td> Male births</td><td>48.8</td><td>64.0</td><td>58.7</td></tr><tr><td> Birth weight (grams, mean &#177; SD)</td><td>2728.3 &#177; 479.5</td><td>2684.3 &#177; 453.6</td><td>2794.8 &#177; 437.6</td></tr><tr><td> No. of pelvic examinations (mean &#177; SD)</td><td>2.37 &#177; 1.25</td><td>2.07 &#177; 1.00</td><td>2.00 &#177; 0.97</td></tr><tr><td>Problems during delivery</td><td></td><td></td><td></td></tr><tr><td> Meconium staining</td><td>2.3</td><td>2.3</td><td>5.3</td></tr><tr><td> Prolonged labor</td><td>2.3</td><td>1.2</td><td>1.3</td></tr><tr><td>Maternal risk factors for infection</td><td></td><td></td><td></td></tr><tr><td> LPV<sup>b</sup> &gt; 24 h</td><td>4.7</td><td>2.3</td><td>2.7</td></tr><tr><td>Chorioamnionitis</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td> Fever in mother</td><td>1.2</td><td>0</td><td>1.3</td></tr><tr><td> Maternal UTI</td><td>0.0</td><td>0.0</td><td>1.3</td></tr><tr><td>Time since birth (hrs:min, mean &#177; SD)</td><td>4:39 &#177; 2.31</td><td>4:35 &#177; 2:49</td><td>4:12 &#177; 2:37</td></tr><tr><td>Community data</td><td>(<i>n</i> = 36)</td><td>(<i>n</i> = 24)</td><td>(<i>n</i> = 19)</td></tr><tr><td>Age of mother (years, mean &#177; SD)</td><td>24.42 &#177; 3.95</td><td>24.62 &#177; 4.13</td><td>25.79 &#177; 3.91</td></tr><tr><td>Male births</td><td>38.9</td><td>50.0</td><td>52.6</td></tr><tr><td>Did the person clean hands before conducting delivery</td><td>97.2</td><td>100.0</td><td>100.0</td></tr><tr><td>New razor blade for cutting the cord</td><td>100.0</td><td>95.8</td><td>100.0</td></tr><tr><td>Baby given bath immediately after delivery</td><td>94.4</td><td>100.0</td><td>100.0</td></tr></table>
0b11cda23f8cc57576aada00e9a017a77ae3101914b52d7f43d8f4ef87d51e4b.png
simple
<table><tr><td># of Subband</td><td>Freq. (Hz)</td><td># of Subband</td><td>Freq. (Hz)</td><td># of Subband</td><td>Freq. (Hz)</td><td># of Subband</td><td>Freq. (Hz)</td></tr><tr><td>1</td><td>86.7</td><td>13</td><td>886.7</td><td>25</td><td>2484.6</td><td>37</td><td>7231.5</td></tr><tr><td>2</td><td>153.3</td><td>14</td><td>953.3</td><td>26</td><td>2715.9</td><td>38</td><td>7904.8</td></tr><tr><td>3</td><td>220</td><td>15</td><td>1020</td><td>27</td><td>2968.8</td><td>39</td><td>8640.9</td></tr><tr><td>4</td><td>286.7</td><td>16</td><td>1115</td><td>28</td><td>3242.2</td><td>40</td><td>9445.4</td></tr><tr><td>5</td><td>353.3</td><td>17</td><td>1218.8</td><td>29</td><td>3547.4</td><td>41</td><td>10,324.9</td></tr><tr><td>6</td><td>420</td><td>18</td><td>1332.3</td><td>30</td><td>3877.7</td><td>42</td><td>11,286.3</td></tr><tr><td>7</td><td>486.7</td><td>19</td><td>1456.3</td><td>31</td><td>4238.7</td><td>43</td><td>12,337.2</td></tr><tr><td>8</td><td>553.3</td><td>20</td><td>1591.9</td><td>32</td><td>4633.4</td><td>44</td><td>13,485.9</td></tr><tr><td>9</td><td>620</td><td>21</td><td>1740.2</td><td>33</td><td>5064.9</td><td>45</td><td>14,741.6</td></tr><tr><td>10</td><td>686.7</td><td>22</td><td>1902.2</td><td>34</td><td>5536.5</td><td>46</td><td>16,114.3</td></tr><tr><td>11</td><td>753.3</td><td>23</td><td>2079.3</td><td>35</td><td>6052</td><td>47</td><td>17,614.7</td></tr><tr><td>12</td><td>820</td><td>24</td><td>2272.9</td><td>36</td><td>6615.5</td><td>48</td><td>19,254.8</td></tr></table>
a61f532824b5ca3158a12619f2ca6ade040a9156e7b12c42c905a678511ed5ac.png
simple
<table><tr><td>Characteristics</td><td>Frequency n = 82</td><td>Percent (%)</td></tr><tr><td><underline>Age</underline>(years)</td><td>Mean Age =27.6, SD =4.5</td><td> </td></tr><tr><td>16&#8211;20</td><td>6</td><td>7.3</td></tr><tr><td>21&#8211;25</td><td>22</td><td>26.8</td></tr><tr><td>26&#8211;30</td><td>37</td><td>45.1</td></tr><tr><td>31&#8211;35</td><td>12</td><td>14.6</td></tr><tr><td>36-40</td><td>5</td><td>6.1</td></tr><tr><td><underline>Marital Status</underline></td><td> </td><td> </td></tr><tr><td>Married</td><td>76</td><td>92.7</td></tr><tr><td>Single</td><td>1</td><td>1.2</td></tr><tr><td>Cohabiting</td><td>2</td><td>2.4</td></tr><tr><td>No response</td><td>3</td><td>3.7</td></tr><tr><td><underline>Occupation</underline></td><td> </td><td> </td></tr><tr><td>Employed</td><td>16</td><td>19.5</td></tr><tr><td>Student</td><td>8</td><td>9.8</td></tr><tr><td>Civil servant</td><td>2</td><td>2.4</td></tr><tr><td>Unemployed</td><td>8</td><td>9.8</td></tr><tr><td>Artisan</td><td>14</td><td>17.1</td></tr><tr><td>Trading</td><td>32</td><td>39</td></tr><tr><td>No response</td><td>2</td><td>2.4</td></tr><tr><td><underline>Educational attainment</underline></td><td> </td><td> </td></tr><tr><td>Primary</td><td>9</td><td>10.9</td></tr><tr><td>JSS</td><td>21</td><td>25.6</td></tr><tr><td>SSS</td><td>11</td><td>13.4</td></tr><tr><td>Poly technique</td><td>21</td><td>25.6</td></tr><tr><td>University</td><td>15</td><td>18.3</td></tr><tr><td>No response</td><td>5</td><td>6.1</td></tr><tr><td><underline>Religion</underline></td><td> </td><td> </td></tr><tr><td>Christianity</td><td> </td><td> </td></tr><tr><td>Islam</td><td>34</td><td> </td></tr><tr><td>48</td><td>41.5</td><td> </td></tr><tr><td>58.5</td><td> </td><td> </td></tr><tr><td><underline>Ethnic group</underline></td><td> </td><td> </td></tr><tr><td>Yoruba</td><td>72</td><td>87.8</td></tr><tr><td>Igbo</td><td>6</td><td>7.3</td></tr><tr><td>No response</td><td>4</td><td>4.8</td></tr></table>
bd2cf2ba84d945804bb194d08f1f6be2a64f135c36b3ac2c01f8a71e3b5575b9.png
simple
<table><tr><td>miR ID</td><td>Present result</td><td>Previous report</td><td>Type of sample</td><td>Reference</td></tr><tr><td>hsa-miR-106b-5p</td><td>&#8593;</td><td>&#8595;</td><td>Brain</td><td>[13]</td></tr><tr><td>hsa-miR-181b-5p</td><td>&#8595;</td><td>&#8595;</td><td>Brain, lymphoblastoid cell line</td><td>[13,16]</td></tr><tr><td>hsa-miR-195-5p</td><td>&#8593;</td><td>&#8593;</td><td>Lymphoblastoid cell line</td><td>[15]</td></tr><tr><td>hsa-miR-19b-3p</td><td>&#8593;</td><td>&#8595;</td><td>Lymphoblastoid cell line</td><td>[14]</td></tr><tr><td>hsa-miR-320a</td><td>&#8595;</td><td>&#8595;</td><td>Lymphoblastoid cell line</td><td>[14]</td></tr><tr><td>hsa-miR-328</td><td>&#8595;</td><td>&#8595;</td><td>Brain</td><td>[13]</td></tr><tr><td>hsa-miR-663a</td><td>&#8595;</td><td>&#8593;</td><td>Lymphoblastoid cell line</td><td>[14]</td></tr></table>
9d8efd68bdbecbb20083b6bdfa56852e472f36eadb5b9fd2c892542064cfd9a7.png
simple
<table><tr><td></td><td>Accuracy (%)</td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>Auc (%)</td></tr><tr><td>FEATURE 1</td><td>95.00</td><td>87.50</td><td>96.87</td><td>&#8212;</td></tr><tr><td>FEATURE 2</td><td>87.80</td><td>100.00</td><td>84.84</td><td>&#8212;</td></tr><tr><td>FEATURE 1&amp;2</td><td>95.00</td><td>87.50</td><td>96.87</td><td>92.00</td></tr><tr><td>FEATURE 1&amp;2 (SVM)*</td><td>97.50</td><td>100.00</td><td>96.97</td><td>93.75</td></tr></table>
f45f3e863575a35088731fc87c4387e07165af174cb538517652b0a332e2444b.png
simple
<table><tr><td>Cell Line</td><td>Tumor Type</td><td>NOTCH1 Mutation</td><td>Effect on NOTCH1 Signaling</td><td>Reference</td></tr><tr><td>KOPT-K1</td><td>T-LL</td><td>L1600P/del(P)*</td><td>Gain</td><td> [3]</td></tr><tr><td>REC-1</td><td>MCL</td><td>del(ECN1)/del(P)*</td><td>Gain</td><td>this paper/ [7]</td></tr><tr><td>MAVER-1</td><td>MCL</td><td>None</td><td>N.A.</td><td> [7]</td></tr><tr><td>HCC1599</td><td>Breast Carcinoma</td><td>del(ECN1)</td><td>Gain</td><td> [10]</td></tr><tr><td>MB-157</td><td>Breast Carcinoma</td><td>del(ECN1)</td><td>Gain</td><td>Unpublished data</td></tr><tr><td>HCC1587</td><td>Breast Carcinoma</td><td>None</td><td>N.A.</td><td> [10]</td></tr></table>
3df5caf6457f6b6cc3971f6703a6d7277a7ed1e00a54a43cece0fc240c6dca2f.png
complex
<table><tr><td>Assessment<sup>1</sup></td><td>Telehone interview</td><td>Baseline visit</td><td>3 month visit</td><td>6 month visit</td><td>12 month visit</td><td>24 month visit</td></tr><tr><td colspan="7">AD patient</td></tr><tr><td>Inclusion criteria</td><td>X</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Demographics, diagnoses, drugs</td><td></td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>CDR</td><td></td><td>X</td><td></td><td></td><td></td><td>X</td></tr><tr><td>MMSE</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>Verbal flow, clock drawing test</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>MNA</td><td></td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Weight, BMI</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Mobility and balance tests by Guralnik</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>FIM</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>NPI</td><td></td><td>X</td><td></td><td>X</td><td></td><td></td></tr><tr><td>Grip strength, blood pressure, heart rate</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Cornell depression scale</td><td></td><td>X</td><td></td><td></td><td>X</td><td></td></tr><tr><td>Falls and fractures</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Use of health and social services, admission to permanent institutional care, mortality</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Spousal caregiver</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Demographics, diagnoses, drugs</td><td></td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Zarit burden scale</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>GDS</td><td></td><td>X</td><td></td><td></td><td>X</td><td></td></tr><tr><td>RAND-36 QOL</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>Mobility and balance tests by Guralnik</td><td></td><td>X</td><td></td><td></td><td>X</td><td></td></tr><tr><td>Use of health and social services, mortality</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr></table>
d92512f93873cc9a162972b752bf9c14b2c6c469c94dba7e2e73428f6e477c76.png
complex
<table><tr><td rowspan="2">Gender</td><td rowspan="2">Age</td><td rowspan="2">Age at onset</td><td colspan="3">Evidence for a diagnosis of epilepsy</td><td rowspan="2">MRI</td></tr><tr><td>EEG</td><td>Other features</td><td>Treatment response</td></tr><tr><td>M</td><td>70</td><td>66</td><td>Non-specific bilateral temporal lobe slowing</td><td>Oroalimentary automatisms, gustatory hallucinations</td><td>Complete</td><td>Normal</td></tr><tr><td>M</td><td>62</td><td>54</td><td>L temporal epileptiform</td><td>Oroalimentary automatisms</td><td>Complete</td><td>Normal</td></tr><tr><td>M</td><td>68</td><td>65</td><td>Non-specific L temporal slowing</td><td>No</td><td>Complete</td><td>Normal</td></tr><tr><td>M</td><td>72</td><td>71</td><td>Non-specific R temporal slowing</td><td>De&#769;ja&#768; vu</td><td>Complete</td><td>Bilateral high T2 signal in hippocampus</td></tr><tr><td>M</td><td>68</td><td>62</td><td>Bilateral (L more marked) mid-anterior temporal sharp and slow-wave epileptiform</td><td>Oroalimentary automatisms; brief unresponsiveness</td><td>Complete</td><td>Normal</td></tr><tr><td>M</td><td>76</td><td>65</td><td>Non-specific bilateral temporal slowing</td><td>Olfactory hallucinations</td><td>Complete</td><td>Normal</td></tr><tr><td>M</td><td>66</td><td>56</td><td>Normal</td><td>Olfactory hallucinations; brief unresponsiveness</td><td>Complete</td><td>Normal</td></tr><tr><td>M</td><td>64</td><td>61</td><td>Bilateral temporal epileptiform</td><td>Olfactory hallucinations; oroalimentary automatisms</td><td>Complete</td><td>Normal</td></tr><tr><td>M</td><td>63</td><td>59</td><td>Normal</td><td>No</td><td>Complete</td><td>Normal</td></tr><tr><td>M</td><td>76</td><td>73</td><td>Normal</td><td>Oroalimentary automatisms; brief unresponsiveness</td><td>Complete</td><td>Normal</td></tr><tr><td>F</td><td>60</td><td>55</td><td>Non-specific bilateral temporal slowing</td><td>Brief unresponsiveness</td><td>Complete</td><td>Normal</td></tr></table>
361ef57d4aa6cf245b50df05b100b87bd433a891f09f9df4dc1245f76bc64131.png
complex
<table><tr><td>level of convergence</td><td>phenotype</td><td>organism</td><td>references</td></tr><tr><td colspan="4"><i>nucleotide</i></td></tr><tr><td>coding mutations in several genes</td><td>rate of proliferation in a novel host and at higher temperature</td><td>X174 virus</td><td>[21]</td></tr><tr><td>Gly119Ser in <i>ace-1</i></td><td>organophosphate resistance</td><td>seven insect species</td><td>[22,23]</td></tr><tr><td colspan="4"><i>gene</i></td></tr><tr><td><i>pykF</i> and <i>nadR</i></td><td>rate of proliferation in a glucose-limited medium</td><td><i>Escherichia coli</i></td><td>[24]</td></tr><tr><td><i>yellow</i></td><td>wing spot</td><td><i>Drosophila tristis</i> and <i>Drosophila biarmipes</i></td><td>[25]</td></tr><tr><td colspan="4"><i>protein accumulation profile</i></td></tr><tr><td>proteins regulated by guanosine tetraphosphate</td><td>rate of proliferation in a glucose-limited medium</td><td><i>E. coli</i></td><td>[26]</td></tr><tr><td colspan="4"><i>molecular pathway</i></td></tr><tr><td>RNA polymerase complex</td><td>rate of proliferation at high temperature</td><td><i>E. coli</i></td><td>[14]</td></tr><tr><td colspan="4"><i>organ</i></td></tr><tr><td>compound eye</td><td>sensitivity to light</td><td>certain annelids, arrow worms, insects</td><td>[7]</td></tr><tr><td colspan="4"><i>behaviour and organs</i></td></tr><tr><td>no sound production and flat wings</td><td>no sound production, protection against parasitoids</td><td>criquets</td><td>[27]</td></tr><tr><td>feeding behaviour and habitat adaptations</td><td>ecology and body morphology</td><td>lizards</td><td>[28]</td></tr></table>
309523be6ad4869ec5ee5e0f2a7c1877961086f9dc7197562a242c7be3537d0b.png
simple
<table><tr><td>Maize gene</td><td>Intron TE insertion(s)</td><td>Maize gene length (Kb)</td><td>Sorghum ortholog gene length (Kb)</td></tr><tr><td><i>ZmTti1</i></td><td>2 Kb hobo DNA transposon</td><td>20.87</td><td>12.1</td></tr><tr><td><i>ZmTti2</i></td><td>6 Kb Gypsy LTR retrotransposon</td><td>9.1</td><td>4.2</td></tr><tr><td><i>ZmATM</i></td><td>2.2 Kb L1/CIN4 retrotransposon</td><td>131</td><td>71</td></tr><tr><td></td><td>2.1 Kb L1/CIN4 retrotransposon</td><td></td><td></td></tr><tr><td></td><td>1.7 Kb L1/CIN4 retrotransposon</td><td></td><td></td></tr><tr><td></td><td>3.1 Kb Ty1/Copia retrotransposon</td><td></td><td></td></tr><tr><td></td><td>1.2 Kb Ty1/Copia retrotransposon</td><td></td><td></td></tr><tr><td><i>ZmATR</i></td><td>2.4 Kb Gypsy LTR retrotransposon</td><td>45</td><td>31</td></tr><tr><td></td><td>10.2 Kb Gypsy LTR retrotransposon</td><td></td><td></td></tr><tr><td></td><td>3 Kb Ty1/Copia retrotransposon</td><td></td><td></td></tr><tr><td></td><td>4.7 Kb Ty1/Copia retrotransposon</td><td></td><td></td></tr><tr><td><i>ZmSMG1</i></td><td>1.4 Kb Ty1/Copia retrotransposon</td><td>30</td><td>22.6</td></tr><tr><td></td><td>2.1 Kb L1/CIN4 retrotransposon</td><td></td><td></td></tr><tr><td><i>ZmTOR</i></td><td>2 Kb L1/CIN4 retrotransposon</td><td>51</td><td>31.8</td></tr><tr><td></td><td>5 Kb Ty1/Copia retrotransposon</td><td></td><td></td></tr></table>
b7879da68c414423e75b676c09ce7719e1d3560f1d63d51c7d9491e0b018d8e5.png
simple
<table><tr><td>Paternal MHC class I Haplotype<sup>a</sup></td><td>Non-BNP calves (<i>n</i> = 21)</td><td>BNP calves (<i>n</i> = 9)</td><td><i>P</i>-value<sup>b</sup></td><td>FDR-derived significance thresholds<sup>c</sup></td></tr><tr><td>A11</td><td>3</td><td>6</td><td>0.008</td><td>0.004</td></tr><tr><td>A14</td><td>0</td><td>1</td><td>0.300</td><td>0.007</td></tr><tr><td>UU3</td><td>0</td><td>1</td><td>0.300</td><td>0.011</td></tr><tr><td>UU9</td><td>3</td><td>0</td><td>0.535</td><td>0.014</td></tr><tr><td>UU8</td><td>2</td><td>1</td><td>1.000</td><td>0.018</td></tr><tr><td>A13</td><td>1</td><td>0</td><td>1.000</td><td>0.021</td></tr><tr><td>UU1</td><td>2</td><td>0</td><td>1.000</td><td>0.025</td></tr><tr><td>A18v2 (UU)</td><td>1</td><td>0</td><td>1.000</td><td>0.029</td></tr><tr><td>A12 (UU)</td><td>2</td><td>0</td><td>1.000</td><td>0.032</td></tr><tr><td>A15v1</td><td>1</td><td>0</td><td>1.000</td><td>0.036</td></tr><tr><td>A19variants</td><td>2</td><td>0</td><td>1.000</td><td>0.039</td></tr><tr><td>A20variant</td><td>1</td><td>0</td><td>1.000</td><td>0.043</td></tr><tr><td>H2</td><td>1</td><td>0</td><td>1.000</td><td>0.046</td></tr><tr><td>H5v2(UU)</td><td>2</td><td>0</td><td>1.000</td><td>0.050</td></tr></table>
6cdc6b909bcabd05a2143992fd3a18db1fd3d2b66bcc1020111cbb639204039a.png
simple
<table><tr><td>ICD-10 Code</td><td># of patients</td><td>Prescribed Antibiotic</td><td>Cases that needed antibiotic</td><td>Cases that needed + received antibiotics</td><td>Appropriate prescription rate (%)</td><td>Adequate prescription rate (%)</td></tr><tr><td>J00</td><td>581</td><td>17</td><td>14</td><td>1</td><td>82.36</td><td>7.14</td></tr><tr><td>J01</td><td>93</td><td>70</td><td>4</td><td>4</td><td>5.71</td><td>100</td></tr><tr><td>J02</td><td>306</td><td>157</td><td>9</td><td>5</td><td>3.18</td><td>2.94</td></tr><tr><td>J03</td><td>166</td><td>138</td><td>16</td><td>15</td><td>11.59</td><td>93.75</td></tr><tr><td>J04</td><td>34</td><td>12</td><td>0</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>J05</td><td>8</td><td>0</td><td>0</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>J06</td><td>191</td><td>117</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>J10</td><td>0</td><td>0</td><td>0</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>J11</td><td>0</td><td>0</td><td>0</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>H65</td><td>8</td><td>6</td><td>2</td><td>2</td><td>33.33</td><td>100</td></tr><tr><td>H66</td><td>6</td><td>6</td><td>6</td><td>6</td><td>100</td><td>100</td></tr><tr><td>Total</td><td>1393</td><td>523</td><td>51</td><td>33</td><td>9.75</td><td>64.70</td></tr></table>
0f6e945ad340f6fda1093caa48824fe33b9dead60965c2c195f3a6213c22dd0f.png
complex
<table><tr><td rowspan="3">G grade</td><td colspan="3">Number of tumor samples</td></tr><tr><td colspan="3">CD146 expression</td></tr><tr><td>Low/absent</td><td>incomplete high</td><td>complete high</td></tr><tr><td>1</td><td></td><td>3</td><td></td></tr><tr><td>2</td><td>4</td><td>3</td><td>12</td></tr><tr><td>3</td><td>2</td><td>9</td><td>7</td></tr><tr><td>4</td><td></td><td></td><td>1</td></tr><tr><td>total</td><td>6</td><td>15</td><td>20</td></tr></table>
d0a4a0b014c47b4c4274eb8b15118bdc302f710e65a46c18dd67ab0a04ad3372.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">Base model</td><td colspan="2">Effect modification model</td></tr><tr><td>OR</td><td>95%CI</td><td>OR</td><td>95%CI</td></tr><tr><td>SNAP participation (ref = eligible non-participants)</td><td>2.02</td><td>1.44-2.83</td><td>2.09</td><td>1.48-2.95</td></tr><tr><td>Age (years)</td><td>1.02</td><td>1.01-1.03</td><td>1.02</td><td>1.01-1.03</td></tr><tr><td>Gender (ref = female)</td><td>0.45</td><td>0.30-0.67</td><td>0.45</td><td>0.30-0.67</td></tr><tr><td colspan="5">Race/ethnicity (ref = Non-Hispanic white)</td></tr><tr><td> Non-Hispanic black</td><td>2.79</td><td>1.45-5.38</td><td>2.76</td><td>1.43-5.32</td></tr><tr><td> Hispanic</td><td>2.15</td><td>1.30-3.56</td><td>2.12</td><td>1.28-3.51</td></tr><tr><td> Other</td><td>1.46</td><td>0.64-3.35</td><td>1.42</td><td>0.62-3.26</td></tr><tr><td colspan="5">Marital status (ref = married)</td></tr><tr><td> Cohabitating, not married</td><td>1.12</td><td>0.70-1.81</td><td>1.11</td><td>0.69-1.79</td></tr><tr><td> Single</td><td>0.94</td><td>0.67-1.32</td><td>0.93</td><td>0.66-1.31</td></tr><tr><td>Working status (ref = yes)</td><td>0.96</td><td>0.70-1.32</td><td>0.95</td><td>0.69-1.32</td></tr><tr><td>Mental health (ref = not having a mental health problem)</td><td>1.53</td><td>0.93-2.50</td><td>1.54</td><td>0.94-2.52</td></tr><tr><td colspan="5">Neighborhood poverty category (ref = not poor)</td></tr><tr><td> Poor</td><td>1.18</td><td>0.78-1.80</td><td>1.16</td><td>0.76-1.77</td></tr><tr><td> Very poor</td><td>1.02</td><td>0.67-1.57</td><td>1.01</td><td>0.66-1.55</td></tr><tr><td>Density unhealthy food outlets</td><td>1.01</td><td>0.98-1.03</td><td>1.00</td><td>0.97-1.03</td></tr><tr><td>SNAP participation* Density unhealthy food outlets</td><td></td><td></td><td>1.02</td><td>0.99-1.05</td></tr></table>
220bbf26653f7edbfa1981758f4b85aa904f47d3a1d016602b9696e94db18db0.png
complex
<table><tr><td>RADIODENCITY OF BONE GRAFTS</td><td colspan="2">At 7<sup>th </sup>day follow-up</td><td colspan="2">At 1st month follow-up</td><td colspan="2">At 6 months follow-up</td><td colspan="2">At 1 year follow-up</td></tr><tr><td></td><td>No. of pts.</td><td>%</td><td>No. of pts.</td><td>%</td><td>No. of pts.</td><td>%</td><td>No. of pts.</td><td>%</td></tr><tr><td>GOOD</td><td>178</td><td>100</td><td>171</td><td>96.1</td><td>162</td><td>91.0</td><td>147</td><td>82.6</td></tr><tr><td>PARTIAL</td><td>00</td><td>00</td><td>03</td><td>1.7</td><td>09</td><td>5.1</td><td>17</td><td>9.5</td></tr><tr><td>LUCENT</td><td>00</td><td>00</td><td>04</td><td>2.2</td><td>07</td><td>3.9</td><td>14</td><td>7.9</td></tr><tr><td>Total</td><td>178</td><td>100.0</td><td>178</td><td>100.0</td><td>178</td><td>100.0</td><td>178</td><td>100</td></tr></table>
a4db1de3ca95a778cc4b49015c455caec52d030bbf98e9cbc82dc216522fafe3.png
simple
<table><tr><td></td><td>1st visitFebruary 2012</td><td>2nd visitApril 2012</td><td>Last visit before starting dialysis June 2014</td></tr><tr><td>Weight (kg)</td><td>84,3</td><td>82,9</td><td>76</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29</td><td>28</td><td>25</td></tr><tr><td>eGFR (mL/min/1,73 m<sup>2</sup>)</td><td>19</td><td>16</td><td>12</td></tr><tr><td>P-Urea (mmol/L)</td><td>28,8</td><td>18,3</td><td>24,4</td></tr><tr><td>P-Creatinine (&#956;mol/L)</td><td>389</td><td>401</td><td>777</td></tr><tr><td>P-Phosphate (mmol/L)</td><td>1,3</td><td>1,3</td><td>1,4</td></tr><tr><td>P-Potassium (mmol/L)</td><td>3,6</td><td>3,8</td><td>4,0</td></tr><tr><td>P-Albumin (g/L)</td><td>38</td><td>39</td><td>38</td></tr><tr><td>Pt(U)-Urea (mmol/d)</td><td></td><td>205 = 47 g protein</td><td>162 = 40 g protein</td></tr></table>
8457bff05290ef2aab7d4b2aa7f14538a88a0fc20c035fe1d93c8fc736cc18b7.png
complex
<table><tr><td>Subject number</td><td>Region of interest</td><td>H&amp;E staining</td><td>APP staining</td></tr><tr><td rowspan="6">Sheep 01</td><td>AL</td><td>Normal</td><td>0</td></tr><tr><td>AR</td><td>Normal</td><td>1</td></tr><tr><td>BL</td><td>Normal</td><td>0</td></tr><tr><td>BR</td><td>Microglial activation</td><td>2</td></tr><tr><td>C</td><td>Focal hemorrhagic necrosis</td><td>2</td></tr><tr><td>D</td><td>Normal</td><td>0</td></tr><tr><td rowspan="6">Sheep 03</td><td>AL</td><td>Normal</td><td>0</td></tr><tr><td>AR</td><td>Normal</td><td>0</td></tr><tr><td>BL</td><td>Normal</td><td>0</td></tr><tr><td>BR</td><td>Normal</td><td>0</td></tr><tr><td>C</td><td>Normal</td><td>0</td></tr><tr><td>D</td><td>Small perivascular petechial hemorrhage</td><td>1</td></tr><tr><td rowspan="6">Sheep 04</td><td>AL</td><td>Normal</td><td>0</td></tr><tr><td>AR</td><td>Normal</td><td>0</td></tr><tr><td>BL</td><td>Normal</td><td>0</td></tr><tr><td>BR</td><td>Small perivascular petechial hemorrhage at edge, artifact?</td><td>0</td></tr><tr><td>C</td><td>Small perivascular petechial hemorrhage at edge, artifact?</td><td>0</td></tr><tr><td>D</td><td>Normal</td><td>0</td></tr><tr><td rowspan="6">Sheep 05</td><td>AL</td><td>Normal</td><td>0</td></tr><tr><td>AR</td><td>Normal</td><td>0</td></tr><tr><td>BL</td><td>Normal</td><td>0</td></tr><tr><td>BR</td><td>Normal</td><td>0.5</td></tr><tr><td>C</td><td>Normal</td><td>0</td></tr><tr><td>D</td><td>Normal</td><td>0</td></tr><tr><td rowspan="6">Sheep 06</td><td>AL</td><td>Localized focus of acute meningitis and SAH in depth of sulcus</td><td>0</td></tr><tr><td>AR</td><td>Normal</td><td>0</td></tr><tr><td>BL</td><td>Normal</td><td>0</td></tr><tr><td>BR</td><td>Normal</td><td>0</td></tr><tr><td>C</td><td>Focal hemorrhage near deep gray nuclei</td><td>2</td></tr><tr><td>D</td><td>Normal</td><td>0</td></tr><tr><td rowspan="6">Sheep 07</td><td>AL</td><td>Normal</td><td>0</td></tr><tr><td>AR</td><td>Normal</td><td>0</td></tr><tr><td>BL</td><td>Normal</td><td>0</td></tr><tr><td>BR</td><td>Normal</td><td>0</td></tr><tr><td>C</td><td>Normal</td><td>0</td></tr><tr><td>D</td><td>Normal</td><td>0</td></tr></table>
0f5b3fe472e074d03a5ec4e214c74af6668c8b17308cd5d892dab581cf095fd6.png
simple
<table><tr><td>Recipient</td><td>No. of embryos transferred</td><td>No. offetuses</td><td>Days of gestation</td><td>Fetal fibroblast cell lines</td><td>Mono-allelic cell lines (%)</td><td>Bi-allelic cell lines (%)</td></tr><tr><td>R725</td><td>205</td><td>6</td><td>26</td><td>F1, F2, F3, F4, F5, F6</td><td>F3, F4, F5(50.0)</td><td>F1, F2(33.3)</td></tr><tr><td>R801</td><td>181</td><td>2</td><td>29</td><td>F7, F8</td><td>-(0%)</td><td>-(0%)</td></tr></table>
690318bff6b688d5493529c3366617f4d259312c08b03a490a30d4105f28f159.png
complex
<table><tr><td>Groups</td><td>Days</td><td>HOMA-IR</td><td>HOMA-&#946;</td></tr><tr><td rowspan="3">NCD</td><td>0</td><td>4.18(3.66&#8212;5.16)<sup>bc</sup></td><td>200.98(143.36&#8211;346-67)<sup>bc</sup></td></tr><tr><td>28</td><td>4.23(3.71&#8211;4.77)<sup>bc</sup></td><td>192.12(186.6&#8211;265.41)<sup>bc</sup></td></tr><tr><td>T28-T0</td><td>&#8722;0.10(&#8722;0.57&#8211;0.83)</td><td>22.96(&#8722;157.98&#8211;63.57)</td></tr><tr><td rowspan="3">HCHFD</td><td>0</td><td>12.31(10.78&#8211;14.96)<sup>abc</sup></td><td>243.13(207.99&#8211;299.08)<sup>bc</sup></td></tr><tr><td>28</td><td>14.41(12.59&#8211;15.86)<sup>abc</sup></td><td>274.65(230.55&#8211;355.33)<sup>Sbc</sup></td></tr><tr><td>T28-T0</td><td>1.8(0.9&#8211;2.9)</td><td>28.87(9.44&#8211;59.39)</td></tr><tr><td rowspan="3">HCHFD200</td><td>0</td><td>11.58(11&#8211;14.86)<sup>abc</sup></td><td>238.48(222.92&#8211;284.91)<sup>bc</sup></td></tr><tr><td>28</td><td>5.31(4.85&#8211;6.41)<sup>Sbc</sup></td><td>240.23(153.31&#8211;417.24)<sup>bc</sup></td></tr><tr><td>T28-T0</td><td>&#8722;6.36(&#8722;9.37_&#8722;5.38)</td><td>&#8722;5.57(&#8722;82.47&#8211;189.53)</td></tr><tr><td rowspan="3">DBC</td><td>0</td><td>28.24(21.39&#8211;29.41)<sup>a</sup></td><td>53.34(44.03&#8211;89.46)<sup>a</sup></td></tr><tr><td>28</td><td>26.86(21.11&#8211;28.75)<sup>a</sup></td><td>56.04(44.24&#8211;89.15)<sup>a</sup></td></tr><tr><td>T28-T0</td><td>&#8722;0.64(&#8722;3.01&#8211;0.13)</td><td>0.86(&#8722;0.31&#8211;3.52)</td></tr><tr><td rowspan="3">DB200</td><td>0</td><td>27.10(20.58&#8211;29.96)<sup>a</sup></td><td>56.68 (49.59&#8211;83.27) <sup>a</sup></td></tr><tr><td>28</td><td>8.74(6.82&#8211;10.73)<sup>Sabc</sup></td><td>110.96(85.22&#8211;132.01) <sup>Sacb</sup></td></tr><tr><td>T28-T0</td><td>&#8722;17.99(&#8722;19.22_&#8722;13.76)</td><td>49.23 (31.78&#8211;68.42)</td></tr><tr><td rowspan="3">DB400</td><td>0</td><td>26.63(21.14&#8211;32.28)<sup>a</sup></td><td>54.44 (49.38&#8211;74.84)</td></tr><tr><td>28</td><td>5.32(4.26&#8211;5.44)<sup>Sbc</sup></td><td>142.75 (97.52&#8211;157.70) <sup>Sbc</sup></td></tr><tr><td>T28-T0</td><td>&#8722;21.23(&#8722;28.01_&#8722;15.89)</td><td>79.00 (48.14&#8211;107.25)</td></tr><tr><td rowspan="3">DBMET</td><td>0</td><td>27.40(23.41&#8211;29.12)<sup>a</sup></td><td>59.08 (49.53&#8211;66.67) <sup>a</sup></td></tr><tr><td>28</td><td>6.48(5.4&#8211;7.28)<sup>Sabc</sup></td><td>122.11 (93.53&#8211;185.55) <sup>Sbc</sup></td></tr><tr><td>T28-T0</td><td>&#8722;21.22(&#8722;23.11_16.91)</td><td>70.99 (26.86&#8211;127.90)</td></tr></table>
65a44b40a95e922cb7de38d8d5818006c6e2de9d9a21ecb9571a651dbb2e35cd.png
simple
<table><tr><td>SVMs Models With Different Input Variable</td><td>Mean Absolute Percentage Error (MAPE) (%)</td></tr><tr><td>(a) Rebound Hammer (RH) Test</td><td>8.92%</td></tr><tr><td>(b) Ultrasonic Pulse Velocity (UPV) Test</td><td>9.25%</td></tr><tr><td>(c) SonReb (RH+UPV) Test</td><td>6.77%</td></tr></table>
308a568c36e98408b978a6eae92632dcd852dccc19ed8c843204e2217d4f6885.png
simple
<table><tr><td>Province</td><td>Area (Hectares)</td><td>National Percentage</td><td>Province</td><td>Area (Hectares)</td><td>National Percentage</td></tr><tr><td>Agusan del Norte</td><td>244.98</td><td>0.1</td><td>Leyte</td><td>5,807.07</td><td>2.26</td></tr><tr><td>Aklan</td><td>1,144.44</td><td>0.45</td><td>Maguindanao</td><td>907.92</td><td>0.35</td></tr><tr><td>Albay</td><td>1,081.17</td><td>0.42</td><td>Marinduque</td><td>2,732.22</td><td>1.06</td></tr><tr><td>Antique</td><td>945.9</td><td>0.37</td><td>Masbate</td><td>5,302.08</td><td>2.06</td></tr><tr><td>Aurora</td><td>497.07</td><td>0.19</td><td>Metropolitan Manila</td><td>39.69</td><td>0.02</td></tr><tr><td>Basilan</td><td>7,641.18</td><td>2.97</td><td>Misamis Occidental</td><td>2,066.49</td><td>0.8</td></tr><tr><td>Bataan</td><td>238.59</td><td>0.09</td><td>Misamis Oriental</td><td>341.19</td><td>0.13</td></tr><tr><td>Batangas</td><td>508.95</td><td>0.2</td><td>Negros Occidental</td><td>4,393.26</td><td>1.71</td></tr><tr><td>Biliran</td><td>231.39</td><td>0.09</td><td>Negros Oriental</td><td>2,004.93</td><td>0.78</td></tr><tr><td>Bohol</td><td>9490.5</td><td>3.69</td><td>Northern Samar</td><td>4,286.52</td><td>1.67</td></tr><tr><td>Bulacan</td><td>391.14</td><td>0.15</td><td>Occidental Mindoro</td><td>1,842.93</td><td>0.72</td></tr><tr><td>Cagayan</td><td>5,175.27</td><td>2.01</td><td>Oriental Mindoro</td><td>2,975.31</td><td>1.16</td></tr><tr><td>Camarines Norte</td><td>3,628.17</td><td>1.41</td><td>Palawan</td><td>5,6261.3</td><td>22.23</td></tr><tr><td>Camarines Sur</td><td>5,315.31</td><td>2.07</td><td>Pampanga</td><td>251.73</td><td>0.1</td></tr><tr><td>Camiguin</td><td>4.95</td><td>0</td><td>Pangasinan</td><td>1,206.63</td><td>0.47</td></tr><tr><td>Capiz</td><td>1,999.8</td><td>0.78</td><td>Quezon</td><td>14,170</td><td>5.51</td></tr><tr><td>Catanduanes</td><td>1,671.3</td><td>0.65</td><td>Romblon</td><td>792.45</td><td>0.31</td></tr><tr><td>Cavite</td><td>35.73</td><td>0.01</td><td>Samar</td><td>10,140.6</td><td>3.94</td></tr><tr><td>Cebu</td><td>2,893.77</td><td>1.13</td><td>Sarangani</td><td>92.61</td><td>0.04</td></tr><tr><td>Compostela Valley</td><td>130.14</td><td>0.05</td><td>Shariff Kabunsuan</td><td>1,018.89</td><td>0.4</td></tr><tr><td>Davao del Norte</td><td>195.57</td><td>0.08</td><td>Siquijor</td><td>70.2</td><td>0.03</td></tr><tr><td>Davao del Sur</td><td>361.53</td><td>0.14</td><td>Sorsogon</td><td>3,895.74</td><td>1.52</td></tr><tr><td>Davao Oriental</td><td>1975.5</td><td>0.77</td><td>South Cotabato</td><td>13.86</td><td>0.01</td></tr><tr><td>Dinagat Islands</td><td>1654.56</td><td>0.64</td><td>Southern Leyte</td><td>643.68</td><td>0.25</td></tr><tr><td>Eastern Samar</td><td>5,595.93</td><td>2.18</td><td>Sultan Kudarat</td><td>949.95</td><td>0.37</td></tr><tr><td>Guimaras</td><td>577.08</td><td>0.22</td><td>Sulu</td><td>2,0564.8</td><td>8</td></tr><tr><td>Ilocos Norte</td><td>127.53</td><td>0.05</td><td>Surigao del Norte</td><td>11867</td><td>4.62</td></tr><tr><td>Ilocos Sur</td><td>228.87</td><td>0.09</td><td>Surigao del Sur</td><td>5,642.55</td><td>2.19</td></tr><tr><td>Iloilo</td><td>1,322.91</td><td>0.51</td><td>Tawi-Tawi</td><td>11,322.2</td><td>4.4</td></tr><tr><td>Isabela</td><td>592.29</td><td>0.23</td><td>Zambales</td><td>981.54</td><td>0.38</td></tr><tr><td>La Union</td><td>144.18</td><td>0.06</td><td>Zamboanga del Norte</td><td>1,961.82</td><td>0.76</td></tr><tr><td>Lanao del Norte</td><td>1,580.94</td><td>0.61</td><td>Zamboanga del Sur</td><td>9,501.66</td><td>3.7</td></tr><tr><td>Lanao del Sur</td><td>620.37</td><td>0.24</td><td>Zamboanga Sibugay</td><td>13,889.2</td><td>5.4</td></tr></table>
2341023bb3d94eb5c48fabf811c9cb5d3e1b081dbcba448ce7e1041dbafca7fc.png
complex
<table><tr><td>Symptom</td><td>Appetite</td><td>Tired-ness</td><td>Depression</td><td>Well-being</td><td>Pain</td><td>Anxiety</td><td>Nausea</td><td>Short of Breath</td><td>Drowsiness</td></tr><tr><td></td><td colspan="9">One Month Before Death (n = 82)</td></tr><tr><td>Appetite</td><td>895.3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Tiredness</td><td>242.4</td><td>399.6</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Depress.</td><td>296.1</td><td>188.5</td><td>513.6</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Well-being</td><td>427.5</td><td>218.8</td><td>320.6</td><td>550.1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Pain</td><td>370.8</td><td>221.8</td><td>231.3</td><td>255.7</td><td>514.4</td><td>0.47</td><td>0.41</td><td>0.40</td><td>0.48</td></tr><tr><td>Anxiety</td><td>336.0</td><td>110.6</td><td>388.1</td><td>390.7</td><td>236.9</td><td>577.2</td><td>0.50</td><td>0.14</td><td>0.57</td></tr><tr><td>Nausea</td><td>172.4</td><td>97.6</td><td>177.7</td><td>144.6</td><td>153.3</td><td>190.3</td><td>297.2</td><td>0.16</td><td>0.40</td></tr><tr><td>Short of Breath</td><td>8.5</td><td>87.5</td><td>43.0</td><td>70.3</td><td>181.2</td><td>66.3</td><td>54.6</td><td>443.5</td><td>0.19</td></tr><tr><td>Drowsy</td><td>353.4</td><td>332.4</td><td>301.2</td><td>321.4</td><td>227.3</td><td>275.9</td><td>143.0</td><td>85.0</td><td>505.8</td></tr><tr><td></td><td colspan="9">One Week Before Death (n = 82)</td></tr><tr><td>Appetite</td><td>1029.2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Tiredness</td><td>318.4</td><td>623.3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Depress.</td><td>250.5</td><td>261.9</td><td>848.6</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Well-being</td><td>426.3</td><td>262.9</td><td>446.2</td><td>549.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Pain</td><td>166.4</td><td>310.1</td><td>276.5</td><td>226.1</td><td>715.9</td><td>0.40</td><td>0.37</td><td>0.42</td><td>0.43</td></tr><tr><td>Anxiety</td><td>205.2</td><td>241.8</td><td>661.9</td><td>372.4</td><td>280.1</td><td>811.5</td><td>0.65</td><td>0.33</td><td>0.49</td></tr><tr><td>Nausea</td><td>150.7</td><td>177.6</td><td>423.6</td><td>300.1</td><td>234.4</td><td>423.5</td><td>620.8</td><td>0.39</td><td>0.39</td></tr><tr><td>Short of Breath</td><td>204.4</td><td>164.4</td><td>347.7</td><td>227.4</td><td>288.5</td><td>243.8</td><td>252.2</td><td>739.6</td><td>0.32</td></tr><tr><td>Drowsy</td><td>406.6</td><td>522.2</td><td>359.0</td><td>376.6</td><td>295.1</td><td>345.6</td><td>250.5</td><td>226.7</td><td>765.1</td></tr></table>
6638f2fa650facf20ad4bd947f556c57c1c555b0fcb91ec4bd2da398ad3e1f5b.png
simple
<table><tr><td></td><td></td><td>Category</td><td></td><td></td><td></td><td></td><td>Category</td><td></td><td></td></tr><tr><td>Patient</td><td>1</td><td>2</td><td>3</td><td>4</td><td>Patient</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>24</td><td>0.14</td><td>0.86</td><td>0</td><td>0</td></tr><tr><td>2</td><td>0</td><td>0</td><td>0.95</td><td>0.05</td><td>25</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>3</td><td>0.5</td><td>0.5</td><td>0</td><td>0</td><td>26</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>4</td><td>0.24</td><td>0.76</td><td>0</td><td>0</td><td>27</td><td>0</td><td>0.93</td><td>0.07</td><td>0</td></tr><tr><td>5</td><td>0</td><td>1</td><td>0</td><td>0</td><td>28</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>6</td><td>0</td><td>1</td><td>0</td><td>0</td><td>29</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>7</td><td>0.68</td><td>0.32</td><td>0</td><td>0</td><td>30</td><td>0.82</td><td>0.18</td><td>0</td><td>0</td></tr><tr><td>8</td><td>0</td><td>0</td><td>1</td><td>0</td><td>31</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>9</td><td>0</td><td>1</td><td>0</td><td>0</td><td>32</td><td>0</td><td>0</td><td>1</td><td>0</td></tr><tr><td>10</td><td>0</td><td>0.85</td><td>0.15</td><td>0</td><td>33</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>11</td><td>0</td><td>0</td><td>0</td><td>1</td><td>34</td><td>0</td><td>1</td><td>0</td><td>0</td></tr><tr><td>12</td><td>0</td><td>0.65</td><td>0.35</td><td>0</td><td>35</td><td>0</td><td>0.93</td><td>0.07</td><td>0</td></tr><tr><td>13</td><td>1</td><td>0</td><td>0</td><td>0</td><td>36</td><td>0</td><td>0</td><td>0.73</td><td>0.27</td></tr><tr><td>14</td><td>0.11</td><td>0.89</td><td>0</td><td>0</td><td>37</td><td>0.14</td><td>0.85</td><td>0.02</td><td>0</td></tr><tr><td>15</td><td>0.99</td><td>0.01</td><td>0</td><td>0</td><td>38</td><td>0</td><td>0.51</td><td>0.49</td><td>0</td></tr><tr><td>16</td><td>1</td><td>0</td><td>0</td><td>0</td><td>39</td><td>0</td><td>0</td><td>1</td><td>0</td></tr><tr><td>17</td><td>1</td><td>0</td><td>0</td><td>0</td><td>40</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>18</td><td>1</td><td>0</td><td>0</td><td>0</td><td>41</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>19</td><td>0</td><td>1</td><td>0</td><td>0</td><td>42</td><td>0.89</td><td>0.11</td><td>0</td><td>0</td></tr><tr><td>20</td><td>0.1</td><td>0.9</td><td>0</td><td>0</td><td>43</td><td>0</td><td>0.93</td><td>0.07</td><td>0</td></tr><tr><td>21</td><td>0</td><td>1</td><td>0</td><td>0</td><td>44</td><td>0.99</td><td>0.01</td><td>0</td><td>0</td></tr><tr><td>22</td><td>0</td><td>1</td><td>0</td><td>0</td><td>45</td><td>0</td><td>1</td><td>0</td><td>0</td></tr><tr><td>23</td><td>0</td><td>1</td><td>0</td><td>0</td><td></td><td></td><td></td><td></td><td></td></tr></table>
8ddcc3872885acda5f6aeef76751430e4984080519a0b2893ed2649750add22e.png
complex
<table><tr><td rowspan="2">Cause of death</td><td colspan="2">Men</td><td colspan="2">Women</td></tr><tr><td>1997 (95% CI)</td><td>2014 (95% CI)</td><td>1997 (95% CI)</td><td>2014 (95% CI)</td></tr><tr><td>I00&#8211;I99 Diseases of the circulatory system</td><td>709.3 (699.9&#8211;718.6)</td><td>401.5 (395.2&#8211;407.8)</td><td>449.8 (444.0&#8211;455.6)</td><td>283.2 (278.9&#8211;287.5)</td></tr><tr><td> I20&#8211;I25 Ischemic heart diseases</td><td>378.6 (371.9&#8211;385.3)</td><td>174.4 (170.3&#8211;178.5)</td><td>194.7 (190.9&#8211;198.6)</td><td>95.3 (92.8&#8211;97.7)</td></tr><tr><td> I60&#8211;I69 Cerebrovascular diseases</td><td>142.6 (138.4&#8211;146.8)</td><td>73.4 (70.7&#8211;76.1)</td><td>117.6 (114.6&#8211;120.6)</td><td>62.8 (60.8&#8211;64.8)</td></tr><tr><td> I30&#8211;I52 Other forms of heart disease</td><td>99.9 (96.3&#8211;103.5)</td><td>100.9 (97.6&#8211;104.1)</td><td>75.5 (73.1&#8211;77.)</td><td>78.5 (76.3&#8211;80.7)</td></tr><tr><td>C00&#8211;D48 Neoplasms</td><td>341.2 (334.9&#8211;347.4)</td><td>289 (283.9&#8211;294.1)</td><td>225.5 (221.2&#8211;229.8)</td><td>208.2 (204.3&#8211;212.1)</td></tr><tr><td> C15&#8211;C26 Malignant neoplasms of digestive organs</td><td>99.8 (96.5&#8211;103.2)</td><td>86 (83.2&#8211;88.7)</td><td>69.6 (67.2&#8211;72.0)</td><td>61.6 (59.5&#8211;63.7)</td></tr><tr><td> C61 Malignant neoplasm prostate</td><td>76.7 (73.6&#8211;79.7)</td><td>61.1 (58.6&#8211;63.5)</td><td>**</td><td>**</td></tr><tr><td> C50&#8211;C50 Malignant neoplasm of breast</td><td>0.3 (0.1&#8211;0.5)</td><td>0.1 (0.0&#8211;0.2)</td><td>32.5 (30.9&#8211;34.1)</td><td>26.5 (25.1&#8211;27.8)</td></tr><tr><td> C51&#8211;C58 Malignant neoplasms of female genital organs</td><td>**</td><td>**</td><td>27.5 (26.0&#8211;29.0)</td><td>22.6 (21.3&#8211;23.9)</td></tr><tr><td> C30&#8211;C39 Malignant neoplasms of respiratory and intrathoracic organs</td><td>54.6 (52.2&#8211;57.1)</td><td>43.1 (41.1&#8211;45.0)</td><td>26.6 (25.0&#8211;28.1)</td><td>36.1 (34.4&#8211;37.7)</td></tr><tr><td> C34 Malignant neoplasm of bronchus and lung</td><td>51.7 (49.3&#8211;54.0)</td><td>40.9 (39.0&#8211;42.8)</td><td>25.5 (24.0&#8211;27.0)</td><td>35.5 (33.9&#8211;37.1)</td></tr><tr><td>J00&#8211;J99 Diseases of the respiratory system</td><td>117.2 (113.3&#8211;121.1)</td><td>71.1 (68.4&#8211;73.7)</td><td>70.1 (67.8&#8211;72.5)</td><td>48.7 (46.8&#8211;50.5)</td></tr><tr><td> J09&#8211;J18 Influenza and pneumonia</td><td>62.2 (59.3&#8211;65.1)</td><td>25.6 (23.9&#8211;27.2)</td><td>41.8 (40.1&#8211;43.6)</td><td>14.2 (13.3&#8211;15.2)</td></tr><tr><td> J40&#8211;J47 Chronic lower respiratory diseases</td><td>42.5 (40.2&#8211;44.8)</td><td>31.9 (30.1&#8211;33.6)</td><td>21.2 (19.9&#8211;22.5)</td><td>28.5 (27.1&#8211;29.9)</td></tr><tr><td>V01&#8211;Y98 External causes of morbidity and mortality</td><td>74.7 (71.9&#8211;77.4)</td><td>69.4 (66.9&#8211;71.9)</td><td>33.2 (31.6&#8211;34.8)</td><td>33 (31.5&#8211;34.5)</td></tr><tr><td> X60&#8211;X84 Intentional self-harm</td><td>20.8 (19.4&#8211;22.2)</td><td>16.6 (15.4&#8211;17.8)</td><td>7.7 (6.9&#8211;8.5)</td><td>7.4 (6.6&#8211;8.5)</td></tr><tr><td> W00&#8211;W19 Falls</td><td>10.1 (9.0&#8211;11.1)</td><td>14.2 (13.0&#8211;15.4)</td><td>5.2 (4.5&#8211;5.8)</td><td>7.5 (6.8&#8211;8.2)</td></tr><tr><td>F00&#8211;F99 Mental and behavioral disorders</td><td>37.5 (35.4&#8211;39.7)</td><td>55.3 (52.9&#8211;57.7)</td><td>34 (32.4&#8211;35.6)</td><td>64.3 (62.3&#8211;66.3)</td></tr><tr><td> F03 Unspecified dementia</td><td>18 (16.4&#8211;19.6)</td><td>37.3 (35.3&#8211;39.3)</td><td>25.3 (23.9&#8211;26.6)</td><td>49.5 (47.8&#8211;51.3)</td></tr><tr><td>G00&#8211;G99 Diseases of the nervous system</td><td>22 (20.5&#8211;23.6)</td><td>41.9 (39.9&#8211;43.9)</td><td>19.9 (18.6&#8211;21.1)</td><td>41.8 (40.1&#8211;43.5)</td></tr><tr><td> G30 Alzheimer&#8217;s disease</td><td>6 (5.2&#8211;6.9)</td><td>20.1 (18.7&#8211;21.6)</td><td>7 (6.3&#8211;7.8)</td><td>26.2 (24.9&#8211;27.4)</td></tr><tr><td>A00&#8211;B99 Certain infectious and parasitic diseases</td><td>12.9 (11.7&#8211;14.2)</td><td>27.1 (25.5&#8211;28.8)</td><td>9 (8.1&#8211;9.8)</td><td>18.2 (17.1&#8211;19.3)</td></tr><tr><td>R00&#8211;R99 Symptoms, signs, abnormal clinical and laboratory findings, not elsewhere classified</td><td>26.7 (24.8&#8211;28.6)</td><td>30.1 (28.4&#8211;31.8)</td><td>25.9 (24.5&#8211;27.3)</td><td>29.3 (27.9&#8211;30.7)</td></tr><tr><td>Total</td><td>1451.1 (1438&#8211;1464)</td><td>1078.6 (1068&#8211;1089)</td><td>944.3 (936&#8211;953)</td><td>793.9 (787&#8211;801)</td></tr></table>
dc26ae1fbb8f0c77dc5c3ac6f7b407f6de2203379779632e28f7acb8cc1cb404.png
simple
<table><tr><td>Marker</td><td>D number</td><td>Primer sequences (5&#8217;&gt;3&#8217;)</td><td>Annealing temperature (&#176;C)</td><td>Product size (bp)</td></tr><tr><td>ATA29H01 </td><td>D12S1048</td><td>GGTCTGCTTAGGTCCCTTTT </td><td>55</td><td>209-229</td></tr><tr><td> </td><td> </td><td>AAGGAACCAAGGAGTGGAAG </td><td> </td><td> </td></tr><tr><td>Mfd75A </td><td>D12S59</td><td>CTCACTCATGCTTGTTTTGA </td><td>60.3</td><td>164-179</td></tr><tr><td> </td><td> </td><td>GATCACGTCAGACTGGGCT </td><td> </td><td> </td></tr><tr><td>AFM092wd11 </td><td>D12S331</td><td>TAACATTTATTCATCTCCATACTGA </td><td>57.8</td><td>175-181</td></tr><tr><td> </td><td> </td><td>ACATGTAAGAGAGNAAGTTTACAAA </td><td> </td><td> </td></tr><tr><td>AFM296yg5 </td><td>D12S345</td><td>CAGCCTGGGTAACAAA </td><td>57.8</td><td>209-238</td></tr><tr><td> </td><td> </td><td>AGCAATGTGTGCATTC </td><td> </td><td> </td></tr><tr><td>UT8102 </td><td>D16S689</td><td>GCCTGGGCGATAAGTGAGA </td><td>56</td><td>209</td></tr><tr><td> </td><td> </td><td>TCACCACAACCCAAACATTC </td><td> </td><td> </td></tr><tr><td>AFM156xb8 </td><td>D16S3026</td><td>CTCCCTGAGCAACAAACACC </td><td>55</td><td>178-210</td></tr><tr><td> </td><td> </td><td>GGTCATTTATATGCGCCTGA </td><td> </td><td> </td></tr><tr><td>AFMa306yf1 </td><td>D16S3063</td><td>AGCTTGTTTTAGCAANAATTTC </td><td>59</td><td>218-260</td></tr><tr><td> </td><td> </td><td>TGCCTGATTCCACCAA </td><td> </td><td> </td></tr><tr><td>AFM342xd9</td><td>D16S3121</td><td>CATGTTGTACATCGTGATGC </td><td>58</td><td>79-85</td></tr><tr><td> </td><td> </td><td>AGCTTTTATTTCCCAGGGGT</td><td> </td><td> </td></tr></table>
adfc4752e768435adc0321ea19cfd6a973e625ef7b68f8b1e8302cc9c51d3137.png
simple
<table><tr><td>Gene</td><td>Forward</td><td>Reverse</td></tr><tr><td>EP1</td><td>5&#8242;-ATGGTGGGCCAGCTTGTC-3&#8242;</td><td>5&#8242;-GCCACCAACACCAGCATTG-3&#8242;</td></tr><tr><td>EP2</td><td>5&#8242;-TCCTTGCCTTTCACGATTT-3&#8242;</td><td>5&#8242;-AGAGCTTGGAGGTCCCATT-3&#8242;</td></tr><tr><td>EP3</td><td>5&#8242;-TGGTCTCCGCTCCTGATAA-3&#8242;</td><td>5&#8242;-TGCATTCTTTCTGCTTCTCC-3&#8242;</td></tr><tr><td>EP4</td><td>5&#8242;-TGCTCTTCTTCAGCCTGTCC-3&#8242;</td><td>5&#8242;-GAGCTACCGAGACCCATGTT-3&#8242;</td></tr><tr><td>FP</td><td>5&#8242;-TCTGGTCTGTGCCCACTTC-3&#8242;</td><td>5&#8242;-GACTCCAATACACCGCTCAAT-3&#8242;</td></tr><tr><td>PGT</td><td>5&#8242;-CTGGTGGATTTCATTAAACGG-3&#8242;</td><td>5&#8242;-GGCTGCTGAGGTGCCATAC-3&#8242;</td></tr><tr><td>MRP4 total</td><td>5&#8242;-AAAGTGCCAAAGTAATCCAGC-3&#8242;</td><td>5&#8242;-GTTCAAAGCCACAGAATCCA-3&#8242;</td></tr><tr><td>MRP4 variant 1</td><td>5&#8242;-CGGGCATACAAAGCAGAA-3&#8242;</td><td>5&#8242;-GGACCCAAAGGCAACG-3&#8242;</td></tr></table>
a0d9dd1bd04aafb3f534244687c82fc437c7bb62206ac2c69c8c50074b8911e8.png
complex
<table><tr><td rowspan="3"></td><td colspan="4">HIV-uninfected<sup>a</sup></td><td colspan="3">HIV-infected<sup>b</sup></td></tr><tr><td>All</td><td>Benin</td><td>Gabon</td><td>Mozambique</td><td>All</td><td>Kenya</td><td>Mozambique</td></tr><tr><td>n = 946</td><td>n = 349</td><td>n = 257</td><td>n = 340</td><td>n = 768</td><td>n = 351</td><td>n = 417</td></tr><tr><td colspan="8">Age (years), mean (SD)</td></tr><tr><td></td><td>24.3 (6.3)</td><td>25.4 (5.2)</td><td>24.4 (6.7)</td><td>23.1 (6.8)</td><td>26.7 (5.7)</td><td>26.9 (5.4)</td><td>26.5 (5.9)</td></tr><tr><td colspan="8">Parity, n (%)</td></tr><tr><td> Primigravidae</td><td>265 (28)</td><td>69 (20)</td><td>66 (26)</td><td>130 (38)</td><td>81 (11)</td><td>30 (9)</td><td>51 (12)</td></tr><tr><td> Multigravidae</td><td>681 (72)</td><td>280 (80)</td><td>191 (74)</td><td>210 (62)</td><td>687 (89)</td><td>321 (91)</td><td>366 (88)</td></tr><tr><td colspan="8">Gestational age at baseline (weeks), mean (SD)</td></tr><tr><td></td><td>21.0 (4.9)</td><td>22.0 (4.1)</td><td>19.5 (5.4)</td><td>21.3 (5.2)</td><td>20.3 (5.5)</td><td>19.9 (5.9)</td><td>20.6 (5.2)</td></tr><tr><td colspan="8">MUAC at baseline (cm), mean (SD)</td></tr><tr><td></td><td>25.9 (3.0)</td><td>25.3 (2.3)</td><td>25.7 (3.6)</td><td>26.8 (3.0)</td><td>26.8 (2.7)</td><td>27.0 (2.7)</td><td>26.7 (2.7)</td></tr><tr><td colspan="8">RPR at baseline, n (%)</td></tr><tr><td> Positive</td><td>9 (1)</td><td>2 (1)</td><td>1 (0)</td><td>6 (2)</td><td>39 (5)</td><td>12 (3)</td><td>27 (7)</td></tr><tr><td> Negative</td><td>928 (99)</td><td>347 (99)</td><td>247 (100)</td><td>334 (98)</td><td>726 (95)</td><td>338 (97)</td><td>388 (93)</td></tr><tr><td colspan="8">Literate, n (%)</td></tr><tr><td> No</td><td>371 (39)</td><td>280 (80)</td><td>34 (13)</td><td>57 (17)</td><td>142 (18)</td><td>16 (5)</td><td>126 (30)</td></tr><tr><td> Yes</td><td>575 (61)</td><td>69 (20)</td><td>223 (87)</td><td>283 (83)</td><td>626 (82)</td><td>335 (95)</td><td>291 (70)</td></tr><tr><td colspan="8">HIV viral load (copies/mL) at baseline, n (%)<sup>c</sup></td></tr><tr><td>&lt; 399</td><td></td><td></td><td></td><td></td><td>181 (24)</td><td>125 (36)</td><td>56 (13)</td></tr><tr><td> 400/999</td><td></td><td></td><td></td><td></td><td>183 (24)</td><td>76 (22)</td><td>107 (26)</td></tr><tr><td> 1000/9999</td><td></td><td></td><td></td><td></td><td>243 (32)</td><td>97 (28</td><td>146 (35)</td></tr><tr><td> 10,000/max</td><td></td><td></td><td></td><td></td><td>123 (16)</td><td>49 (14)</td><td>74 (18)</td></tr><tr><td> UNK</td><td></td><td></td><td></td><td></td><td>38 (5)</td><td>4 (1)</td><td>34 (8)</td></tr><tr><td colspan="8">CD4 (cells/&#956;L) at baseline, n (%)<sup>d</sup></td></tr><tr><td>&lt; 350</td><td></td><td></td><td></td><td></td><td>279 (36)</td><td>137 (39)</td><td>142 (34)</td></tr><tr><td> 350/max</td><td></td><td></td><td></td><td></td><td>460 (60)</td><td>212 (60)</td><td>248 (59)</td></tr><tr><td> UNK</td><td></td><td></td><td></td><td></td><td>29 (4)</td><td>2 (1)</td><td>27 (6)</td></tr><tr><td colspan="8">Maternal haemoglobin at baseline (g/dL), mean (SD)</td></tr><tr><td></td><td>10.4 (1.5)</td><td>10.3 (1.2)</td><td>10.3 (1.4)</td><td>10.7 (1.8)</td><td>10.1 (1.7)</td><td>10.2 (1.9)</td><td>10.0 (1.6)</td></tr><tr><td colspan="8">IPTp, n (%)</td></tr><tr><td> Antimalarial 1<sup>e</sup></td><td>629 (66)</td><td>230 (66)</td><td>172 (67)</td><td>227 (67)</td><td>390 (51)</td><td>174 (50)</td><td>216 (52)</td></tr><tr><td> Antimalarial 2<sup>e</sup></td><td>317 (34)</td><td>119 (34)</td><td>85 (33)</td><td>113 (33)</td><td>378 (49)</td><td>177 (50)</td><td>201 (48))</td></tr><tr><td colspan="8">Gestational age at delivery (weeks),<sup>f</sup> mean (SD)</td></tr><tr><td></td><td>39.6 (1.7)</td><td>39.2 (1.2)</td><td>41.1 (1.8)</td><td>38.9 (1.2)</td><td>38.8 (1.2)</td><td>ND</td><td>38.8 (1.2)</td></tr><tr><td colspan="8">Preterm birth,<sup>g</sup> n (%)</td></tr><tr><td> No</td><td>867 (95)</td><td>328 (95)</td><td>238 (95)</td><td>301 (95)</td><td>374 (96)</td><td>ND</td><td>374 (96)</td></tr><tr><td> Yes</td><td>44 (5)</td><td>16 (5)</td><td>13 (5)</td><td>15 (5)</td><td>17 (4)</td><td>ND</td><td>17 (4)</td></tr></table>
f877a26669b3fc5ffec99081e9a715ef527ca60647f80597719203699a27e273.png
complex
<table><tr><td rowspan="3">Body Areas</td><td colspan="6">Severity of Hirsutism</td><td rowspan="3"><i>p</i></td></tr><tr><td colspan="2">Mild</td><td colspan="2">Moderate</td><td colspan="2">Severe</td></tr><tr><td>Mean</td><td>SE *</td><td>Mean</td><td>SE</td><td>Mean</td><td>SE</td></tr><tr><td>Upper lip</td><td>1.99</td><td>0.07</td><td>2.60</td><td>0.07</td><td>3.10</td><td>0.22</td><td>&lt;0.001</td></tr><tr><td>Chin</td><td>2.07</td><td>0.11</td><td>3.16</td><td>0.10</td><td>3.95</td><td>0.05</td><td>&lt;0.001</td></tr><tr><td>Upper back</td><td>0.53</td><td>0.05</td><td>1.30</td><td>0.09</td><td>2.55</td><td>0.23</td><td>&lt;0.001</td></tr><tr><td>Lower back</td><td>0.64</td><td>0.06</td><td>2.08</td><td>0.11</td><td>3.40</td><td>0.17</td><td>&lt;0.001</td></tr><tr><td>Upper arm</td><td>0.25</td><td>0.04</td><td>1.01</td><td>0.10</td><td>2.75</td><td>0.26</td><td>&lt;0.001</td></tr><tr><td>Thighs</td><td>2.07</td><td>0.07</td><td>3.13</td><td>0.07</td><td>3.70</td><td>0.11</td><td>&lt;0.001</td></tr><tr><td>Chest</td><td>0.30</td><td>0.05</td><td>0.96</td><td>0.09</td><td>2.60</td><td>0.21</td><td>&lt;0.001</td></tr><tr><td>Upper abdomen</td><td>1.01</td><td>0.07</td><td>2.22</td><td>0.08</td><td>3.25</td><td>0.16</td><td>&lt;0.001</td></tr><tr><td>Lower abdomen</td><td>3.48</td><td>0.08</td><td>3.88</td><td>0.04</td><td>4.00</td><td>0.00</td><td>&lt;0.001</td></tr><tr><td>Sideburn</td><td>1.33</td><td>0.07</td><td>2.91</td><td>0.10</td><td>3.90</td><td>0.07</td><td>&lt;0.001</td></tr><tr><td>Lower jaw/neck</td><td>0.66</td><td>0.08</td><td>1.34</td><td>0.11</td><td>3.00</td><td>0.23</td><td>&lt;0.001</td></tr><tr><td>Buttock/perineum</td><td>0.67</td><td>0.08</td><td>1.92</td><td>0.12</td><td>2.90</td><td>0.27</td><td>&lt;0.001</td></tr><tr><td>Total m-FG score 9 areas</td><td>12.33</td><td>0.20</td><td>20.34</td><td>0.22</td><td>28.10</td><td>0.47</td><td>&lt;0.001</td></tr><tr><td>Total score for 3 new areas</td><td>3.33</td><td>0.21</td><td>6.17</td><td>0.23</td><td>9.40</td><td>1.00</td><td>&lt;0.001</td></tr><tr><td>Total score for all 12 areas</td><td>15.67</td><td>0.33</td><td>26.51</td><td>0.40</td><td>37.85</td><td>1.07</td><td>&lt;0.001</td></tr></table>
0dc06eadc7ce4e20647bce2d7726e0b5bc3ceb9805143ee027081c74823df2f6.png
complex
<table><tr><td>Technique</td><td>Comments</td></tr><tr><td colspan="2">PRECONTRAST</td></tr><tr><td>Dark blood stacks typically in axial, coronal and sagittal planes e.g. HASTE</td><td>Provides vessel wall imaging as well as complementary information to CE-MRA regarding lumen</td></tr><tr><td>Noncontrast bright blood stack(s) e.g. SSFP</td><td> </td></tr><tr><td> </td><td colspan="2">CONTRAST</td></tr><tr><td>3D contrast-enhanced magnetic resonance angiography e.g. spoiled gradient echo</td><td>Appropriate vasculature should be covered depending on clinical questions and known or suspected diagnosis (see Table 2)</td><td> </td></tr><tr><td> </td><td colspan="2">POSTCONTRAST</td></tr><tr><td>T1-weighted vessel wall imaging e.g. VIBE or FAME</td><td>Additional vessel wall imaging, particularly useful to delineate thickening and thrombus</td><td> </td></tr><tr><td> </td><td colspan="2">CARDIAC ACQUISITIONS</td></tr><tr><td>Multiplane cine imaging e.g. SSFP Aortic valve velocity-encoded cine Myocardial imaging: T2 precontrast, T1W early post contrast, late post-gadolinium imaging</td><td>May be appropriate when aortic root disease involves the aortic valve or when myocardial inflammation is suspected, particularly in small-vessel vasculitides</td><td> </td></tr></table>
930c6741d6537af6153b99c60b1a85cc445d1a4ff72133c8959ce7c57e2f9cc1.png
simple
<table><tr><td>Gene symbol</td><td>Gene name</td><td>Log<sub>2</sub>FC (P/M)</td><td>FDR</td></tr><tr><td>Igj</td><td>Immunoglobulin joining chain</td><td>8.6779562</td><td>2.29E-11</td></tr><tr><td>Ly6c2</td><td>Lymphocyte antigen 6 complex, locus C2</td><td>12.30121239</td><td>2.92E-09</td></tr><tr><td>Slfn4</td><td>Schlafen 4</td><td>15.5668286</td><td>1.75E-06</td></tr><tr><td>Lcn2</td><td>Lipocalin 2</td><td>7.312076677</td><td>3.37E-05</td></tr><tr><td>Slpi</td><td>Secretory leukocyte peptidase inhibitor</td><td>12.73813718</td><td>5.33E-05</td></tr><tr><td>Ccdc126</td><td>Coiled-coil domain containing 126</td><td>&#8722;8.341365207</td><td>0.000225043</td></tr><tr><td>Atp5g3</td><td>ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C3 (subunit 9)</td><td>&#8722;11.69540624</td><td>0.000280756</td></tr><tr><td>Fsd1l</td><td>Fibronectin type III and SPRY domain containing 1-like</td><td>&#8722;6.703008314</td><td>0.000462131</td></tr><tr><td>Dnajc12</td><td>DnaJ heat shock protein family</td><td>&#8722;14.11777559</td><td>0.000618267</td></tr><tr><td>Rbm8a</td><td>RNA binding motif protein 8a</td><td>&#8722;11.28615955</td><td>0.001526552</td></tr><tr><td>Fat3</td><td>FAT atypical cadherin 3</td><td>&#8722;14.08641235</td><td>0.003575335</td></tr><tr><td>Col3a1</td><td>Collagen, type III, alpha 1</td><td>14.61654737</td><td>0.003584831</td></tr><tr><td>Akap17b</td><td>A kinase (PRKA) anchor protein 17B</td><td>&#8722;10.53057236</td><td>0.009607167</td></tr><tr><td>Cysltr1</td><td>Cysteinyl leukotriene receptor 1</td><td>&#8722;14.65367542</td><td>0.009752316</td></tr><tr><td>Sgip1</td><td>SH3-domain GRB2-like (endophilin) interacting protein 1</td><td>&#8722;6.380242524</td><td>0.011651515</td></tr><tr><td>Pou2af1</td><td>POU domain, class 2, associating factor 1</td><td>9.055182034</td><td>0.019402858</td></tr><tr><td>Dnm1</td><td>Dynamin 1</td><td>&#8722;12.9307709</td><td>0.050431759</td></tr></table>
da835a91fafb1974f8068a4146d6f5a96528773b66bbef70c67cf35807f66987.png
simple
<table><tr><td>Variable</td><td>Baseline</td><td>6 months</td></tr><tr><td>Energy (Kcal)</td><td>2225 &#177; 1109</td><td>1589 &#177; 384 **</td></tr><tr><td>Carbohydrate (g)</td><td>273 &#177; 194</td><td>199 &#177; 74 *</td></tr><tr><td>Protein (g)</td><td>98 &#177; 36</td><td>78 &#177; 23 *</td></tr><tr><td>Fat (g)</td><td>84 &#177; 39</td><td>55 &#177; 18 **</td></tr><tr><td>Starch (g)</td><td>148 &#177; 48</td><td>114 &#177; 36 *</td></tr><tr><td>Sugar (g)</td><td>121 &#177; 171</td><td>74 &#177; 64</td></tr><tr><td>Non-starch polysaccharide (g)</td><td>18 &#177; 5</td><td>14 &#177; 3 **</td></tr><tr><td>Saturated fatty acids (g)</td><td>30 &#177; 16</td><td>20 &#177; 6 **</td></tr><tr><td>Monounsaturated fatty acids (g)</td><td>29 &#177; 12</td><td>19 &#177; 7 **</td></tr><tr><td>Polyunsaturated fatty acids (g)</td><td>16 &#177; 8</td><td>10 &#177; 4 **</td></tr></table>
a0ded3f2af5127bd996b7d6abda419dc72289f41d05390271d6499e1f4b606fd.png
simple
<table><tr><td></td><td>Knee pain<i>n </i>= 404</td><td>Symptomaticknee OA<i>n </i>= 109</td><td>OR (95% CI)</td></tr><tr><td>Pain unbearable at times</td><td>36%</td><td>59%</td><td>2.0 (1.3 to 3.3)</td></tr><tr><td>Limited activity</td><td>39%</td><td>64%</td><td>2.4 (1.5 to 4.0)</td></tr><tr><td>Herbal medicine</td><td>25%</td><td>60%</td><td>4.4 (2.7 to 7.5)</td></tr><tr><td>Acupuncture</td><td>20%</td><td>40%</td><td>2.2 (1.3 to 3.8)</td></tr><tr><td>Massage</td><td>4%</td><td>6%</td><td>1.2 (0.4 to 3.3)</td></tr><tr><td>Other TCM</td><td>26%</td><td>35%</td><td>1.6 (0.9 to 2.6)</td></tr><tr><td>NSAIDs</td><td>78%</td><td>88%</td><td>2.1 (1.1 to 4.4)</td></tr><tr><td>Paracetamol</td><td>2%</td><td>6%</td><td>3.4 (1.0 to 11.2)</td></tr><tr><td>Other Western medicine</td><td>13%</td><td>21%</td><td>2.0 (1.0 to 4.0)</td></tr><tr><td>Physiotherapy</td><td>10%</td><td>17%</td><td>1.1 (0.5 to 2.2)</td></tr><tr><td>Doctor past year?</td><td>33%</td><td>59%</td><td>2.9 (1.8 to 4.8)</td></tr></table>
227bbc83cf3746211a67b68be817d86b08d463ede9f786d54144076700949c23.png
complex
<table><tr><td colspan="7">S-RNase Region (codon positions)</td></tr><tr><td>Test</td><td>HVa (1-38)</td><td>HVb (44-62)</td><td>C3 (63-68)</td><td>V1 (69-84)</td><td>C4 (85-93)</td><td>V2 (94-131)</td></tr><tr><td>&#969;p/&#969;s&#945;<i>Physalis </i>codons</td><td>7,8, 10,11, 13,14,15, 26, 33</td><td>44, 46, 4952, 53,56 (0.97), 5962</td><td>----</td><td>69, 71, 84</td><td>87 (0.98)</td><td>9, 101, 104, 110, 111,112, 119 (0.96), 120 (0.96),123, 124 (0.97), 125127 (0.95), 129, 131</td></tr><tr><td>FEL CSPb<i>Physalis </i>codons</td><td>8, 9,13, 24,26 (0.08), 31</td><td>46, 53</td><td>-</td><td>84</td><td>87</td><td>96, 99, 116, 125127, 129, 131</td></tr><tr><td>FEL Clade A<i>Physalis </i>codons</td><td>3, 6, 9,10, 13</td><td>46, 56</td><td>-</td><td></td><td>87, 89, 90</td><td>96, 99, 110, 121</td></tr><tr><td>FEL Clade C<i>Physalis </i>codons</td><td>9, 14, 24</td><td>44, 57</td><td>-</td><td></td><td>92</td><td>97, 127, 129</td></tr><tr><td>FEL Clade Sc<i>Solanum </i>codons</td><td>21, 22, 23, 2930, 32, 34, 35, 38</td><td>60</td><td>Clade A as forground-</td><td>77</td><td></td><td>103, 106, 109</td></tr><tr><td>FEL Clade Sc<i>Solanum </i>codons</td><td>23, 31</td><td>47, 48, 50</td><td>Clade C as forground-</td><td>80</td><td></td><td>124</td></tr></table>
d6b4d8751feb7a62f5a566b4769def58acf393b3e64b0fbcb28298c0a0123e93.png
complex
<table><tr><td>Species</td><td>Volume (&#956;L)</td><td>Mycotoxin</td><td>Extraction Procedure</td><td>Detection Technique</td><td>LOD (&#956;g/L)</td><td>LOQ (&#956;g/L)</td><td>Reference</td></tr><tr><td colspan="8"><i>Single mycotoxin</i></td></tr><tr><td>Human</td><td>50</td><td>OTA</td><td>LLE: CH<sub>2</sub>Cl<sub>2</sub></td><td>ELISA vs. CE-LIF (CE/laser-induced FD)</td><td>0.5</td><td>-</td><td>[39]</td></tr><tr><td>Human</td><td>-</td><td>OTA</td><td>IAC</td><td>HPLC-FD</td><td>-</td><td>-</td><td>[42]</td></tr><tr><td>Human</td><td>-</td><td>OTA</td><td>SPE: Sep-Pak RP-18. IAC: Ochraprep</td><td>HPLC-FD</td><td>0.1</td><td>0.4</td><td>[44]</td></tr><tr><td>Human</td><td>-</td><td>OTA</td><td>LLE: CHCl<sub>3</sub>/HCl</td><td>HPLC-FD</td><td>0.05</td><td>-</td><td>[35]</td></tr><tr><td>Human</td><td>2000</td><td>OTA</td><td>LLE: CHCl<sub>3</sub></td><td>HPLC-FD LC-ESI-MS/MS</td><td>0.01</td><td>0.07</td><td>[36]</td></tr><tr><td>Human</td><td>6000</td><td>OTA</td><td>SPE: C18</td><td>HPLC-FD</td><td>0.1</td><td>0.2</td><td>[41]</td></tr><tr><td>Human</td><td>1000</td><td>OTA</td><td>LLE: CHCl<sub>3</sub>, SPE</td><td>HPLC-FD</td><td>0.05</td><td>-</td><td>[37]</td></tr><tr><td>Human</td><td>2000&#8211;3000</td><td>OTA</td><td>LLE: CHCl<sub>3</sub>, IAC: Ochraprep</td><td>ELISA and HPLC-FD</td><td>-</td><td>0.050</td><td>[38]</td></tr><tr><td>Human</td><td>-</td><td>OTA</td><td>IAC: Ochraprep</td><td>HPLC-FD</td><td>-</td><td>0.1</td><td>[43]</td></tr><tr><td>Human</td><td>-</td><td>AFB1</td><td>IAC: Easi-Extract Aflatoxin</td><td>ELISA</td><td>-</td><td>-</td><td>[50]</td></tr><tr><td>Rat</td><td>100</td><td>ZON</td><td>LLE: TBME</td><td>LC-MS/MS</td><td>-</td><td>0.5</td><td>[48]</td></tr><tr><td>Rat</td><td>100</td><td>ZON</td><td>LLE: TBME</td><td>HPLC-FD</td><td>-</td><td>10</td><td>[49]</td></tr><tr><td>Swine</td><td>800</td><td>OTA</td><td>LLE: CH<sub>2</sub>Cl<sub>2</sub></td><td>HPLC</td><td>0.1</td><td>-</td><td>[40]</td></tr><tr><td>Chicken</td><td>250</td><td>DON</td><td>LLE: ACN</td><td>LC-MS/MS</td><td>0.1&#8211;0.2</td><td>1</td><td>[46,47]</td></tr><tr><td>Horse</td><td>2000</td><td>OTA</td><td>LLE: CH<sub>2</sub>Cl<sub>2</sub>, IAC: Ochratest</td><td>ELISA, HPLC-FD</td><td>0.015</td><td>-</td><td>[21]</td></tr><tr><td colspan="8"><i>Multi-mycotoxin</i></td></tr><tr><td>Human</td><td>500</td><td>OTA, OT&#945;</td><td>LLE: CHCl<sub>3</sub>/isopropanol</td><td>HPLC-FD</td><td>0.05</td><td>0.1</td><td>[58]</td></tr><tr><td>Chicken</td><td>20&#8211;250</td><td>EN B, EN B1</td><td>LLE: ACN</td><td>LC/MS/MS, UHPLC-HRMS</td><td>0.000091&#8211;0.00017</td><td>0.025</td><td>[45]</td></tr><tr><td>Pig</td><td>250</td><td>EN A, A1, B, B1</td><td>LLE: ACN</td><td>LC-MS/MS</td><td>0.01&#8211;0.001</td><td>0.1&#8211;0.2</td><td>[52,53]</td></tr><tr><td>Pig</td><td>250</td><td>DON, T-2, HT-2, OTA, FB1, AFB1, ZON, ZAN, &#945;-ZOL, &#946;-ZOL, &#945;-ZAL, &#946;-ZAL, DOM-1</td><td>LLE: ACN</td><td>LC-MS/MS</td><td>0.01&#8211;0.52</td><td>0.5&#8211;10</td><td>[51,54]</td></tr><tr><td>Chicken, pig, laying hens, turkey poults</td><td>250</td><td>ZON, &#945;-ZOL, &#946;-ZOL, ZAN, &#945;-ZAL, &#946;-ZAL</td><td>LLE: ACN</td><td>LC&#8211;MS/MS (U)HPLC&#8211;HR-MS</td><td>0.004&#8211;0.07</td><td>0.2&#8211;5</td><td>[55,57]</td></tr><tr><td>Chicken, Pig</td><td>250</td><td>DON, 3-ADON, 15-ADON, DOM-1</td><td>LLE: ACN</td><td>LC&#8211;MS/MS</td><td>0.01&#8211;0.7</td><td>0.1&#8211;2</td><td>[56]</td></tr><tr><td>Fish</td><td>250</td><td>AFB1, AFB2, AFG1, AFG2, OTA, FUS-X, STG, FB1, FB2, FB3, BEA, EN A, EN A1, EN B, EN B1</td><td>DLLME: ACN/EtOAc</td><td>LC/MS/MS</td><td>0.1&#8211;12.0</td><td>1.5&#8211;17.0</td><td>[59]</td></tr></table>
a184f66ee31023854512c4f4c81f43e56c55c9e7a1a7b80b8d4c9243cf232136.png
simple
<table><tr><td>Product/active ingredient(s)</td><td>Formulation</td><td>Country of origin*</td><td>2005 availability (n = 29)</td><td>Named in the top 3 sellers in 2005 (n = 28)</td><td>Mean selling price 2005<sup>&#8224;</sup></td></tr><tr><td>1. artemether/lumefantrine</td><td>20/120 mg tablets, <i>co-formulated</i></td><td>Switzerland</td><td>21 (72.4%)</td><td>5 (17.9%)</td><td>$ 7.59</td></tr><tr><td>2. artesunate and mefloquine</td><td>200 mg and 250 mg tablets, <i>co-packaged</i></td><td>Switzerland</td><td>17 (58.6%)</td><td>0</td><td>$ 7.05</td></tr><tr><td>3. artesunate</td><td>50 mg tablets</td><td>China</td><td>6 (20.7%)</td><td>0</td><td>$ 4.62</td></tr><tr><td>4. artesunate</td><td>50 mg tablets</td><td>France</td><td>24 (82.8%)</td><td>7 (25.0%)</td><td>$ 5.48</td></tr><tr><td>5. artesunate</td><td>50 mg tablets</td><td>Switzerland</td><td>8 (27.6%)</td><td>0</td><td>$ 5.26</td></tr><tr><td>6. artesunate</td><td>50 mg tablets</td><td>Belgium</td><td>28 (96.6%)</td><td>3 (10.7%)</td><td>$ 3.53</td></tr><tr><td>7. artesunate</td><td>50 mg tablets</td><td>India</td><td>17 (58.6%)</td><td>0</td><td>$ 2.51</td></tr><tr><td>8. artesunate</td><td>100 mg tablets</td><td>Belgium</td><td>28 (96.6%)</td><td>28 (100%)</td><td>$ 4.99</td></tr><tr><td>9. artesunate</td><td>100 mg tablets</td><td>Tanzania</td><td>7 (24.1%)</td><td>1 (3.6%)</td><td>$ 2.19</td></tr><tr><td>10. artesunate</td><td>100 mg tablets</td><td>Tanzania</td><td>20 (69.0%)</td><td>6 (21.4%)</td><td>$ 1.92</td></tr><tr><td>11. artesunate</td><td>100 mg tablets</td><td>Kenya</td><td>2 (6.9%)</td><td>0</td><td>$ 2.31</td></tr><tr><td>12. artesunate</td><td>200 mg tablets</td><td>Switzerland</td><td>19 (65.5%)</td><td>1 (3.6%)</td><td>$ 6.72</td></tr><tr><td>13. artemether</td><td>40 mg tablets</td><td>India</td><td>8 (27.6% 0</td><td>0</td><td>$ 2.24</td></tr><tr><td>14. artemether</td><td>50 mg tablets</td><td>China</td><td>24 (82.8%)</td><td>15 (53.6%)</td><td>$ 4.74</td></tr><tr><td>15. artemether</td><td>180 mg/60 ml suspension</td><td>Belgium</td><td>18 (62.1%)</td><td>0</td><td>$ 4.65</td></tr><tr><td>16. artemether</td><td>300 mg/100 ml suspension</td><td>Belgium</td><td>3 (10.3%)</td><td>0</td><td>$ 5.75</td></tr><tr><td>17. dihydroartemisinin</td><td>60 mg tablets</td><td>Korea</td><td>18 (62.1%)</td><td>0</td><td>$ 4.36</td></tr><tr><td>18. dihydroartemisinin</td><td>60 mg tablets</td><td>China</td><td>25 (86.2%)</td><td>9 (35.7%)</td><td>$ 4.55</td></tr><tr><td>19. dihydroartemisinin</td><td>160 mg/80 ml suspension</td><td>China</td><td>20 (69.0%)</td><td>0</td><td>$ 4.18</td></tr></table>
86443e811e0145c8b6511ad24d81220eec1087b3a92973e6073417cf237359f2.png
complex
<table><tr><td></td><td colspan="3">Overall survival</td><td colspan="3">Distant disease-free survival</td></tr><tr><td></td><td>HR</td><td>95% CI</td><td><i>P</i></td><td>HR</td><td>95% CI</td><td><i>P</i></td></tr><tr><td>pT2 + pT3</td><td>1.75</td><td>0.99 to 3.10</td><td>0.06</td><td>1.33</td><td>0.83 to 2.15</td><td>0.24</td></tr><tr><td>Molecular subtype</td><td></td><td></td><td>0.02</td><td></td><td></td><td>0.08</td></tr><tr><td> Basal</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td> Luminal A</td><td>0.22</td><td>0.08 to 0.60</td><td></td><td>0.46</td><td>0.25 to 0.85</td><td></td></tr><tr><td> HER2</td><td>0.25</td><td>0.03 to 1.85</td><td></td><td>0.53</td><td>0.16 to 1.73</td><td></td></tr><tr><td> Luminal B</td><td>0.87</td><td>0.48 to 1.59</td><td></td><td>0.82</td><td>0.49 to 1.38</td><td></td></tr><tr><td>Adjuvant chemotherapy</td><td>0.96</td><td>0.38 to 2.45</td><td>0.94</td><td></td><td></td><td></td></tr></table>
90f87ed6a577c7a2903c828da6c831139ad45fcae06a8d5dba102619a3bbe356.png
simple
<table><tr><td>Reference strains</td><td>International code<sup>1</sup></td><td>Source</td></tr><tr><td><i>L</i>.(<i>L</i>.)<i>mexicana </i></td><td>MHOM/BZ/62/BEL21</td><td>1</td></tr><tr><td><i>L</i>.(<i>L</i>.)<i>mexicana </i></td><td>MHOM/BZ/62/M379</td><td>1</td></tr><tr><td><i>L</i>.(<i>L</i>.)<i>amazonensis </i></td><td>IFLA/BR/67/PH8</td><td>1</td></tr><tr><td><i>L</i>.(<i>L</i>.)<i>amazonensis </i></td><td>MHOM/BR/73/M2269</td><td>1</td></tr><tr><td><i>L</i>.(<i>L</i>.)<i>garnhami </i></td><td>MHOM/VE/75/HM76</td><td>1</td></tr><tr><td><i>L</i>.(<i>L</i>.)<i>garnhami </i></td><td>MHOM/VE/76/JAP78</td><td>1</td></tr><tr><td><i>L</i>.(<i>L</i>.)<i>pifanoi </i></td><td>MHOM/VE/57/LL1</td><td>1</td></tr></table>
ab06a966021fbe991c8c14e13469afa08f6b6c4190b7736daea7138c93183ed3.png
complex
<table><tr><td>IHC</td><td colspan="2">FISH</td></tr><tr><td> </td><td>Positive</td><td>Negative</td></tr><tr><td>Positive</td><td>9</td><td>5</td></tr><tr><td>Negative</td><td>2</td><td>6</td></tr><tr><td>P value</td><td>0.183</td><td> </td></tr></table>
10ff450962b0330df253bff1d926143fae6bed1af0bc7c559258b7cfddb8de61.png
simple
<table><tr><td>Amplicon</td><td>Test of equality*</td><td>Test of variance**</td></tr><tr><td>Cav</td><td>p = 0.24</td><td>p &lt; 0.001</td></tr><tr><td>CTGF</td><td>p &lt; 0.001</td><td>p &lt; 0.001</td></tr><tr><td>Eln</td><td>p = 1</td><td>p &lt; 0.001</td></tr><tr><td>FN</td><td>p = 0.65</td><td>p &lt; 0.001</td></tr><tr><td>L27</td><td>p = 0.8</td><td>p &lt; 0.001</td></tr><tr><td>Perl</td><td>p = 1</td><td>p &lt; 0.001</td></tr><tr><td>PAI-1</td><td>p = 0.93</td><td>p &lt; 0.001</td></tr></table>
c93ef19ef8da8c1d2fbf437d7143ac0f53c96bdacda570e01bab1df071dfd6a3.png
simple
<table><tr><td>Scenarios (Detailed description in Method section)and total number of respondents</td><td><i>Expected responses (Detailed description in </i>Method<i> section)</i></td><td><i>Most often selected strategy by French respondents(N = 99)</i></td><td>Agreement in French study with expected choice(Yes/No/Partial)</td><td><i>Most often selected strategy by Swedish respondents</i>[[2]] <i>(N = 59)</i></td><td>Agreement in previous Swedish study with expected choice(Yes/No/Partial)</td><td>Agreement between French and previous Swedish study(Yes/No/Partial)</td></tr><tr><td>1 N = 96</td><td><i>Quick fix</i></td><td>Quick fix (41%)</td><td>Yes</td><td><i>Quick fix (54%)</i></td><td>Yes</td><td>Yes</td></tr><tr><td>2 N = 97</td><td><i>Quick fix or Symptom- guided MC</i></td><td>Clinical findings-guided MC (53%) (moderate consensus)</td><td>No</td><td><i>Symptom-guided MC (44%)</i></td><td>Yes</td><td>No</td></tr><tr><td>3 N = 91</td><td><i>Try again</i></td><td>2<sup>nd</sup> opinion (21%) or try again (20%)</td><td>Partial</td><td><i>Try again (42%)</i></td><td>Yes</td><td>Partial</td></tr><tr><td>4 N = 95</td><td><i>Symptom-guided MC or (possibly) Clinical findings-guidedMC</i></td><td>Symptom-guided MC (39%) or Clinical findings- guided MC(39%)</td><td>Yes</td><td><i>Symptom-guided MC (46%)</i></td><td>Yes</td><td>Yes</td></tr><tr><td>5 N = 95</td><td><i>Try again or External help-keep in touch</i></td><td>2<sup>nd</sup> opinion (27%)</td><td>No</td><td><i>Try again (25%) or Clinical findings- guided MC(24%)</i></td><td>Yes</td><td>No</td></tr><tr><td>6 N = 92</td><td><i>Try again or External help-keep in touch</i></td><td>External help- keep in touch (27%) or try again (26%)</td><td>Yes</td><td><i>Try again (37%)</i></td><td>Yes</td><td>Yes</td></tr><tr><td>7 N = 92</td><td><i>Try again or external help-keep in touch</i></td><td>2<sup>nd</sup> opinion (48%)</td><td>No</td><td><i>Try again (32%)</i></td><td>Yes</td><td>No</td></tr><tr><td>8 N = 92</td><td><i>2</i><sup><i>nd</i></sup><i>opinion</i></td><td>2<sup>nd</sup> opinion (71%) (excellent consensus)</td><td>Yes</td><td><i>2</i><sup><i>nd</i></sup><i>opinion (59%)</i></td><td>Yes</td><td>Yes</td></tr><tr><td>9 N = 91</td><td><i>2</i><sup><i>nd</i></sup><i>opinion</i></td><td>2<sup>nd</sup> opinion (61%) (moderate consensus)</td><td>Yes</td><td><i>2</i><sup><i>nd</i></sup><i>opinion (59%)</i></td><td>Yes</td><td>Yes</td></tr></table>
86104853957dcb90debbd5a16345fe229dabf4d2379efa6d605bafb63511ceae.png
complex
<table><tr><td>Genotype</td><td colspan="2">Number of subjects</td><td colspan="3">Overall effect</td><td colspan="3">Heterogeneity</td></tr><tr><td></td><td>COPD</td><td>Total</td><td>OR (95%CI)</td><td>Z</td><td>p</td><td>Chi<sup>2</sup></td><td>p</td><td>I<sup>2 </sup>(%)</td></tr><tr><td>GA/GG</td><td>1432/1201</td><td>6227/6188</td><td>1.27 (1.15- 1.40)</td><td>4.81</td><td>&lt;10<sup>-5</sup></td><td>7.71</td><td>0.17</td><td>35</td></tr><tr><td>AA/GG</td><td>438/1201</td><td>1621/6188</td><td>1.50 (1.30- 1.73)</td><td>5.51</td><td>&lt;10<sup>-5</sup></td><td>2.02</td><td>0.85</td><td>0</td></tr></table>
cb39a28b12963463ce7cfdb79eabd2ab1982a5c1590c0ea844d313ff8afc6383.png
simple
<table><tr><td>Sample name</td><td>Total reads</td><td>Total mapped</td><td>Multiple mapped</td><td>Uniquely mapped</td></tr><tr><td>L1</td><td>51313614</td><td>37633474 (73.34 %)</td><td>1891840 (3.69 %)</td><td>35741634 (69.65 %)</td></tr><tr><td>L2</td><td>38408586</td><td>28132542 (73.25 %)</td><td>1626290 (4.24 %)</td><td>26506252 69.01 %)</td></tr><tr><td>L3</td><td>38156116</td><td>23779230 (62.32 %)</td><td>1254082 (3.29 %)</td><td>22525148 (59.03 %)</td></tr><tr><td>L4</td><td>28642682</td><td>18996768 (66.32 %)</td><td>873594 (3.05 %)</td><td>18123174 (63.27 %)</td></tr><tr><td>L5</td><td>29417132</td><td>18996768 (64.58 %)</td><td>2319892 (7.89 %)</td><td>16676876 (56.69 %)</td></tr><tr><td>L6</td><td>34296982</td><td>24799284 (72.31 %)</td><td>1048878 3.06%)</td><td>23750406 (69.25 %)</td></tr><tr><td>L7</td><td>28755318</td><td>16604970 (57.75 %)</td><td>896548 (3.12 %)</td><td>15708422 (54.63 %)</td></tr><tr><td>L8</td><td>31712370</td><td>21846718 (68.89 %)</td><td>980318 (3.09 %)</td><td>20866400 (65.80 %)</td></tr><tr><td>L9</td><td>28387782</td><td>17806510 (62.73 %)</td><td>917208 (3.24 %)</td><td>16889302 (59.49 %)</td></tr><tr><td>L10</td><td>32217694</td><td>20532020 (63.73 %)</td><td>896152 (2.78 %)</td><td>19635868 (60.95 %)</td></tr><tr><td>H1</td><td>27038432</td><td>19212408 (71.06 %)</td><td>944260 (3.50 %)</td><td>18268148 (67.56 %)</td></tr><tr><td>H2</td><td>32458530</td><td>23913728 (73.67 %)</td><td>999786 (3.08 %)</td><td>22913942 (70.59 %)</td></tr><tr><td>H3</td><td>31355676</td><td>23459842 (74.82 %)</td><td>933980 (2.98 %)</td><td>22525862 (71.84 %)</td></tr><tr><td>H4</td><td>32236792</td><td>22698066 (70.41 %)</td><td>949798 (2.95 %)</td><td>21748268 (67.46 %)</td></tr><tr><td>H5</td><td>31144146</td><td>20791688 (66.76 %)</td><td>1004534 (3.23 %)</td><td>19787154 63.53 %)</td></tr><tr><td>H6</td><td>32072196</td><td>22910946 (71.44 %)</td><td>1293062 (4.04 %)</td><td>21617884 (67.40 %)</td></tr><tr><td>H7</td><td>38188984</td><td>25973682 (68.01 %)</td><td>1154850 (3.02 %)</td><td>24818832 64.99 %)</td></tr><tr><td>H8</td><td>32100360</td><td>23224306 (72.35 %)</td><td>945914 (2.95 %)</td><td>22278392 (69.40 %)</td></tr><tr><td>H9</td><td>30227962</td><td>20288464 (67.12 %)</td><td>997090 (3.30 %)</td><td>19291374 (63.82 %)</td></tr><tr><td>H10</td><td>29321524</td><td>19085218 (65.09 %)</td><td>1073550 (3.66 %)</td><td>18011668 (61.43 %)</td></tr><tr><td>H11</td><td>32631714</td><td>21820588 (66.87 %)</td><td>1021428 (3.13 %)</td><td>20799160 (63.74 %)</td></tr><tr><td>H12</td><td>26763546</td><td>14871754 (55.57 %)</td><td>748546 (2.80 %)</td><td>14123208 (52.77 %)</td></tr><tr><td>H13</td><td>28755192</td><td>16809674 (58.46 %)</td><td>870238 (3.03 %)</td><td>15939436 (55.43 %)</td></tr></table>
96f8875d467911661196450432415c82caf1b78ff44c87d70708cb6fbc06b815.png
complex
<table><tr><td></td><td colspan="2">Personality Disorder</td><td colspan="2">Healthy control</td></tr><tr><td></td><td>Passednumber, rate</td><td>Failednumber, rate</td><td><i>Passed</i><i>number, rate</i></td><td><i>Failed</i><i>number, rate</i></td></tr><tr><td>Hand lowering</td><td>55, 71.4%</td><td>22, 28.6%</td><td><i>106, 68.8%</i></td><td><i>48, 31.2%</i></td></tr><tr><td>Moving hands apart</td><td>52, 67.5%</td><td>25, 32.5%</td><td><i>108, 70.1%</i></td><td><i>46, 29.9%</i></td></tr><tr><td>Mosquito hallucination</td><td>44, 57.1%</td><td>33, 42.9%</td><td><i>89, 57.8%</i></td><td><i>65, 42.2%</i></td></tr><tr><td>Taste hallucination</td><td>55, 71.4%</td><td>22, 33.8%</td><td><i>98, 63.6%</i></td><td><i>56, 36.4%</i></td></tr><tr><td>Arm rigidity</td><td>52, 67.5%</td><td>25, 32.5%</td><td><i>99, 64.3%</i></td><td><i>55, 35.7%</i></td></tr><tr><td>Dream</td><td>38, 49.4%*</td><td>39, 50.6%</td><td><i>55, 35.7%</i></td><td><i>99, 64.3%</i></td></tr><tr><td>Age regression</td><td>65, 84.4%</td><td>12, 15.6%</td><td><i>127, 82.5%</i></td><td><i>27, 17.5%</i></td></tr><tr><td>Arm immobilization</td><td>42, 54.5%</td><td>35, 45.5%</td><td><i>76, 49.4%</i></td><td><i>78, 50.6%</i></td></tr><tr><td>Anosmia to ammonia</td><td>16, 20.8%</td><td>61, 79.2%</td><td><i>39, 25.3%</i></td><td><i>115, 74.7%</i></td></tr><tr><td>Hallucinated voice</td><td>7, 9.1%</td><td>70, 90.9%</td><td><i>10, 6.5%</i></td><td><i>144, 93.5%</i></td></tr><tr><td>Negative visual hallucination</td><td>23, 29.9%</td><td>54, 70.1%</td><td><i>52, 33.8%</i></td><td><i>102, 66.2%</i></td></tr><tr><td>Posthypnotic amnesia</td><td>22, 28.6%*</td><td>55, 71.4%</td><td><i>23, 14.9%</i></td><td><i>131, 85.1%</i></td></tr></table>
75e2b1e699d93a136cbcba555a39da0a6dd72e11fc78c58a7207fbf6e99c01e4.png
simple
<table><tr><td>Gene name</td><td>Description</td><td>Adjusted <i>P</i> value (DB/WT)</td><td>Adjusted <i>P</i> value (GGQL/DB)</td></tr><tr><td>Pgam1</td><td>Phosphoglycerate mutase 1</td><td>&lt;0.0001</td><td>0.0038</td></tr><tr><td>Igf1</td><td>Insulin-like growth factor 1</td><td>0.0060</td><td>0.0029</td></tr><tr><td>Cpeb4</td><td>Cytoplasmic polyadenylation element binding protein 4</td><td>0.0141</td><td>0.0283</td></tr><tr><td>Slc38a2</td><td>Solute carrier family 38, member 2</td><td>0.0000</td><td>&lt;0.0001</td></tr><tr><td>Vegfa</td><td>Vascular endothelial growth factor A</td><td>0.0001</td><td>0.0005</td></tr><tr><td>Banp</td><td>BTG3-associated nuclear protein</td><td>&lt;0.0001</td><td>0.0100</td></tr><tr><td>Rbm38</td><td>RNA-binding motif protein 38</td><td>0.0078</td><td>0.0380</td></tr><tr><td>Rasgef1b</td><td>RasGEF domain family, member 1B</td><td>0.0003</td><td>0.0037</td></tr><tr><td>Anxa3</td><td>Annexin A3</td><td>&lt;0.0001</td><td>0.0309</td></tr><tr><td>Cyp1a1</td><td>Cytochrome P450, family 1, subfamily a, polypeptide 1</td><td>&lt;0.0001</td><td>0.0016</td></tr><tr><td>Trib1</td><td>Tribbles homolog 1 (Drosophila)</td><td>0.0004</td><td>0.0118</td></tr><tr><td>Nphp3</td><td>Nephronophthisis 3 (adolescent)</td><td>&lt;0.0001</td><td>0.0275</td></tr><tr><td>Fhl3</td><td>Four and a half LIM domains 3</td><td>0.0036</td><td>0.0045</td></tr><tr><td>Serpine1</td><td>Serine (or cysteine) peptidase inhibitor, clade E, member 1</td><td>&lt;0.0001</td><td>0.0016</td></tr><tr><td>Acer2</td><td>Alkaline ceramidase 2</td><td>&lt;0.0001</td><td>0.0016</td></tr><tr><td>Arhgap32</td><td>Rho GTPase activating protein 32</td><td>&lt;0.0001</td><td>&lt;0.0001</td></tr><tr><td>Atf4</td><td>Activating transcription factor 4</td><td>0.0044</td><td>0.0016</td></tr><tr><td>Zc3h6</td><td>Zinc finger CCCH type containing 6</td><td>&lt;0.0001</td><td>0.0136</td></tr><tr><td>Tet1</td><td>Tet methylcytosine dioxygenase 1</td><td>0.0006</td><td>0.0016</td></tr><tr><td>Klk1b26</td><td>Kallikrein 1-related petidase b26</td><td>0.0146</td><td>0.0189</td></tr><tr><td>Ppp1r3c</td><td>Protein phosphatase 1, regulatory (inhibitor) subunit 3C</td><td>0.0000</td><td>0.0029</td></tr><tr><td>Ttc30b</td><td>Tetratricopeptide repeat domain 30B</td><td>&lt;0.0001</td><td>0.0054</td></tr><tr><td>Fign</td><td>Fidgetin</td><td>&lt;0.0001</td><td>0.0195</td></tr><tr><td>AI593442</td><td>Expressed sequence AI593442</td><td>&lt;0.0001</td><td>0.0350</td></tr><tr><td>5730480H06Rik</td><td>RIKEN cDNA 5730480H06 gene</td><td>0.0019</td><td>0.0029</td></tr><tr><td>Gm26703</td><td>Predicted gene, 26703</td><td>&lt;0.0001</td><td>&lt;0.0001</td></tr></table>
f77f91fb3423483dc45cd52b948182e23f9cf72c3159874da2462dc9452ec947.png
simple
<table><tr><td>Risk Factor Increase</td><td>Risk Factor</td><td>Mean % Change in Daily Visits per Risk Factor Increase</td><td>T-test p-value</td></tr><tr><td>0.01 ppm</td><td>Ozone</td><td>3.2 (1.4, 5)</td><td>0.000</td></tr><tr><td>1 &#956;g m<sup>-3</sup></td><td>PM2.5</td><td>-0.2 (-0.6, 0.2)</td><td>0.331</td></tr><tr><td>1000 spores m<sup>-3</sup></td><td>Mold Count</td><td>-0.2 (-1.1, 0.7)</td><td>0.707</td></tr><tr><td>10 grains m<sup>-3</sup></td><td>Weed Pollen</td><td>-2.9 (-6.8, 1.1)</td><td>0.148</td></tr><tr><td>100 grains m<sup>-3</sup></td><td>Tree Pollen</td><td>1.8 (0.9, 2.6)</td><td>0.000</td></tr><tr><td>10 grains m<sup>-3</sup></td><td>Grass Pollen</td><td>1.6 (-2, 5.4)</td><td>0.378</td></tr><tr><td>1&#176;F</td><td>Temperature</td><td>0.2 (0.1, 0.4)</td><td>0.007</td></tr></table>
6213fe61e50c9d449c956aa8455e7af15492014904c332b5e038e657e7c0a423.png
complex
<table><tr><td>Knockout mouse</td><td>Phenotype</td><td>Reference</td></tr><tr><td rowspan="2">TRPC1</td><td>No effect on Ang II-induced cardiac hypertrophy</td><td rowspan="2">(39)</td></tr><tr><td>Reduced pathological cardiac hypertrophy by double knockout with TRPC4</td></tr><tr><td rowspan="2">TRPC3</td><td>Resistant to pressure-overload-induced cardiac remodeling</td><td>(4, 5, 18)</td></tr><tr><td>Reduced ischemia&#8211;reperfusion (I/R) injury by triple knockout with TRPC6 and TRPC7</td><td>(59)</td></tr><tr><td rowspan="2">TRPC4</td><td>No effect on Ang II-induced cardiac hypertrophy</td><td rowspan="2">(39)</td></tr><tr><td>Reduced pathological cardiac hypertrophy by double knockout with TRPC4</td></tr><tr><td>TRPC5</td><td>No further reduction of pathological cardiac hypertrophy to that of double knockout of TRPC1/C4</td><td>(39)</td></tr><tr><td rowspan="2">TRPC6</td><td>Resistant to pressure-overload induced cardiac remodeling</td><td>(18)</td></tr><tr><td>Reduced I/R injury by triple knockout with TRPC3 and TRPC7</td><td>(59)</td></tr><tr><td>TRPC7</td><td>Reduced I/R injury by triple knockout with TRPC3 and TRPC6</td><td>(59)</td></tr></table>
dcbe0a72fb6d98870e2900aaf20bf0dc7a4448f9bae65433ee54b22eb913ecd5.png
simple
<table><tr><td>Category</td><td>Variables</td><td>Key references</td></tr><tr><td>Personal social learning indicators</td><td>Willingness to share ideas with other stakeholders</td><td>Pelling and High (2005); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray, Roux, and Hill (2010); Muro and Jeffrey (2012); Bos, Brown, and Farrelly (2013); Cundill et al. (2013).</td></tr><tr><td></td><td>Development of trust among stakeholders</td><td>Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Cundill et al. (2013)</td></tr><tr><td></td><td>Participation by all stakeholders</td><td>Pelling et al. (2008); Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012)</td></tr><tr><td></td><td>Capacity for conflict resolution</td><td>Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)</td></tr><tr><td></td><td>Collective action towards project goals</td><td>Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013)</td></tr><tr><td></td><td>Continuous interaction and feedback</td><td>Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010)</td></tr><tr><td></td><td>Flexibility in planning and implementation</td><td>Pelling and High (2005); Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)</td></tr><tr><td></td><td>Willingness to share information</td><td>Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013)</td></tr><tr><td>Organisational variables</td><td>Empowerment of junior employees to experiment</td><td>Pelling and High (2005); Pelling et al. (2008); Nilsson and Swartling (2009); Cundill (2010); Bos et al. (2013)</td></tr><tr><td></td><td>Existence of processes to translate feedback into changed practices</td><td>Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Bos et al. (2013); Ta&#768;bara et al. (2010)</td></tr><tr><td></td><td>Sufficient budget to regularly engage with stakeholders</td><td>Cundill (2010); Roux et al. (2011); Murray et al. (2010); Cundill et al. (2013)</td></tr><tr><td></td><td>Continuous updating of project or planning processes</td><td>Nilsson and Swartling (2009); Muro and Jeffrey (2012); Ta&#768;bara et al. (2010).</td></tr><tr><td></td><td>Support for locally initiated projects</td><td>Bos et al. (2013); Cundill et al. (2013)</td></tr><tr><td></td><td>Development of local stakeholders&#8217; capacity to engage with projects or interventions</td><td>Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)</td></tr></table>
2c98d43ab0e084b7c6f3bdd39843ecdca776df0261aa318b91484859a15f4ce1.png
simple
<table><tr><td>Tissue</td><td>miRNA</td><td>Molecular targets</td><td>Functions</td><td>Reference</td></tr><tr><td>Aging heart</td><td>miR-21 &#8593;</td><td>ERK&#8211;MAP kinase signaling</td><td>Profibrotic [role on cardiac fibroblast (CFs)]</td><td>(51)</td></tr><tr><td>Aging heart</td><td>miR-22 &#8593;</td><td>Mimecan/Osteoglycin</td><td>Accelerate CF senescence and migration</td><td>(52)</td></tr><tr><td>Aging heart</td><td>miR-18 and miR-19 &#8595;</td><td>Thrombospondin-1 and connective tissue growth factor</td><td>Anti-heart failure-related fibrosis during aging</td><td>(58)</td></tr><tr><td>Aging heart</td><td>miR-17-3p &#8595;</td><td>PAR-4</td><td>Reduce CF cellular senescence</td><td>(61)</td></tr><tr><td>Aging heart</td><td>miR-34a &#8593;</td><td>Phosphatase 1 nuclear targeting subunit</td><td>Increase age-related cardiomyocyte apoptosis and cardiac dysfunction</td><td>(62)</td></tr><tr><td>Vascular aging</td><td>miR-34a &#8593;</td><td>SIRT1</td><td>Stimulates senescence in endothelial cell and vascular smooth muscle cells</td><td>(68, 71)</td></tr><tr><td>Vascular aging</td><td>miR-217 &#8593;</td><td>SIRT1</td><td>Stimulates endothelial senescence decreasing nitric oxide</td><td>(73)</td></tr><tr><td>Vascular aging</td><td>miR-29 &#8593;</td><td>Collagen and elastin</td><td>Extracellular matrix impairment (risk of age-related aortic aneurism)</td><td>(74&#8211;77)</td></tr><tr><td>Vascular aging</td><td>miR-146 &#8593; or &#8595;</td><td>IRAK and NOX4</td><td>Pro-inflammation or anti-oxidative stress</td><td>(78, 79)</td></tr><tr><td>Vascular aging</td><td>miR-92 &#8595;</td><td>Tumor necrosis factor &#945; receptor 1 and collagen type 1</td><td>miR-92 reduction mimic arterial aging</td><td>(80)</td></tr></table>
4216056c5d1af6e0a647c8d359a2fb2ee36c923c6e10d1d5a59cfa457e27c1fe.png
complex
<table><tr><td></td><td colspan="6">Cisplatin excretion</td></tr><tr><td></td><td colspan="2">0&#8211;12 h</td><td colspan="2">12&#8211;24 h</td><td colspan="2">24&#8211;48 h</td></tr><tr><td></td><td>SCT (R/<i>p</i> value)</td><td>ULiR (<i>p</i> value)</td><td>SCT (R/<i>p</i> value)</td><td>ULiR (<i>p</i> value)</td><td>SCT (R/<i>p</i> value)</td><td>ULiR (<i>p</i> value)</td></tr><tr><td>Number variation (range)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Haemoglobin</td><td>0.000/1.000</td><td>0.7375</td><td>0.047/0.737</td><td>0.7835</td><td>0.024/0.867</td><td>0.0609</td></tr><tr><td> Leukocytes</td><td>0.101/0.471</td><td>0.4833</td><td>0.256/0.064</td><td>0.1695</td><td>0.162/0.247</td><td>0.1122</td></tr><tr><td> Neutrophils</td><td>0.125/0.372</td><td>0.4689</td><td>0.237/0.088</td><td>0.0969</td><td>0.183/0.190</td><td>0.0740</td></tr><tr><td> Lymphocytes</td><td>0.071/0.613</td><td>0.2391</td><td>0.118/0.401</td><td>0.9156</td><td>0.073/0.605</td><td>0.1955</td></tr><tr><td> Platelets</td><td>&#8722;0.170/0.223</td><td>0.3899</td><td>0.063/0.653</td><td>0.6527</td><td>&#8722;0.350/0.806</td><td>0.9802</td></tr><tr><td> Creatinine</td><td>&#8722;0.055/0.698</td><td>0.7700</td><td>0.105/0.459</td><td>0.5176</td><td>0.290/0.037</td><td>0.3827</td></tr><tr><td> Creatinine clearance</td><td>0.009/0.951</td><td>0.9380</td><td>0.096/0.496</td><td>0.7957</td><td>0.259/0.063</td><td>0.3884</td></tr><tr><td></td><td>SCT (R/<i>p</i> value)</td><td>ULoR (<i>p</i> value)</td><td>SCT (R/<i>p</i> value)</td><td>ULoR (<i>p</i> value)</td><td>SCT (R/<i>p</i> value)</td><td>ULoR (<i>p</i> value)</td></tr><tr><td>Severity by grade</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Anaemia</td><td>0.073/0.601</td><td>0.3811</td><td>0.141/0.315</td><td>0.4889</td><td>0.025/0.858</td><td>0.3717</td></tr><tr><td> Leukopenia</td><td>0.041/0.771</td><td>0.8971</td><td>&#8722;0.039/0.784</td><td>0.5143</td><td>0.061/0.663</td><td>0.7397</td></tr><tr><td> Neutropenia</td><td>&#8722;0.007/0.960</td><td>0.9863</td><td>&#8722;0.067/0.632</td><td>0.3471</td><td>0.047/0.741</td><td>0.7066</td></tr><tr><td> Lymphopenia</td><td>0.071/0.613</td><td>0.4500</td><td>0.118/0.401</td><td>0.2684</td><td>0.073/0.605</td><td>0.7810</td></tr><tr><td> Thrombocytopenia</td><td>0.038/0.786</td><td>0.3511</td><td>&#8722;0.067/0.631</td><td>0.2847</td><td>&#8722;0.020/0.889</td><td>0.4774</td></tr><tr><td> Increase in serum creatinine</td><td>&#8722;0.069/0.627</td><td>0.6263</td><td>0.200/0.155</td><td>0.9527</td><td>0.325/0.019</td><td>0.1462</td></tr><tr><td> Reduction in creatinine clearance</td><td>&#8722;0.100/0.483</td><td>0.4715</td><td>0.249/0.078</td><td>0.9217</td><td>0.276/0.050</td><td>0.7730</td></tr><tr><td> Nausea</td><td>&#8722;0.065/0.642</td><td>0.6791</td><td>&#8722;0.124/0.377</td><td>0.5203</td><td>0.009/0.949</td><td>0.7742</td></tr><tr><td> Vomiting</td><td>&#8722;0.101/0.471</td><td>0.4140</td><td>&#8722;0.154/0.270</td><td>0.7819</td><td>&#8722;0.024/0.866</td><td>0.9087</td></tr><tr><td> Diarrhoea</td><td>&#8722;0.195/0.161</td><td>0.1685</td><td>&#8722;0.103/0.463</td><td>0.3765</td><td>&#8722;0.044/0.754</td><td>0.6894</td></tr></table>
634eb4c98902f0157fadaf5899518dcb568207cc6b13371d78c421171af4c047.png
complex
<table><tr><td rowspan="3">Type of TEAE observed</td><td colspan="4">No. (%) of subjects</td></tr><tr><td colspan="2">ESRD subjects (<i>n</i> = 8)</td><td rowspan="2">Healthy subjects (<i>n</i> = 8)</td><td rowspan="2">Total (<i>N</i> = 16)</td></tr><tr><td>Dosing after hemodialysis</td><td>Dosing before hemodialysis</td></tr><tr><td>Any TEAE</td><td>3 (37.5)</td><td>2 (25.0)</td><td>1 (12.5)</td><td>5 (31.3)</td></tr><tr><td>Upper RTI</td><td>2 (25.0)</td><td>0</td><td>0</td><td>2 (12.5)</td></tr><tr><td>Viral upper RTI</td><td>1 (12.5)</td><td>0</td><td>0</td><td>1 (6.3)</td></tr><tr><td>Dizziness</td><td>1 (12.5)</td><td>0</td><td>0</td><td>1 (6.3)</td></tr><tr><td>Headache</td><td>0</td><td>1 (12.5)</td><td>0</td><td>1 (6.3)</td></tr><tr><td>Infusion site erythema</td><td>0</td><td>0</td><td>1 (12.5)</td><td>1 (6.3)</td></tr><tr><td>Bronchospasm</td><td>0</td><td>1 (12.5)</td><td>0</td><td>1 (6.3)</td></tr><tr><td>Papular rash</td><td>1 (12.5)</td><td>0</td><td>0</td><td>1 (6.3)</td></tr></table>
84a0df35d85cd0e263ae144ea3c33ab2517ae96f237a6b71320d68bb5b231fb9.png
complex
<table><tr><td colspan="2">Clinical N staging</td></tr><tr><td>cN0</td><td>3 (11.5%)</td></tr><tr><td>cN1</td><td>6 (23.1%)</td></tr><tr><td>cN2</td><td>14 (53.8%)</td></tr><tr><td>cN3</td><td>3 (11.5%)</td></tr></table>
86121301a7a292f1a0fb3550553f33854ee8bea15120246272ff946cfa5ab49a.png
simple
<table><tr><td>Species (tax id, short name)</td><td>Number of proteins</td><td>Number of PPI</td><td>Source</td></tr><tr><td><i>E. coli</i> K12 (83333, eco)</td><td>4121</td><td>216426</td><td>SNDB [22]</td></tr><tr><td><i>S. typhimurium</i> (99287, stm)</td><td>4239</td><td>94609</td><td>SNDB [22]</td></tr><tr><td><i>C. crescentus</i> (190650, ccr)</td><td>3365</td><td>40524</td><td>SNDB [22]</td></tr><tr><td>Yeast (4932, sce)</td><td>4738</td><td>15417</td><td>DIP [13]</td></tr><tr><td>Fly (7227, dme)</td><td>7165</td><td>23484</td><td>DIP [13]</td></tr><tr><td>Worm (6239, cel)</td><td>3029</td><td>3393</td><td>DIP [13]</td></tr></table>
84b5bfd938f3a90c8ff6e9b5d3141760aa80f0ceb05ef7de0a0fb7d37643627c.png
simple
<table><tr><td>Noise</td><td>Cluster Number</td><td>GO MF (-log P-value)</td><td>GO BP (-log P-value)</td><td>GO CC (-log P-value)</td></tr><tr><td>0%</td><td>50</td><td>5.18</td><td>7.44</td><td>6.38</td></tr><tr><td>5%</td><td>44.15 &#177; 2.28</td><td>5.19 &#177; 0.19</td><td>7.34 &#177; 0.31</td><td>6.52 &#177; 0.35</td></tr><tr><td>10%</td><td>42.49 &#177; 2.50</td><td>5.13 &#177; 0.28</td><td>7.26 &#177; 0.33</td><td>6.50 &#177; 0.35</td></tr><tr><td>15%</td><td>39.94 &#177; 2.69</td><td>5.20 &#177; 0.28</td><td>7.31 &#177; 0.44</td><td>6.51 &#177; 0.49</td></tr><tr><td>20%</td><td>37.43 &#177; 3.40</td><td>5.28 &#177; 0.48</td><td>7.54 &#177; 0.62</td><td>6.66 &#177; 0.53</td></tr><tr><td>25%</td><td>35.13 &#177; 2.98</td><td>5.29 &#177; 0.42</td><td>7.47 &#177; 0.54</td><td>6.59 &#177; 0.54</td></tr></table>
55fb7c423c9d09851b8b2761beed2469e453c8a0bb38cd8b2fe5fc6bbafd878e.png
simple
<table><tr><td>Variables</td><td>Total (<i>n</i> = 223)</td><td>U (<i>n</i> = 99)</td><td>B (<i>n</i> = 37)</td><td>V (<i>n</i> = 30)</td><td>B + V (<i>n</i> = 57)</td></tr><tr><td>Anxious/depressed <i>n</i> (%)</td><td>16.0 (7.2)</td><td>4.0 (4.0)</td><td>3.0 (8.1)</td><td>4.0 (13.3)</td><td>5.0 (8.8)</td></tr><tr><td>Withdrawn/depressed <i>n</i> (%)</td><td>15.0 (6.7)</td><td>3.0 (3.0)</td><td>5.0 (13.5)</td><td>3.0 (10.0)</td><td>4.0 (7.0)</td></tr><tr><td>Somatic complaints <i>n</i> (%)</td><td>28.0 (12.6)</td><td>11.0 (11.1)</td><td>7.0 (18.9)</td><td>3.0 (10.0)</td><td>7.0 (12.3)</td></tr><tr><td>Social problems <i>n</i> (%)</td><td>13.0 (5.8)</td><td>2.0 (2.0)</td><td>2.0 (5.4)</td><td>5.0 (16.7)</td><td>4.0 (7.0)</td></tr><tr><td>Thought problems <i>n</i> (%)</td><td>19.0 (8.5)</td><td>6.0 (6.1)</td><td>6.0 (16.2)</td><td>4.0 (13.3)</td><td>3.0 (5.3)</td></tr><tr><td>Attention problems <i>n</i> (%)</td><td>19.0 (8.5)</td><td>4.0 (4.0)</td><td>2.0 (5.4)</td><td>5.0 (16.7)</td><td>8.0 (14.0)</td></tr><tr><td>Rule-breaking <i>n</i> (%)</td><td>12.0 (5.4)</td><td>1.0 (1.0)</td><td>2.0 (5.4)</td><td>3.0 (10.0)</td><td>6.0 (10.5)</td></tr><tr><td>Aggressive behavior <i>n</i> (%)</td><td>20.0 (9.0)</td><td>3.0 (3.0)</td><td>1.0 (2.7)</td><td>7.0 (23.3)</td><td>9.0 (15.8)</td></tr><tr><td>Internalizing <i>n</i> (%)</td><td>34.0 (15.3)</td><td>10.0 (10.1)</td><td>8.0 (21.6)</td><td>7.0 (23.3)</td><td>9.0 (15.8)</td></tr><tr><td>Externalizing <i>n</i> (%)</td><td>30.0 (13.5)</td><td>7.0 (7.1)</td><td>3.0 (8.1)</td><td>8.0 (26.7)</td><td>12.0 (21.1)</td></tr><tr><td>Total <i>n</i> (%)</td><td>36.0 (16.1)</td><td>10.0 (10.1)</td><td>6.0 (16.2)</td><td>8.0 (26.7)</td><td>12.0 (21.1)</td></tr></table>
bd6d9d3128175b649e02b2831c7ed0f777da2d5aba08f89be9818c398450c68f.png
complex
<table><tr><td colspan="2">Age (yr)*</td><td>37.14 &#177; 7.58</td></tr><tr><td colspan="2">Employment record (yr)*</td><td>11.48&#177;4.47</td></tr><tr><td rowspan="3">Educational level**</td><td>Two trained courses after diploma</td><td>8(2.23)</td></tr><tr><td>Baccalaureate</td><td>311(86.11)</td></tr><tr><td>Masters/doctorate</td><td>42(11.66)</td></tr><tr><td rowspan="3">Marital status **</td><td>Married</td><td>72(19.91)</td></tr><tr><td>Single</td><td>279(77.21)</td></tr><tr><td>Divorced/Widow</td><td>10(2.88)</td></tr><tr><td rowspan="2">Gender</td><td>Female</td><td>339(93.94)</td></tr><tr><td>Male</td><td>22(6.06)</td></tr><tr><td rowspan="3">Current work setting **</td><td>General hospital</td><td>232(64.35)</td></tr><tr><td>Primary health care center</td><td>109(30.21)</td></tr><tr><td>Private hospital</td><td>20(5.54)</td></tr></table>
a4c04f52cd9ea4f6a90d54c3a7e8671e7e79b51cd9ab9d4c131e018a24ffb402.png
complex
<table><tr><td rowspan="2">Land</td><td rowspan="2">SE index* <sup>a</sup></td><td colspan="3">NO<sub>2</sub></td><td rowspan="2">Education* <sup>b</sup></td><td colspan="3">NO<sub>2</sub></td></tr><tr><td>n</td><td>Mean</td><td>S. D.</td><td>n</td><td>Mean</td><td>S. D.</td></tr><tr><td rowspan="5">Urban &lt;50%</td><td>1.04-1.24</td><td>11</td><td>18.71</td><td>4.31</td><td>2.72-3.03</td><td>11</td><td>17.14</td><td>6.11</td></tr><tr><td>1.25-1.34</td><td>16</td><td>13.29</td><td>3.55</td><td>3.04-3.24</td><td>13</td><td>13.40</td><td>4.62</td></tr><tr><td>1.35-1.46</td><td>10</td><td>11.69</td><td>4.81</td><td>3.25-3.49</td><td>25</td><td>10.01</td><td>3.97</td></tr><tr><td>1.47-1.65</td><td>24</td><td>12.43</td><td>5.65</td><td>3.50-3.82</td><td>12</td><td>13.30</td><td>6.04</td></tr><tr><td>1.66-2.05</td><td>5</td><td>5.39</td><td>1.94</td><td>3.83-4.26</td><td>8</td><td>15.27</td><td>6.14</td></tr><tr><td rowspan="5">Urban &#8805;50%</td><td>1.04-1.24</td><td>14</td><td>22.15</td><td>5.85</td><td>2.72-3.03</td><td>3</td><td>14.91</td><td>6.01</td></tr><tr><td>1.25-1.34</td><td>23</td><td>21.95</td><td>4.87</td><td>3.04-3.24</td><td>10</td><td>23.89</td><td>5.62</td></tr><tr><td>1.35-1.46</td><td>14</td><td>23.99</td><td>1.60</td><td>3.25-3.49</td><td>26</td><td>23.06</td><td>3.68</td></tr><tr><td>1.47-1.65</td><td>10</td><td>25.35</td><td>1.58</td><td>3.50-3.82</td><td>15</td><td>23.23</td><td>3.89</td></tr><tr><td>1.66-2.05</td><td>2</td><td>24.29</td><td>0.81</td><td>3.83-4.26</td><td>10</td><td>25.41</td><td>1.51</td></tr><tr><td rowspan="5">All</td><td>1.04-1.24</td><td>25</td><td>20.64</td><td>5.42</td><td>2.72-3.03</td><td>14</td><td>16.66</td><td>5.93</td></tr><tr><td>1.25-1.34</td><td>39</td><td>18.40</td><td>6.11</td><td>3.04-3.24</td><td>23</td><td>17.96</td><td>7.27</td></tr><tr><td>1.35-1.46</td><td>24</td><td>18.87</td><td>6.99</td><td>3.25-3.49</td><td>51</td><td>16.66</td><td>7.60</td></tr><tr><td>1.47-1.65</td><td>34</td><td>16.23</td><td>7.66</td><td>3.50-3.82</td><td>27</td><td>18.82</td><td>6.99</td></tr><tr><td>1.66-2.05</td><td>7</td><td>10.79</td><td>9.36</td><td>3.83-4.26</td><td>18</td><td>20.90</td><td>6.60</td></tr></table>
296447801ec1b121cc2d2b61456e0083e15e04bb3400ab72e0e9517a79eae53a.png
simple
<table><tr><td>Meta-Method</td><td>Mean Error</td></tr><tr><td>Fisher</td><td>0.276</td></tr><tr><td>POE with <i>Bss/Wss </i></td><td>0.375</td></tr><tr><td>POE with <i>IC </i></td><td>0.301</td></tr><tr><td>GeneMeta</td><td>0.525</td></tr><tr><td>RankProd</td><td>0.475</td></tr><tr><td>Simple</td><td>0.617</td></tr><tr><td>Cross-Validation</td><td>0.329</td></tr><tr><td>mDEDS</td><td>0.277</td></tr></table>
285e4a0c9c0bae47de998878964cd767337374a5aa2223074335d54b2c403390.png
complex
<table><tr><td>Question</td><td>Level of ecological framework targeted</td></tr><tr><td colspan="2">Introduction</td></tr><tr><td>1. How long have you worked/lived in [name of agency or community]?</td><td>N/A</td></tr><tr><td colspan="2">Meaning of Good Health</td></tr><tr><td>First, I want you to think about your own health and life.</td><td rowspan="3">Intra-Personal</td></tr><tr><td>2. What do you consider &#8220;good health&#8221;?</td></tr><tr><td>3. What do you think it means to live a healthy lifestyle?</td></tr><tr><td>Now I want you think about [insert name of community]. I&#8217;d like for you to think about the community residents that you see every day and interact with either personally or for your job. I also want you to think about the community&#8217;s physical environment, stores, restaurants, health and human services, community programs, and so on.</td><td rowspan="5">Community/Institutional</td></tr><tr><td>4. What does it mean for a community to be &#8220;healthy&#8221;?</td></tr><tr><td>5. Do you consider your community to be healthy?</td></tr><tr><td>6. How would you rate the health of this community as a whole on a scale of 1 to 5, with 1 being poor and 5 being excellent?</td></tr><tr><td><i>Probe:</i> What factors did you take into account with your rating?</td></tr><tr><td colspan="2">Enabling and Inhibiting Factors of Good Health</td></tr><tr><td>7. What are the values around being healthy in this community?</td><td rowspan="6">Inter-Personal</td></tr><tr><td>8. What are the unique characteristics (strengths) in [insert name of community] that help residents in being healthy?</td></tr><tr><td><i>Probe:</i> What other characteristics within this community support being healthy?</td></tr><tr><td>9. What are the unique characteristics (weaknesses) in [insert name of community] that prevent residents from being healthy?</td></tr><tr><td><i>Probe:</i> What other characteristics within your community discourage residents from being healthy?</td></tr><tr><td>10. Which of these characteristics, good and not good, are specific to the [insert Native/MSFW/Latino] culture in this community?</td></tr><tr><td>11. What are the biggest (or most important/pressing) health-related concerns in this community?</td><td rowspan="2">Community/Institutional</td></tr><tr><td><i>Probe:</i> In your point of view, what are the factors that contribute to these health problems?</td></tr><tr><td>12. What resources are available or in place in [insert name of community] to support healthy living among the residents?</td><td rowspan="3">Macro Level/Public Policy</td></tr><tr><td><i>Probe:</i> How much are these resources used by community residents?</td></tr><tr><td><i>Probe:</i> How widely known are these resources by community residents?</td></tr><tr><td colspan="2">Wrap Up</td></tr><tr><td>13. What are other important health issues in this community that we have not discussed so far?</td><td>All</td></tr></table>
f6b99bfd90033c9b7a816569decdbdb08b0a4a56666a195130a0f92c3ae46ad6.png
complex
<table><tr><td>Drug</td><td>Cases (n=32)</td><td>Controls (n=64)</td><td>p</td></tr><tr><td colspan="4">Zidovudine</td></tr><tr><td>Yes</td><td>11</td><td>12</td><td>0.15</td></tr><tr><td>No</td><td>21</td><td>52</td><td> </td></tr><tr><td colspan="4">Lamivudine</td></tr><tr><td>Yes</td><td>17</td><td>28</td><td>0.5</td></tr><tr><td>No</td><td>15</td><td>36</td><td> </td></tr><tr><td colspan="4">Tenofovir</td></tr><tr><td>Yes</td><td>15</td><td>35</td><td>0.6</td></tr><tr><td>No</td><td>17</td><td>29</td><td> </td></tr><tr><td colspan="4">Emtricitabine</td></tr><tr><td>Yes</td><td>4</td><td>20</td><td>0.08</td></tr><tr><td>No</td><td>28</td><td>44</td><td> </td></tr><tr><td colspan="4">Emtricitabine+tenofovir</td></tr><tr><td>Yes</td><td>4</td><td>20</td><td>0.08</td></tr><tr><td>No</td><td>28</td><td>44</td><td> </td></tr><tr><td colspan="4">Zidovudine+lamivudine</td></tr><tr><td>Yes</td><td>7</td><td>11</td><td>0.8</td></tr><tr><td>No</td><td>25</td><td>53</td><td> </td></tr><tr><td colspan="4">Didanosine</td></tr><tr><td>Yes</td><td>4</td><td>4</td><td>0.4</td></tr><tr><td>No</td><td>28</td><td>60</td><td> </td></tr><tr><td colspan="4">Abacavir</td></tr><tr><td>Yes</td><td>3</td><td>4</td><td>0.6</td></tr><tr><td>No</td><td>29</td><td>60</td><td> </td></tr><tr><td colspan="4">Efavirenz</td></tr><tr><td>Yes</td><td>11</td><td>20</td><td>0.9</td></tr><tr><td>No</td><td>21</td><td>44</td><td> </td></tr><tr><td colspan="4">Nevirapine</td></tr><tr><td>Yes</td><td>3</td><td>6</td><td>1</td></tr><tr><td>No</td><td>29</td><td>58</td><td> </td></tr><tr><td colspan="4">Atazanavir</td></tr><tr><td>Yes</td><td>6</td><td>16</td><td>0.6</td></tr><tr><td>No</td><td>26</td><td>48</td><td> </td></tr><tr><td colspan="4">Fosamprenavir</td></tr><tr><td>Yes</td><td>2</td><td>2</td><td>0.6</td></tr><tr><td>No</td><td>30</td><td>62</td><td> </td></tr><tr><td colspan="4">Lopinavir/ritonavir</td></tr><tr><td>Yes</td><td>2</td><td>5</td><td>1</td></tr><tr><td>No</td><td>30</td><td>59</td><td> </td></tr></table>
0fbcca7e6e48de508b8c1f067ff9196d0711323e34dab8336b7637fd51576d50.png
complex
<table><tr><td>Characteristics</td><td>Frequency (%)</td><td>OR (95% CI)</td><td>p-value</td></tr><tr><td>Gender</td><td> </td><td> </td><td>&lt;0.001</td></tr><tr><td>Male</td><td>335 (65.4)</td><td>Reference</td><td rowspan="2"> </td></tr><tr><td>Female</td><td>503 (76.1)</td><td>1.90 (1.44-2.51)</td></tr><tr><td>Age (years)</td><td> </td><td> </td><td>0.347</td></tr><tr><td>20&#8211;39</td><td>369 (69.5)</td><td>Reference</td><td rowspan="3"> </td></tr><tr><td>40&#8211;59</td><td>312 (71.6)</td><td>1.14 (0.84-1.54)</td></tr><tr><td>&#8805; 60</td><td>157 (76.2)</td><td>1.39 (0.88-2.19)</td></tr><tr><td>Educational level</td><td> </td><td> </td><td>0.620</td></tr><tr><td>Low-intermediate education</td><td>107 (67.3)</td><td>Reference</td><td rowspan="2"> </td></tr><tr><td>High education</td><td>728 (72.1)</td><td>1.10 (0.75-1.62)</td></tr><tr><td>Monthly income</td><td> </td><td> </td><td>0.202</td></tr><tr><td>&lt; 500 Kuwaiti Dinars (KD)</td><td>176 (68.2)</td><td>Reference</td><td rowspan="3"> </td></tr><tr><td>500&#8211;1000 Kuwaiti Dinars (KD)</td><td>334 (74.1)</td><td>1.29 (0.91-1.83)</td></tr><tr><td>&gt; 1000 Kuwaiti Dinars (KD)</td><td>329 (72.6)</td><td>1.37 (0.96-1.97)</td></tr><tr><td>Personal health</td><td> </td><td> </td><td>0.258</td></tr><tr><td>Excellent</td><td>320 (69.1)</td><td>Reference</td><td rowspan="3"> </td></tr><tr><td>Very good</td><td>348 (71.5)</td><td>1.11 (0.83-1.49)</td></tr><tr><td>Good/Fair</td><td>170 (76.2)</td><td>1.41 (0.94-2.13)</td></tr><tr><td>Chronic disease</td><td> </td><td> </td><td>0.798</td></tr><tr><td>Yes</td><td>297 (74.1)</td><td>Reference</td><td> </td></tr><tr><td>No</td><td>541 (70.1)</td><td>0.96 (0.69-1.3)</td><td> </td></tr></table>
58a29756315fbc4554597cc45304ed519d33d1dbfb0b9a8e7e5ac8e7a695897c.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="3">Univariate</td><td colspan="3">Multivariate</td></tr><tr><td><i>P</i></td><td>HR</td><td>95% CI</td><td><i>P</i></td><td>HR</td><td>95% CI</td></tr><tr><td>Sex</td><td>0.880</td><td>1.021</td><td>0.778-1.339</td><td>0.266</td><td>1.176</td><td>0.883-1.566</td></tr><tr><td>Age</td><td>0.059</td><td>1.011</td><td>1.000-1.022</td><td>0.466</td><td>1.004</td><td>0.993-1.016</td></tr><tr><td>Tumor size</td><td>0.474</td><td>1.002</td><td>0.997-1.007</td><td>0.381</td><td>1.002</td><td>0.997-1.008</td></tr><tr><td>KPS</td><td>&lt;0.001</td><td>0.964</td><td>0.954-0.974</td><td>&lt;0.001</td><td>0.974</td><td>0.963-0.986</td></tr><tr><td>Resection</td><td>0.014</td><td>0.731</td><td>0.568-0.940</td><td>0.091</td><td>0.800</td><td>0.618-1.036</td></tr><tr><td>Adjuvant treatment</td><td>&lt;0.001</td><td>0.577</td><td>0.487-0.684</td><td>0.001</td><td>0.726</td><td>0.597-0.884</td></tr><tr><td>MGMT promoter</td><td>0.162</td><td>0.823</td><td>0.626-1.081</td><td>0.925</td><td>1.015</td><td>0.749-1.375</td></tr><tr><td>IDH1-R132H mutation</td><td>0.006</td><td>0.450</td><td>0.255-0.794</td><td>0.018</td><td>0.489</td><td>0.270-0.885</td></tr><tr><td>Serum albumin level</td><td>&lt;0.001</td><td>0.938</td><td>0.912-0.964</td><td>0.023</td><td>0.966</td><td>0.938-0.995</td></tr></table>
915beb632d0c2800020d6c6e7bd92c23a832811575052b51a64c34fa8827fd21.png
complex
<table><tr><td><i>Exposure to iAs in Water</i></td><td>N<sup>a</sup></td><td colspan="2">Range</td><td>AM</td><td>GM</td><td>GSD</td></tr><tr><td>iAs, current concentration (ppb)</td><td>258</td><td>3.1</td><td>215.2</td><td>42.9</td><td>24.4</td><td>2.9</td></tr><tr><td>iAs, cumulative exposure 1993-2008 (ppm.years)</td><td>255</td><td>0.0</td><td>6.73</td><td>1.8</td><td>1.3</td><td>2.3</td></tr><tr><td>iAs, cumulative exposure 1993-1997 (ppm.years)</td><td>255</td><td>0.0</td><td>5.8</td><td>0.7</td><td>0.5</td><td>2.8</td></tr><tr><td>iAs, cumulative exposure 1998-2002 (ppm.years)</td><td>255</td><td>0.0</td><td>4.5</td><td>0.6</td><td>0.5</td><td>2.3</td></tr><tr><td>iAs, cumulative exposure 2002-2007 (ppm.years)</td><td>255</td><td>0.0</td><td>1.2</td><td>0.5</td><td>0.4</td><td>2.1</td></tr><tr><td><i>Metabolites of iAs in Urine (ng/mL)</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>tAs</td><td>256</td><td>2.3</td><td>233.7</td><td>41.2</td><td>24.7</td><td>2.8</td></tr><tr><td>iAs<sup>III </sup></td><td>257</td><td>0.1</td><td>37.2</td><td>4.2</td><td>2.1</td><td>3.4</td></tr><tr><td>MAs<sup>III </sup></td><td>257</td><td>ND</td><td>2.4</td><td>0.4</td><td>0.1</td><td>2.3</td></tr><tr><td>DMAs<sup>III</sup></td><td>257</td><td>ND</td><td>64.8</td><td>4.7</td><td>0.9</td><td>3.2</td></tr><tr><td>iAs<sup>V</sup></td><td>257</td><td>ND</td><td>32.9</td><td>1.4</td><td>1.5</td><td>4.7</td></tr><tr><td>MAs<sup>V </sup></td><td>257</td><td>0.1</td><td>36.2</td><td>5.0</td><td>1.1</td><td>1.1</td></tr><tr><td>DMAs<sup>V</sup></td><td>257</td><td>0.1</td><td>162.6</td><td>22.5</td><td>2.4</td><td>1.3</td></tr><tr><td>DMAs/MAs ratio</td><td>257</td><td>0.4</td><td>26.4</td><td>5.6</td><td>4.8</td><td>1.7</td></tr><tr><td>MAs/iAs ratio</td><td>257</td><td>0.0</td><td>5.1</td><td>1.3</td><td>1.1</td><td>2.0</td></tr></table>
29adf2912bb570f0c8d6b4e5e4d0ca8a119dbdac2ff626710f0e04df5fbbd9e9.png
simple
<table><tr><td>Variable</td><td>Survivors (<i>n</i> = 36)</td><td>Nonsurvivors (<i>n</i> = 25)</td><td>P value</td></tr><tr><td>cTnT (pg/mL), median (IQL) </td><td>20 (18&#8211;24)</td><td>34.5 (27.5&#8211;41.5)</td><td>&lt;0.05*</td></tr></table>
cbf255a42a56b8f19dc369f2edba6113298d5a0dc6c23b40d7f6b913dc7d4317.png
complex
<table><tr><td>Gene</td><td colspan="2">Positions and nt sequence sizes (bp)</td><td colspan="2">Start and stop codons</td><td colspan="2">tRNA Anti-codons</td><td colspan="2">Intergenic nt (bp)</td></tr><tr><td></td><td>PL (5&#8217;-3&#8217;)</td><td>PC (5&#8217;-3&#8217;)</td><td>PL</td><td>PC</td><td>PL</td><td>PC</td><td>PL</td><td>PC</td></tr><tr><td><i>cox</i>3</td><td>1-645 (645)</td><td>1-645 (645)</td><td>ATG/TAG</td><td>ATG/TAG</td><td></td><td></td><td>0</td><td>0</td></tr><tr><td>tRNA-His (H)</td><td>647-714 (68)</td><td>647-715 (69)</td><td></td><td></td><td>GTG</td><td>GTG</td><td>1</td><td>3</td></tr><tr><td><i>cyt</i>b</td><td>717-1829 (1113)</td><td>720-1832 (1113)</td><td>ATG/TAG</td><td>ATG/TAG</td><td></td><td></td><td>2</td><td>4</td></tr><tr><td>SNCR</td><td>1830-1894 (64)</td><td>1833-1890 (58)</td><td></td><td></td><td></td><td></td><td>0</td><td>0</td></tr><tr><td><i>nad</i>4L</td><td>1895-2158 (264)</td><td>1891-2154 (264)</td><td>ATG/TAG</td><td>ATG/TAG</td><td></td><td></td><td>0</td><td>0</td></tr><tr><td><i>nad</i>4</td><td>2119-3399 (1281)</td><td>2115-3395 (1281)</td><td>GTG/TAG</td><td>GTG/TAG</td><td></td><td></td><td>&#8722;40</td><td>&#8722;40</td></tr><tr><td>tRNA-Gln (Q)</td><td>3404-3469 (66)</td><td>3398-3462 (65)</td><td></td><td></td><td>TTG</td><td>TTG</td><td>4</td><td>2</td></tr><tr><td>tRNA-Phe (F)</td><td>3501-3567 (67)</td><td>3489-3553 (65)</td><td></td><td></td><td>GAA</td><td>GAA</td><td>31</td><td>26</td></tr><tr><td>tRNA-Met (M)</td><td>3565-3629 (65)</td><td>3553-3615 (63)</td><td></td><td></td><td>CAT</td><td>CAT</td><td>&#8722;3</td><td>&#8722;1</td></tr><tr><td><i>atp</i>6</td><td>3630-4145 (516)</td><td>3616-4131 (516)</td><td>ATG/TAG</td><td>ATG/TAG</td><td></td><td></td><td>0</td><td>0</td></tr><tr><td><i>nad</i>2</td><td>4153-5025 (873)</td><td>4139-5011 (870)</td><td>ATA/TAG</td><td>GTG/TAG</td><td></td><td></td><td>7</td><td>7</td></tr><tr><td>tRNA-Val (V)</td><td>5049-5112 (64)</td><td>5014-5077 (64)</td><td></td><td></td><td>TAC</td><td>TAC</td><td>23</td><td>2</td></tr><tr><td>tRNA-Ala (A)</td><td>5122-5187 (66)</td><td>5085-5154 (70)</td><td></td><td></td><td>TGC</td><td>TGC</td><td>9</td><td>7</td></tr><tr><td>tRNA-Asp (D)</td><td>5197-5266 (70)</td><td>5165-5229 (65)</td><td></td><td></td><td>GTC</td><td>GTC</td><td>9</td><td>10</td></tr><tr><td><i>nad</i>1</td><td>5269-6165 (897)</td><td>5233-6129 (897)</td><td>ATG/TAG</td><td>ATG/TAG</td><td></td><td></td><td>2</td><td>3</td></tr><tr><td>tRNA-Asn (N)</td><td>6170-6235 (66)</td><td>6142-6207 (66)</td><td></td><td></td><td>GTT</td><td>GTT</td><td>4</td><td>12</td></tr><tr><td>tRNA-Pro (P)</td><td>6235-6300 (66)</td><td>6208-6270 (63)</td><td></td><td></td><td>TGG</td><td>TGG</td><td>&#8722;1</td><td>0</td></tr><tr><td>tRNA-Ile (I)</td><td>6302-6363 (62)</td><td>6272-6334 (63)</td><td></td><td></td><td>GAT</td><td>GAT</td><td>1</td><td>1</td></tr><tr><td>tRNA-Lys (K)</td><td>6370-6435 (66)</td><td>6344-6409 (66)</td><td></td><td></td><td>CTT</td><td>CTT</td><td>6</td><td>9</td></tr><tr><td><i>nad</i>3</td><td>6436-6792 (357)</td><td>6410-6766 (357)</td><td>ATG/TAG</td><td>ATG/TAG</td><td></td><td></td><td>0</td><td>0</td></tr><tr><td>tRNA-Ser (S1)</td><td>6810-6868 (59)</td><td>6785-6843 (59)</td><td></td><td></td><td>GCT</td><td>GCT</td><td>17</td><td>18</td></tr><tr><td>tRNA-Trp (W)</td><td>6878-6941 (64)</td><td>6853-6915 (63)</td><td></td><td></td><td>TCA</td><td>TCA</td><td>9</td><td>9</td></tr><tr><td><i>cox</i>1</td><td>6942-8486 (1545)</td><td>6916-8460 (1545)</td><td>ATA/TAG</td><td>GTG/TAG</td><td></td><td></td><td>0</td><td>0</td></tr><tr><td>tRNA-Thr (T)</td><td>8500-8561 (62)</td><td>8470-8534 (65)</td><td></td><td></td><td>TGT</td><td>TGT</td><td>13</td><td>9</td></tr><tr><td><i>rrn</i>L</td><td>8562-9556 (995)</td><td>8535-9520 (986)</td><td></td><td></td><td></td><td></td><td>0</td><td>0</td></tr><tr><td>tRNA-Cys (C)</td><td>9557-9623 (67)</td><td>9527-9586 (60)</td><td></td><td></td><td>GCA</td><td>GCA</td><td>0</td><td>6</td></tr><tr><td><i>rrn</i>S</td><td>9624-10372 (749)</td><td>9592-10340 (749)</td><td></td><td></td><td></td><td></td><td>0</td><td>5</td></tr><tr><td><i>cox</i>2</td><td>10373-10954 (582)</td><td>10341-10919 (579)</td><td>ATG/TAG</td><td>ATG/TAG</td><td></td><td></td><td>0</td><td>0</td></tr><tr><td><i>nad</i>6</td><td>10948-11400 (453)</td><td>10920-11372 (453)</td><td>GTG/TAG</td><td>GTG/TAG</td><td></td><td></td><td>&#8722;7</td><td>0</td></tr><tr><td>tRNA-Tyr (Y)</td><td>11420-11485 (66)</td><td>11389-11455 (67)</td><td></td><td></td><td>GTA</td><td>GTA</td><td>19</td><td>16</td></tr><tr><td>tRNA-Leu (L1)</td><td>11496-11557 (62)</td><td>11470-11536 (67)</td><td></td><td></td><td>TAG</td><td>TAG</td><td>10</td><td>14</td></tr><tr><td>tRNA-Ser (S2)</td><td>11558-11624 (67)</td><td>11538-11609 (72)</td><td></td><td></td><td>TGA</td><td>TGA</td><td>0</td><td>1</td></tr><tr><td>tRNA-Leu (L2)</td><td>11644-11708 (65)</td><td>11646-11710 (65)</td><td></td><td></td><td>TAA</td><td>TAA</td><td>19</td><td>36</td></tr><tr><td>tRNA-Arg (R)</td><td>11709-11775 (67)</td><td>11713-11779 (67)</td><td></td><td></td><td>TCG</td><td>TCG</td><td>0</td><td>2</td></tr><tr><td><i>nad</i>5</td><td>11775-13358 (1584)</td><td>11780-13360 (1581)</td><td>GTG/TAA</td><td>ATG/TAG</td><td></td><td></td><td>&#8722;1</td><td>0</td></tr><tr><td>tRNA-Gly (G)</td><td>13359-13431 (73)</td><td>13365-13433 (69)</td><td></td><td></td><td>TCC</td><td>TCC</td><td>0</td><td>4</td></tr><tr><td>tRNA-Glu (E)</td><td>13440-13507 (68)</td><td>13451-13515 (65)</td><td></td><td></td><td>TTC</td><td>TTC</td><td>8</td><td>17</td></tr><tr><td>LNCR</td><td>13508-14050 (543)</td><td>13516-14014 (499)</td><td></td><td></td><td></td><td></td><td>0</td><td>0</td></tr></table>
72bf72ed490d72b9ba0b75ca167e9ce0859020b1d6f8d69d275cfac491fe001f.png
complex
<table><tr><td>Materials employed</td><td>Composition</td><td>Manufacturer</td></tr><tr><td rowspan="2">GC Fuji II Universal Restorative</td><td>Powder: 95% fluoroaluminosilicate glass (amorphous)5% polyacrylic acid</td><td rowspan="2">G.C. Corporation, Tokyo, Japan </td></tr><tr><td>Liquid: 50% distilled water40% polyacrylic acid</td></tr><tr><td>GC Fuji II Capsule</td><td>Powder/liquid ratio (g/g) 0.30/0.11</td><td>G.C. Corporation, Tokyo, Japan</td></tr><tr><td>GC Fuji II Universal Restorative Liquid</td><td>50% distilled water40% polyacrylic acid</td><td>G.C. Corporation, Tokyo, Japan</td></tr><tr><td>GC Dentin Conditioner</td><td>10% polyacrylic acid</td><td>G.C. Corporation, Tokyo, Japan</td></tr></table>
42101e5986d4fa445bfac8a75cab577e832c703643371812bb4b44782d4a846f.png
simple
<table><tr><td>Data set</td><td>Number of instances</td><td>Number of attributes</td></tr><tr><td>Sonar</td><td>208</td><td>60</td></tr><tr><td>Live disorder</td><td>345</td><td>6</td></tr><tr><td>Breast cancer</td><td>680</td><td>10</td></tr><tr><td>Cystic fibrosis</td><td>177</td><td>Depends on q</td></tr><tr><td>Leukemia</td><td>355</td><td>Depends on q</td></tr><tr><td>Lung cancer</td><td>91</td><td>54675</td></tr></table>
cdf47841f2d916fb1e4ee0ff8b3fad3b82d3897cefdcf645f8851df59559f396.png
simple
<table><tr><td> </td><td>Group O (<i>n</i> = 40)</td><td>Group L (<i>n</i> = 39)</td><td><i>p</i> values<sup>a</sup></td></tr><tr><td>Surgical indication</td><td> </td><td> </td><td>0.968<sup>b</sup></td></tr><tr><td> Inflammation</td><td>3 (7.50)</td><td>3 (7.69)</td><td> </td></tr><tr><td> Stricture</td><td>24 (60.00)</td><td>23 (58.97)</td><td> </td></tr><tr><td> Internal fistula/mass</td><td>11 (27.50)</td><td>10 (25.64)</td><td> </td></tr><tr><td> Hemorrhage</td><td>2 (5.00)</td><td>3 (7.69)</td><td> </td></tr><tr><td>Type of surgery </td><td> </td><td> </td><td>0.629<sup>b</sup></td></tr><tr><td> Small bowel resection</td><td>11 (27.50)</td><td>10 (25.64)</td><td> </td></tr><tr><td> Ileocolic resection</td><td>21 (52.50)</td><td>24 (61.54)</td><td> </td></tr><tr><td> Colonic resection</td><td>8 (20.00)</td><td>5 (12.82)</td><td> </td></tr><tr><td>Hand-assisted anastomosis</td><td> </td><td>11 (28.21)</td><td> </td></tr><tr><td>Length of incision (cm)</td><td>10.30 &#177; 1.79</td><td>5.00 &#177; 1.23</td><td>&lt;0.001</td></tr><tr><td>Operation duration (min)</td><td>86.85 &#177; 24.31</td><td>121.53 &#177; 33.62</td><td>&lt;0.001</td></tr><tr><td>Blood loss (mL)</td><td>122.25 &#177; 53.61</td><td>54.10 &#177; 21.97</td><td>&lt;0.001</td></tr></table>
e0ca55f97f2c4d76cc367df20dbbe3b28fa131afde67ed36f0527441a76fa5bc.png
simple
<table><tr><td></td><td>No history of MTSS</td><td>History of MTSS</td><td>P-value</td><td>Effect size (r)</td></tr><tr><td>Navicular Drop (mm)</td><td>7.1 &#177; 2.0</td><td>7.1 &#177; 1.9</td><td>0.98</td><td>0.01</td></tr><tr><td>Leg Heel Alignment (&#176;)</td><td>5.0 &#177; 1.4</td><td>5.1 &#177; 2.0</td><td>0.72</td><td>0.08</td></tr></table>
f51fdfd6081615fbcc41d2b658c3bbc683b24b97256c765ddad786296650af8e.png
simple
<table><tr><td><underline>Sociodemographics</underline></td><td><underline>% of full sample</underline></td></tr><tr><td>Age (mean, SD)</td><td>32.6, 13.0</td></tr><tr><td>Minority/racial group member</td><td>50.2</td></tr><tr><td>Not married</td><td>45.0</td></tr><tr><td>No. children in household</td><td>49.6</td></tr><tr><td>No education beyond high school</td><td>37.4</td></tr><tr><td>Not employed</td><td>45.4</td></tr><tr><td>Income below federal poverty line</td><td>17.9</td></tr><tr><td><underline>Physical health</underline></td><td></td></tr><tr><td>Not pregnant</td><td>94.7</td></tr><tr><td>Smokes</td><td>13.6</td></tr><tr><td>Fair/poor health</td><td>17.3</td></tr><tr><td><underline>Mental health</underline></td><td></td></tr><tr><td>PTSD symptoms</td><td>6.3</td></tr><tr><td>Anxiety symptoms</td><td>21.8</td></tr><tr><td>Depression symptoms</td><td>13.7</td></tr><tr><td>Overwhelmed by stress</td><td>12.5</td></tr><tr><td><underline>Mental health help</underline></td><td></td></tr><tr><td>Poor mental health</td><td>14.2</td></tr><tr><td>Perceived need for mental health help</td><td>23.2</td></tr><tr><td>Utilized mental health help</td><td>9.8</td></tr><tr><td><underline>Adult victimization</underline></td><td></td></tr><tr><td>Intimate partner violence</td><td>9.9</td></tr><tr><td>Physically assaulted</td><td>19.7</td></tr><tr><td>Sexually assaulted</td><td>10.6</td></tr><tr><td>Death of someone close</td><td>29.7</td></tr><tr><td><underline>Childhood victimization</underline></td><td></td></tr><tr><td>Lived in foster care</td><td>3.4</td></tr><tr><td>Lived with someone abusing substances</td><td>22.3</td></tr><tr><td>Lived with someone mentally ill</td><td>16.8</td></tr><tr><td>Lived with mother victimized by violence</td><td>18.4</td></tr><tr><td>Lived with someone incarcerated</td><td>7.6</td></tr><tr><td>Emotionally abused by adult in home</td><td>18. 4</td></tr><tr><td>Physically assaulted</td><td>19.1</td></tr><tr><td>Sexually assaulted</td><td>11.2</td></tr></table>
948fb813213a24dfdf1215e26e809378d76bdecca5582c2beb23d10528fbcba8.png
simple
<table><tr><td></td><td>GUH (N = 34)</td><td>WHC (N = 21)</td><td>Total (N = 55)</td></tr><tr><td>Age (N = 55)</td><td>M = 55.4 SD = 8.2</td><td>M = 53.7 SD = 6.7</td><td>M = 54.7 SD = 7.6</td></tr><tr><td>Race/Ethnicity #</td><td></td><td></td><td></td></tr><tr><td> White (N = 19)</td><td>50%</td><td>10.5%</td><td>35.8%</td></tr><tr><td> African American (N = 30)</td><td>38.2%</td><td>89.5%</td><td>56.6%</td></tr><tr><td> Other (N = 4)</td><td>11.8%</td><td>0</td><td>7.5%</td></tr><tr><td>Education</td><td></td><td></td><td></td></tr><tr><td> &lt; HS grad (N = 14)</td><td>20.6%</td><td>33.3%</td><td>25.5%</td></tr><tr><td> Voc/trade or some college (N = 12)</td><td>14.7%</td><td>33.3%</td><td>21.8%</td></tr><tr><td> College Graduate (N = 7)</td><td>20.6%</td><td>0</td><td>12.7%</td></tr><tr><td> Graduate work/degree (N = 22)</td><td>44.1%</td><td>33.3%</td><td>40.0%</td></tr><tr><td>Marital Status</td><td></td><td></td><td></td></tr><tr><td> Married (N = 37)</td><td>70.6%</td><td>61.9%</td><td>67.3%</td></tr><tr><td> Other (N = 18)</td><td>29.4%</td><td>38.1%</td><td>32.7%</td></tr><tr><td>Internet access at home/work</td><td></td><td></td><td></td></tr><tr><td> Yes (N = 41)</td><td>82.4%</td><td>61.9%</td><td>74.5%</td></tr><tr><td> No (N = 14)</td><td>17.6%</td><td>38.1%</td><td>25.5%</td></tr><tr><td>Home/Work Computer Internet Usage (among those with access at home/work)</td><td></td><td></td><td></td></tr><tr><td> Few times yr/few times month (N = 7)</td><td>7.1%</td><td>38.5%</td><td>17.1%</td></tr><tr><td> Once/twice a wk (N = 5)</td><td>14.3%</td><td>7.7%</td><td>12.2%</td></tr><tr><td> Daily (N = 29)</td><td>78.6%</td><td>53.8%</td><td>70.7%</td></tr><tr><td>Receiving Health Related Information #</td><td></td><td></td><td></td></tr><tr><td> Prefers Internet (N = 23)</td><td>47.1%</td><td>36.8%</td><td>43.4%</td></tr><tr><td> Prefers Booklet (N = 30)</td><td>52.9%</td><td>63.2%</td><td>56.6%</td></tr><tr><td>Willingness to Read Prostate Cancer Info on the Internet #</td><td></td><td></td><td></td></tr><tr><td> Definitely/Probably would (N = 42)</td><td>76.5%</td><td>84.2%</td><td>79.3%</td></tr><tr><td> Definitely/Probably would not (N = 11)</td><td>23.5%</td><td>15.8%</td><td>20.7%</td></tr><tr><td>Awareness of Disagreement in Medical Community Regarding Whether to Screen for PrCa</td><td></td><td></td><td></td></tr><tr><td> Unaware of disagreement (N = 45)</td><td>82.4%</td><td>81.0%</td><td>81.8%</td></tr><tr><td> Aware of disagreement (N = 4)</td><td>2.9%</td><td>14.3%</td><td>7.3%</td></tr><tr><td> Not Sure (N = 6)</td><td>14.7%</td><td>4.8%</td><td>10.9%</td></tr></table>